US6306870B1 - N-cinnamoyl derivatives of beta-carboline - Google Patents

N-cinnamoyl derivatives of beta-carboline Download PDF

Info

Publication number
US6306870B1
US6306870B1 US09/592,514 US59251400A US6306870B1 US 6306870 B1 US6306870 B1 US 6306870B1 US 59251400 A US59251400 A US 59251400A US 6306870 B1 US6306870 B1 US 6306870B1
Authority
US
United States
Prior art keywords
carbolin
tetrahydro
propene
phenyl
methylenedioxyphenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US09/592,514
Inventor
Agnes Bombrun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Icos Corp
Original Assignee
Icos Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9609777.9A external-priority patent/GB9609777D0/en
Priority claimed from GBGB9609820.7A external-priority patent/GB9609820D0/en
Application filed by Icos Corp filed Critical Icos Corp
Application granted granted Critical
Publication of US6306870B1 publication Critical patent/US6306870B1/en
Assigned to ICOS CORPORATION, A WASHINGTON CORPORATION reassignment ICOS CORPORATION, A WASHINGTON CORPORATION MERGER (SEE DOCUMENT FOR DETAILS). Assignors: ICOS CORPORATION, A DELAWARE CORPORATION
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Definitions

  • This invention relates to a series of carboline derivatives, to processes for their preparation, pharmaceutical compositions containing them, and their use as therapeutic agents.
  • the invention relates to carboline derivatives which are potent and selective inhibitors of cyclic guanosine 3′,5′-monophosphate specific phosphodiesterase (cGMP specific PDE) having utility in a variety of therapeutic areas where such inhibition is thought to be beneficial, including the treatment of cardiovascular disorders.
  • cGMP specific PDE cyclic guanosine 3′,5′-monophosphate specific phosphodiesterase
  • the present invention provides compounds of formula (I)
  • R 0 represents -hydrogen or -halogen
  • R 1 is selected from the group consisting of:
  • Het represents 5- or 6-membered heterocyclic group as defined above
  • Het represents a 5- or 6-membered heterocyclic group as defined above
  • R 2 is selected from the group consisting of:
  • R 1 and R 2 together form a 3- or 4-membered alkylene or alkenylene chain, optionally containing at least one heteratom;
  • R 3 is selected from the group consisting of:
  • R 4 is hydrogen
  • R 3 and R 4 together form a 3- or 4-membered alkylene or alkenylene chain, optionally containing at least one heteratom;
  • R a and R b which may be the same or different, are independently selected from hydrogen and C 1-6 alkyl;
  • R c represents phenyl or C 4-6 cycloalkyl, which phenyl or C 4-6 cycloalkyl can be optionally substituted by one or more halogen atoms, one or more —C( ⁇ O)OR a or one or more —OR a ;
  • n is an integer selected from 1, 2 and 3;
  • n is an integer selected from 1 and 2;
  • alkyl or alkylene as used herein respectively contain the appropriate indicated number of carbon atoms and appropriately include straight chained and branched alkyl or alkylene groups, typically methyl, methylene, ethyl and ethylene groups, and straight chained and branched propyl, propylene, butyl and butylene groups.
  • C 2-6 alkenylene as used herein contains 2 to 6 carbon atoms and appropriately includes straight chained and branched alkenylene groups, in particular ethenylene or the like.
  • C 4-6 cycloalkyl denotes cyclic groups containing 4 to 6 carbon atoms, namely cyclobutane, cyclopentane and cyclohexane.
  • halogen as used herein includes fluorine, chlorine, bromine and iodine.
  • 5- or 6-membered heterocyclic group as used herein includes 5- or 6-membered heterocycloalkyl and heteroaryl groups, e.g. tetrahydrofuranyl, piperidyl, piperazinyl pyrrolidinyl, morpholinyl, pyridyl, imidazolyl, furyl, and tetrazolyl.
  • heteroaryl groups e.g. tetrahydrofuranyl, piperidyl, piperazinyl pyrrolidinyl, morpholinyl, pyridyl, imidazolyl, furyl, and tetrazolyl.
  • R o represents hydrogen.
  • R o may represent halogen, in particular fluorine.
  • R 1 may represent any of the substituents as hereinbefore described, or more particularly may represent any of —OR a , —O—C 2-4 alkyleneNR a R b , —O—C 1-4 alkyleneHet and —O—C 2-4 alkylene-OR a .
  • R 1 represents —O—C 2-4 alkylene NR a R b , wherein suitably C 2-4 alkylene may represent ethylene and aptly, R a and R b may independently represent methyl.
  • R 2 represents hydrogen.
  • R 1 and R 2 together form a 3- or 4-membered alkylene or alkenylene chain optionally containing at least one heteratom as hereinbefore described
  • R 1 and R 2 together form a methylenedioxy chain, an ethyleneoxy chain, an ethylenedioxy chain, an ethenyleneoxy chain, a propylene chain, a butylene chain or —NR a ethylene-O—.
  • R 1 and R 2 together form methylenedioxy, propylene or —N(CH 3 )—(CH 2 ) 2 —O—.
  • R 3 and R 4 together form a 3- or 4-membered alkylene or alkenylene chain, optionally containing at least one heteratom as hereinbefore described.
  • R 3 and R 4 together form a methylenedioxy chain, an ethyleneoxy chain, an ethylenedioxy chain, an ethenyleneoxy chain, a propylene chain, a butylene chain or —NR a ethylene-O—.
  • R 3 and R 4 together form a methylenedioxy chain, an ethyleneoxy chain, an ethylenedioxy chain, an ethenyleneoxy chain or a propylene chain.
  • R 3 and R 4 together form methylenedioxy or ethyleneoxy, most particularly ethyleneoxy.
  • R 5 is selected from the group consisting of —OH, —OC 2-4 alkylene NR a R b and O—C 1-4 alkylene Het, wherein Het is as hereinbefore described and
  • R 6 represents
  • C represents a 5- or 6-membered rn which may be saturated or partially or fully unsaturated and comprises carbon atoms and optionally one or two heteroatoms selected from oxygen, sulphur and nitrogen, optionally substituted by C 1-4 alkyl;
  • R 5 represents —OC 2-4 alkylene NR a R b , in particular —OCH 2 CH 2 N(CH 3 ) 2 .
  • R 5 may represent —O—C 1-4 alkylene Het, where Het may suitable be piperidyl, pyrrolidinyl (optionally substituted by C 1-4 alkyl, e.g. methyl) or morpholinyl.
  • R 6 represents
  • the compounds of formula (I) may contain one or more asymmetric centres and thus can exist as enantiomers or diastereoisomers. It is to be understood that the invention includes both mixtures and separate individual isomers of the compounds of formula (I).
  • the pharmaceutically acceptable salts of the compounds of formula (I) which contain a basic centre are acid addition salts formed with pharmaceutically acceptable acids.
  • examples include the hydrochloride, hydrobromide, sulphate or bisulphate, phosphate or hydrogen phosphate, acetate, benzoate, succinate, fumarate, maleate, lactate, citrate, tartrate, gluconate, methanesulphonate, benzenesulphonate and p-toluenesulphonate salts.
  • Compounds of the formula (I) can also provide pharmaceutically acceptable metal salts, in particular alkali metal salts, with bases, Examples include the sodium and potassium salts.
  • Particular individual compounds of the invention include:
  • a specific compound of the invention is:
  • compounds of the present invention are potent and selective inhibitors of cGMP specific PDE.
  • compounds of formula (I) are of interest for use in therapy, specifically for the treatment of a variety of conditions where inhibition of cGMP specific PDE is thought to be beneficial.
  • cGMP levels are elevated, which in turn can give rise to beneficial anti-platelet, anti-neutrophil, anti-vasospastic, vasodilatory, natriuretic and diuretic activities as well as potentiation of the effects of endothelium-derived relaxing factor (EDRF), nitrovasodilators, atrial natriuretic factor (ANF), brain natriuretic peptide (BNP), C-type natriuretic peptide (CNP) and endothelium-dependent relaxing agents such as bradykinin, acetylcholine and 5-HT 1 .
  • EDRF endothelium-derived relaxing factor
  • NAF atrial natriuretic factor
  • BNP brain natriuretic peptide
  • CNP C-type natriuretic peptide
  • endothelium-dependent relaxing agents such as bradykinin, acetylcholine and 5-HT 1 .
  • the compounds of formula (I) therefore have utility in the treatment of a number of disorders, including stable, unstable and variant (Prinzmetal) angina, hypertension, pulmonary hypertension, congestive heart failure, renal failure, atherosclerosis, conditions of reduced blood vessel patency (e.g. post-percutaneous transluminal coronary angioplasty), peripheral vascular disease, vascular disorders such as Raynaud's disease, inflammatory diseases, stroke, bronchitis, chronic asthma, allergic asthma, allergic rhinitis, glaucoma, erectile dysfunction and diseases characterised by disorders of gut motility (e.g. irritable bowel syndrome).
  • disorders of gut motility e.g. irritable bowel syndrome
  • references herein to treatment extend to prophylaxis as well as treatment of established conditions.
  • a compound of formula (I), or a physiologically acceptable salt or solvate thereof can be administered as the raw compound, or as a pharmaceutical composition containing either entity.
  • a compound of formula (I) for use in the treatment of stable, unstable and variant (Prinzmetal) angina, hypertension, pulmonary hypertension, chronic obstructive pulmonary disease, congestive heart failure, renal failure, atherosclerosis, conditions of reduced blood vessel patency, (e.g. post-PTCA), peripheral vascular disease, vascular disorders such as Raynaud's disease, inflammatory diseases. stroke. bronchitis, chronic asthma, allergic asthma, allergic rhinitis, glaucoma, erectile dysfunction or diseases characterised by disorders of gut motility (e.g. IBS).
  • IBS gut motility
  • a compound of formula (I) for the manufacture of a medicament for the treatment of stable, unstable and variant (Prinzmetal) angina, hypertension, pulmonary hypertension, chronic obstructive pulmonary disease, congestive heart failure, renal failure, atherosclerosis, conditions of reduced blood vessel patency, (e.g. post-PTCA), peripheral vascular disease, vascular disorders such as Raynaud's disease, inflammatory diseases, stroke, bronchitis, chronic asthma, allergic asthma, allergic rhinitis, glaucoma, erectile dysfunction or diseases characterised by disorders of gut motility (e.g. IBS).
  • IBS gut motility
  • the invention provides a method of treating stable, unstable and variant (Prinzmetal) angina, hypertension, pulmonary hypertension, chronic obstructive pulmonary disease, congestive heart failure, renal failure, atherosclerosis, conditions of reduced blood vessel patency, (e.g. post-PTCA), peripheral vascular disease, vascular disorders such as Raynaud's disease, inflammatory diseases, stroke, bronchitis, chronic asthma, allergic asthma, allergic rhinitis, glaucoma, erectile dysfunction or diseases characterised by disorders of gut motility (e.g. IBS) in a human or non-human animal body which comprises administering to said body a therapeutically effective amount of a compound with formula (I).
  • Compounds of the invention may be administered by any suitable route, for example by oral, buccal, sub-lingual, rectal, vaginal, nasal, topical or parenteral (including intravenous, intramuscular, subcutaneous and intracoronary) administration. Oral administration is generally preferred.
  • oral dosages of a compound of formula (I) will generally be in the range of from 0.5-800 mg daily for an average adult patient (70 kg).
  • individual tablets or capsules contain from 0.2-400 mg of active compound, in a suitable pharmaceutically acceptable vehicle or carrier, for administration in single or multiple doses, once or several times per day.
  • Dosages for intravenous, buccal or sublingual administration will typically be within the range of from 0.1-400 mg per single dose as required.
  • the physician will determine the actual dosing regimen which will be most suitable for an individual patient and it will vary with the age, weight and response of the particular patient.
  • the above dosages are exemplary of the average case but there can be individual instances in which higher or lower dosage ranges may be merited, and such are within the scope of this invention.
  • a compound of the formula (I) can be administered alone, but will generally be administered in admixture with a pharmaceutical carrier selected with regard to the intended route of administration and standard pharmaceutical practice.
  • the compound may be administered orally, buccally or sublingually, in the form of tablets containing excipients such as starch or lactose, or in capsules or ovules either alone or in admixture with excipients, or in the form of elixirs or suspensions containing flavouring or colouring agents.
  • Such liquid preparations may be prepared with pharmaceutically acceptable additives such as suspending agents (e.g.
  • a compound may also be injected parenterally, for example intravenously, intramuscularly, subcutaneously or intracoronarily.
  • the compound is best used in the form of a sterile aqueous solution which may contain other substances, for example salts, or monosaccharides such as mannitol or glucose, to make the solution isotonic with blood.
  • the invention provides in a further aspect a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of the formula (I) together with a pharmaceutically acceptable diluent or carrier therefor.
  • a process of preparing a pharmaceutical composition comprising a compound of formula (I), which process comprises mixing a compound of formula (I) together with a pharmaceutically acceptable diluent or carrier therefor.
  • a compound of formula (I) may also be used in combination with other therapeutic agents which may be useful in the treatment of the above-mentioned disease states.
  • the invention thus provides, in another aspect, a combination of a compound of formula (I) together with another therapeutically active agent.
  • compositions comprising a combination as defined above together with a pharmaceutically acceptable diluent or carrier comprise a further aspect of the invention.
  • reaction is carried out in the presence of 1,3-dicyclohexylcarbodiimide (DCC) or 1-(3-dimethylaminopropyl)-3-ethylcarbodiumide (EDCI) and 1-hydroxybenzotriazole (HOBT) in a suitable organic solvent, such as dimethylformamide (DMF) or dichloromethane (DCM) for several hours, e.g. 8 hours to 2 days.
  • DCC 1,3-dicyclohexylcarbodiimide
  • EDCI 1-(3-dimethylaminopropyl)-3-ethylcarbodiumide
  • HOBT 1-hydroxybenzotriazole
  • a suitable organic solvent such as dimethylformamide (DMF) or dichloromethane (DCM) for several hours, e.g. 8 hours to 2 days.
  • DMF dimethylformamide
  • DCM dichloromethane
  • Compounds of formula (I) may be prepared as individual enantiomers from the appropriate enantiomer of formula (II) or as a racemic mixture from the appropriate racemic compound of formula (II).
  • Individual enantiomers of the compounds of the invention may be prepared from racemates by resolution using methods known in the art for the separation of racemic mixtures into their constituent enantiomers, for example using HPLC on a chiral column such as Hypersil naphtyl urea or using separation of salts of diastereoisomers.
  • a compound of formula (II) may be prepared by Pictet-Spengler cyclization between a tryptamine derivative of formula (IV) and an aldehyde of formula (V)
  • the reaction may conveniently be effected in a suitable solvent such as a halogenated hydrocarbon (e.g. dichloromethane) or an aromatic hydrocarbon (e.g. toluene) in the presence of an acid such as trifluoroacetic acid (TFA).
  • a suitable solvent such as a halogenated hydrocarbon (e.g. dichloromethane) or an aromatic hydrocarbon (e.g. toluene) in the presence of an acid such as trifluoroacetic acid (TFA).
  • TFA trifluoroacetic acid
  • the reaction may conveniently be carried out at a temperature of from 20° C. to reflux to provide a compound of formula (II) in one step.
  • the reaction may also be carried out in a solvent such as an aromatic hydrocarbon (e.g. toluene) under reflux optionally using a Dean-stark apparatus to trap the water produced.
  • racemic compounds of formula (II) Enantiomers may be obtained from a resolution with N-acetyl leucine using fractional crystallization in EtOAc:MeOH as solvent. (R) and (S) enantiomers may be isolated as salts depending upon whether N-acetyl-(D) and (L)-leucine was used as the starting material.
  • a compound of formula (III) can be prepared from a corresponding aldehyde of formula (VI)
  • a compound of formula (III) may be prepared from a compound of formula (VI) by a Knoevenhagel reaction employing malonic acid.
  • Compounds of this invention may be isolated in association with solvent molecules by crystallization from or evaporation of an appropriate solvent.
  • the pharmaceutically acceptable acid addition salts of the compounds of formula (I) which contain a basic centre may be prepared in a conventional manner.
  • a solution of the free base may be treated with a suitable acid, either neat or in a suitable solution, and the resulting salt isolated either by filtration or by evaporation under vacuum of the reaction solvent.
  • Pharmaceutically acceptable base addition salts may be obtained in an analogous manner by treating a solution of a compound of formula (I) with a suitable base. Both types of salt may be formed or interconverted using ion-exchange resin techniques.
  • rt room temperature
  • DMSO dimethylsulphoxide
  • NBS N-bromosuccinimide
  • THF tetrahydrofuran
  • TFA trifluoroacetic acid
  • PTSA p-toluene sulphonic acid
  • AIBN 2,2′-azobis isobutyronitrile
  • TBDMSCl tert-butyldimethylsilyl chloride
  • This product was prepared using a two-step procedure.
  • a solution of tryptamine (32.4 g, 0.2 mol) and 2,3-dihydrobenzofuran-5-carboxaldehyde (30.0 g, 1 equiv.) in toluene (1 L) was heated under reflux for 4 hours. After removal of 4 mL of water and evaporation of toluene the residue was dissolved in DCM (1 L) in the presence of TFA (31 mL, 2 equiv.). The resulting mixture was stirred at rt for 16 hours. Then 1 L of a saturated aqueous solution of NaHCO 3 was added. After extraction with DCM and drying over MgSO 4 , the organic solution was evaporated in vacuo. Recrystallization from DCM:iPr 2 O (2:30) gave the title compound as white crystals in a 80% yield.
  • N-(4-Formylphenyl)-N-methylacetamide (1.0 g, 46%) was obtained as an oil from N-(4-formylphenyl)acetamide (2.0 g, 12.2 mmol) in THF in the presence of iodomethane (1.2 mL, 1.5 equiv.) and NaH (0.73 g, 1.5 equiv., 60% in mineral oil).
  • 4-(2-Dimethylaminoethoxy)benzaldehyde (20.6 g, 65%) was obtained by alklylation of 4-hydroxybenzaldehyde (20 g, 164 mmol) in DMF with dimethylaminoethyl chloride (144 g, 8 equiv.) and K 2 CO 3 (24,9 g, 1.1 equiv.) for 16 hours at 80° C.
  • N-Cyclohexyl-4-formylbenzamide (0.6 g, 60%) was obtained by oxidation of N-cyclohexyl-4-(hydroxymethyl)benzamide (1.0 g, 4.29 mol) with MnO 2 (0.2 g, 22 equiv.), as a white powder.
  • N-Cyclohexyl-4-(hydroxymethyl)benzamide(1.0 g, 66%) was obtained as white crystals by coupling 4-(hydroxymethyl)benzoic acid with cyclohexylamine (0.75 mL, 1 equiv.) in the presence of Et 3 N (0.95 mL, 1.0 equiv.), EDCl (1.2 g, 1.0 equiv.) and HOBT (0.88 g, 1.0 equiv.).
  • 3-Chloro4-formylbenzoic acid, methyl ester (4.0 g, 81%) was prepared by reaction of 4-bromomethyl-3-chlorobenzoic acid, methyl ester (6.0 g, 26 mmol) with silver p-toluenesulfonate (15.0 g, 2.0 equiv.) in 100 mL of DMSO in the presence of Et 3 N (100 mL, 7 equiv.) at rt for 1 hour.
  • 2-Chloro-3-nitrobenzaldehyde (150 mg, 20%) was prepared by reaction of 1-bromomethyl-2-chloro-3-nitrobenzene (1.0 g, 3.9 mmol) with silver p-toluenesulfonate (1.94 g, 1.75 equiv.) in DMSO in the presence of Et 3 N (4 mL, 7 equiv.) at rt for 1 hour.
  • 4-(2-Dimethylamino-1-methylethoxy)benzaldehyde (2.1 g, 18%) was obtained as an orange oil by refluxing for 12 hours, 4-hydroxybenzaldehyde (7 g, 57 mmol), K 2 CO 3 (8.7 g, 1.1 equiv.) and 2-chloropropyldimethylamine, hydrochloride (13.6 g, 1.5 equiv.) in DMF.
  • (E)-3-[4-(3-Dimethylaminopropenyl)phenyl]acrylic acid, methyl ester was prepared by the following way: (2-dimethylaminoethyl)triphenylphosphonium bromide (7.2 g, 17.4 mmol) in 30 mL of DMF was treated with KHMDS (27 mL, 1.01 equiv., 0.5 M in toluene) at ⁇ 78° C. for one hour. At ⁇ 40° C., 3-(4-formylphenyl)acrylic acid, methyl ester (2.54 g, 13.3 mmol, prepared according to the procedure of Syper, L.; Miochowski, J.
  • This product was prepared by refluxing for four hours (E)-3-[4-(2-(tertbutyldimethylsilanyloxy)-3-dimethylaminopropanyl)phenyl]acrylic acid, methyl ester (0.8 g, 2.03 mmol) and NaOH (1N) (4 mL, 2 equiv.) in 10 mL of MeOH. Evaporation of the solvent in vacuo and treatment with 5 mL of HCl (1 N) gave the title compound (0.4 g, 60%) as a beige solid solid.
  • 4-(3-Dimethylamino-2-hydroxypropoxy)benzaldehyde (8.2 g, 61%) was obtained as an a yellow oil, by reaction of 4-oxiranylmethoxybenzaldehyde (6 g, 33.6 mmol, prepared according to the procedure of Baldwin, J. J., Hirchmann, R.; Lumma, W. C.; Ponticello, G. S.; Sweet, C. S.; Scriabine, A. J. Med. Chem. 1977, 20, 1024-1029) in 100 mL of MeOH with dimethylamine (34 mL, 2 equiv.). The resulting mixture was stirred at reflux for 2 days. Evaporation in vacuo gave a residue that was taken up in DCM, washed with brine and dried over MgSO 4 and evaporated in vacuo.
  • This product was prepared by refluxing for two hours a solution of Example 25 (0.2 g, 0.6 mmol), mesyl chloride (0.1 mL, 5 equiv.), Et 3 N (0.4 mL, 5 equiv.) in 20 mL of THF.
  • Example 28 Into a solution of Example 28 (0.2 g, 0.4 mmol) in 50 mL of MeOH was bubbled ammonia and the resulting mixture was stirred at 35° C. for two days. The mixture was concentrated in vacuo to give a residue which was washed with 2 ⁇ 30 mL of water. Extraction, drying over MgSO 4 and concentration in vacuo gave a residue that was purified via radial chromatography using DCM:MeOH (90:10) as eluting solvent and via preparative chromatography (20 ⁇ 20-cm plate, 0.5 mm , SiO 2 ) using the same eluant. The title compound (0.025 g, 13%) was isolated as white crystals after recrystallization from MeOH:H 2 O.
  • This product was prepared by refluxing for four hours a stirred solution of Example 28 (0.5 g, 1.04 mmol) and NaOH (1N) (5.2 mL, 5 equiv.) in 50 mL of MeOH. After evaporation of the solvent in vacuo, the residue was treated with 10 mL of HCl (1N). A solid precipitated out and was filtered off. Recrystallization from MeOH gave the title compound (0.35 g, 72%) as white crystals.
  • This product was prepared by stirring a solution of Example 23 (0.3 g, 0.66 mmol) in 40 mL of MeOH with NaBH 4 (0.1 g, 4 equiv.) at rt for two hours. Evaporation of the solvent gave a residue which was dissolved in DCM (100 mL) and washed twice with water (50 mL). Extraction with DCM, drying over MgSO 4 and evaporation in vacuo gave the title compound (0.2 g, 67%) as white crystals after recrystallization from EtOH.
  • This product was prepared by stirring a solution of Example 31 (0.2 g, 0.43 mmol) in 50 mL of THF with benzylamine (0.5 mL, 9 equiv.), Et 3 N (1 mL) and diphenylphosphoryl azide (0.5 mL). After two days the reaction mixture was concentrated in vacuo. The residue was taken up in 100 mL of DCM and washed with 3 ⁇ 50 mL of water. Drying over Na 2 SO 4 and evaporation of the solvent gave a residue which was purified via flash chromatography with cyclohexane and Et 2 O. Evaporation in vacuo and recrystallization from EtOH gave the title compound (0.03 g, 13%) as white crystals.
  • Example 31 The same method as employed in the preparation of Example 20 but starting from Example 31 and benzenesulfonamide gave after recrystallization from EtOH:H 2 O the title compound as white crytals in a 20% yield.
  • This product was prepared by condensation of Example 25 (0.2 g, 0.46 mmol) with 2,2-dimethylpropionyl chloride (0.09 mL, 1.5 equiv.) and NaOH (1N) (0.7 mL, 1.5 equiv.) in a mixture of EtOAc:DCM (6:1). When starting material had disappeared, 40 mL of a mixture of DCM:H 2 O (2:1) was added. Extraction with DCM, washing with a saturated aqueous solution of NH 4 Cl and brine, drying over MgSO 4 and evaporation of the solvent in vacuo gave the title compound (0.2 g, 83%) after recrystallization from EtOH:H 2 O (1:1).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Carboline derivatives of formula (I), are potent and selective inhibitors of cyclic guanosine 3′,5′-monophoshate specific phosphodiesterase (cGMP specific PDE) and have utility in a variety of therapeutic areas where such inhibition is thought to be beneficial, including the treatment of cardivascular disorders.
Figure US06306870-20011023-C00001

Description

CROSS-REFERENCE TO RELATED APPLICATION
This application is a divisional of U.S. patent application Ser. No. 09/155,811, filed Apr. 23, 1999 now U.S. Pat. No. 6,117,881, which is the U.S. national phase application International Application No. PCT/EP96/02277, filed on May 5, 1997.
This invention relates to a series of carboline derivatives, to processes for their preparation, pharmaceutical compositions containing them, and their use as therapeutic agents. In particular, the invention relates to carboline derivatives which are potent and selective inhibitors of cyclic guanosine 3′,5′-monophosphate specific phosphodiesterase (cGMP specific PDE) having utility in a variety of therapeutic areas where such inhibition is thought to be beneficial, including the treatment of cardiovascular disorders.
Thus, according to a first aspect, the present invention provides compounds of formula (I)
Figure US06306870-20011023-C00002
wherein
R0 represents -hydrogen or -halogen;
R1 is selected from the group consisting of:
-hydrogen,
—NO2,
-trifluoromethyl,
-trifluoromethoxy,
-halogen,
-cyano,
a 5- or 6-membered heterocyclic group containing at least one heteroatom selected from oxygen, nitrogen and sulphur (optionally substituted by —C(═O)ORa or C1-4alkyl),
—C1-6alkyl optionally substituted by —ORa,
—C1-3alkoxy,
—C(═O)Ra,
—O—C(═O)Ra,
—C(═O)ORa,
—C1-4alkylene C(═O)ORa,
—O—C1-4alkylene —C(═O)ORa,
—C1-4alkylene-O—C1-4alkylene-C(═O)ORa,
—C(═O)NRaSO2Rc,
—C(═O)C1-4alkylene Het, wherein Het represents 5- or 6-membered heterocyclic group as defined above,
—C1-4alkylene NRaRb,
—C2-6alkenyleneNRaRb,
—C(═O)NRaRb,
—C(═O)NRaRc,
—C(═O)NRaC1-4alkylene ORb
—C(═O)NRaC1-4alkylene Het, wherein Het represents a 5- or 6-membered heterocyclic group as defined above,
—ORa
—OC2-4alkylene NRaRb,
—OC1-4alkylene-CH(ORa)CH2 NRaRb,
—O—C1-4alkylene Het, wherein Het represents a 5- or 6-membered heterocyclic group as defined above,
—O—C2-4alkylene-ORa
—O—C2-4alkylene-NRa—C(═O)—ORb,
—NRaRb,
—NRaC1-4alkyleneNRaRb,
—NRaC(═O)Rb,
—NRaC(═O)NRaRb,
—N(SO2C1-4alkyl)2,
—NRa(SO2C1-4alkyl),
—SO2NRaRb, and
—OSO2trifluoromethyl;
R2 is selected from the group consisting of:
-hydrogen,
-halogen,
—ORa,
—C1-6 alkyl,
—NO2, and
—NRaRb,
or R1 and R2, together form a 3- or 4-membered alkylene or alkenylene chain, optionally containing at least one heteratom;
R3 is selected from the group consisting of:
-hydrogen,
-halogen,
—NO2,
-trifluoromethoxy,
—C1-6alkyl, and
—C(═O)ORa;
R4 is hydrogen,
or R3 and R4 together form a 3- or 4-membered alkylene or alkenylene chain, optionally containing at least one heteratom;
Ra and Rb, which may be the same or different, are independently selected from hydrogen and C1-6alkyl;
Rc represents phenyl or C4-6cycloalkyl, which phenyl or C4-6cycloalkyl can be optionally substituted by one or more halogen atoms, one or more —C(═O)ORa or one or more —ORa;
n is an integer selected from 1, 2 and 3;
m is an integer selected from 1 and 2;
and pharmaceutically acceptable salts and solvates (e.g. hydrates) thereof.
The terms alkyl or alkylene as used herein respectively contain the appropriate indicated number of carbon atoms and appropriately include straight chained and branched alkyl or alkylene groups, typically methyl, methylene, ethyl and ethylene groups, and straight chained and branched propyl, propylene, butyl and butylene groups. The term C2-6alkenylene as used herein contains 2 to 6 carbon atoms and appropriately includes straight chained and branched alkenylene groups, in particular ethenylene or the like.
The terms C4-6 cycloalkyl denotes cyclic groups containing 4 to 6 carbon atoms, namely cyclobutane, cyclopentane and cyclohexane.
The term halogen as used herein includes fluorine, chlorine, bromine and iodine.
The term 5- or 6-membered heterocyclic group as used herein includes 5- or 6-membered heterocycloalkyl and heteroaryl groups, e.g. tetrahydrofuranyl, piperidyl, piperazinyl pyrrolidinyl, morpholinyl, pyridyl, imidazolyl, furyl, and tetrazolyl.
Appropriately, Ro represents hydrogen. Alternatively Ro may represent halogen, in particular fluorine.
R1 may represent any of the substituents as hereinbefore described, or more particularly may represent any of —ORa, —O—C2-4alkyleneNRaRb, —O—C1-4alkyleneHet and —O—C2-4alkylene-ORa. In particular, R1 represents —O—C2-4alkylene NRaRb, wherein suitably C2-4alkylene may represent ethylene and aptly, Ra and Rb may independently represent methyl.
Particularly suitably R2 represents hydrogen. Alternatively, in the case where R1 and R2 together form a 3- or 4-membered alkylene or alkenylene chain optionally containing at least one heteratom as hereinbefore described, suitably R1 and R2 together form a methylenedioxy chain, an ethyleneoxy chain, an ethylenedioxy chain, an ethenyleneoxy chain, a propylene chain, a butylene chain or —NRa ethylene-O—. Aptly, R1 and R2 together form methylenedioxy, propylene or —N(CH3)—(CH2)2—O—.
Suitably R3 and R4, together form a 3- or 4-membered alkylene or alkenylene chain, optionally containing at least one heteratom as hereinbefore described. Particularly suitably R3 and R4 together form a methylenedioxy chain, an ethyleneoxy chain, an ethylenedioxy chain, an ethenyleneoxy chain, a propylene chain, a butylene chain or —NRaethylene-O—. Aptly R3 and R4 together form a methylenedioxy chain, an ethyleneoxy chain, an ethylenedioxy chain, an ethenyleneoxy chain or a propylene chain. In particular, R3 and R4 together form methylenedioxy or ethyleneoxy, most particularly ethyleneoxy.
A particular subgroup of compounds according to the present invention can be represented by formula (Ia)
Figure US06306870-20011023-C00003
wherein
R5 is selected from the group consisting of —OH, —OC2-4alkylene NRaRband O—C1-4alkylene Het, wherein Het is as hereinbefore described and
R6 represents
Figure US06306870-20011023-C00004
wherein C represents a 5- or 6-membered rn which may be saturated or partially or fully unsaturated and comprises carbon atoms and optionally one or two heteroatoms selected from oxygen, sulphur and nitrogen, optionally substituted by C1-4alkyl;
and pharmaceutically acceptable salts and solvates (e.g. hydrates thereof).
Typically, R5 represents —OC2-4alkylene NRaRb, in particular —OCH2CH2N(CH3)2. Alternatively, R5 may represent —O—C1-4alkylene Het, where Het may suitable be piperidyl, pyrrolidinyl (optionally substituted by C1-4alkyl, e.g. methyl) or morpholinyl.
Particularly aptly R6 represents
Figure US06306870-20011023-C00005
The compounds of formula (I) may contain one or more asymmetric centres and thus can exist as enantiomers or diastereoisomers. It is to be understood that the invention includes both mixtures and separate individual isomers of the compounds of formula (I).
The pharmaceutically acceptable salts of the compounds of formula (I) which contain a basic centre are acid addition salts formed with pharmaceutically acceptable acids. Examples include the hydrochloride, hydrobromide, sulphate or bisulphate, phosphate or hydrogen phosphate, acetate, benzoate, succinate, fumarate, maleate, lactate, citrate, tartrate, gluconate, methanesulphonate, benzenesulphonate and p-toluenesulphonate salts. Compounds of the formula (I) can also provide pharmaceutically acceptable metal salts, in particular alkali metal salts, with bases, Examples include the sodium and potassium salts.
Particular individual compounds of the invention include:
(E)-1-(1-Phenyl-1,3,4,9-tetrahydro-β-carbolin-2-yl)-3-phenylpropene-1-one
(E)-1-(1-Phenyl-1,3,4,9-tetrahydro-β-carbolin-2-yl)-3-(4-nitrophenyl)propene-1-one
(E)-1-(1-Phenyl-1,3,4,9-tetrahydro-β-carbolin-2-yl)-3-(4-trifluoromethylphenyl)propene-1-one
(E)-1-(1-Phenyl-1,3,4,9-tetrahydro-β-carbolin-2-yl)-3-(4-methoxyphenyl)propene-1 one
(E)-1-[1-(4-Methoxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(4-trifluoromethylphenyl)propene-1-one
(E)-N-[4-[3-Oxo-3-(1-phenyl-1,3,4,9-tetrahydro-β-carbolin-2-yl)propenyl]phenyl]acetamide
(E)-1-[1-(4-Methoxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)-3-phenylpropene-1-one
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-phenyl-propene-1-one
(E)-1-(1-Phenyl-1,3,4,9-tetrahydro-β-carbolin-2-yl)-3-(4-formylphenyl)propene-1-one
(E)-N-[4-[3-Oxo-3-(1-(4-nitrophenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)propenyl]-phenyl]acetamide
(E)-1-[1-(4-Nitrophenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-phenylpropene-1-one
(E)-1-[1-(4-Trifluoromethoxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-phenylpropene-1-one
(E)-1-[1-(4-Methylphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-phenylpropene-1-one
(E)-N-[4-[3-Oxo-3-(1-(3,4-methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)-propenyl]phenyl]acetamide
(E)-4-[3-Oxo-3-(1-phenyl-1,3,4,9-tetrahydro-β-carbolin-2-yl)-propenyl]benzoic acid, methyl ester
(E)-1-[1-(2-Chlorophenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-phenylpropene-1-one
(E)-1-(1-Phenyl-1,3,4,9-tetrahydro-β-carbolin-2-yl)-3-(3,4-Methylenedioxyphenyl)-propene-1-one
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(4-bromophenyl)propene-1-one
(E)-1-[1-(4-Chlorophenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-phenylpropene-1-one
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(4-ethoxyphenyl)propene-1-one
(E)-4-[3-Oxo-3-(1-(3,4-methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)propenyl]acetic acid, phenyl ester
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(4-hydroxyphenyl)propene-1-one
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(4-formylphenyl)propene-1-one
(E)-1-[4-[3-Oxo-3-(1-(3,4-methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)-propenyl]phenyl]-3-phenylurea
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(4-aminophenyl)propene-1-one
(E)-1-[1-(3,4-Methylenedioxy-phenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(4-nitro-phenyl)-propene-1-one
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-[(4-bis(methylsulfonyl)aminophenyl]propene-1-one
(E)-4-[3-Oxo-3-[1-(3,4-methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-propenyl]benzoic acid, methyl ester
(E)-N-[4-[3-Oxo-3-[1-(3,4-methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]propenyl]phenyl]methanesulfonamide
(E)-4-[3-Oxo-3-[1-(3,4-methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]propenyl]benzamide]
(E)-4-[3-Oxo-3-[1-(3,4-methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-propenyl]benzoic acid
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(4-cyanophenyl)propene-1-one
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(4-trifluoromethylphenyl)propene-1-one
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(3,4-methylenedioxyphenyl)propene-1-one
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(4-chlorophenyl)propene-1-one
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)-3-(4-trifluoromethoxyphenyl)propene-1-one
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(4-methylphenyl)propene-1-one
(E)-[4-[3-Oxo-3-(1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)propenyl]phenyl]urea
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(4-hydroxymethylphenyl)propene-1-one
(E)-N-Benzyl4-[3-oxo-3-(1-(3,4-methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)propenyl]benzamide
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(2,4-dichlorophenyl)propene-1-one
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(3-methoxy-4-hydroxyphenyl)propene-1-one
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(3-hydroxy-4-methoxyphenyl)propene-1-one
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(4-fluorophenyl)propene-1-one
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-indan-5-yl-1-propene-1-one
(E)-N-[4-[3-Oxo-3-(1-(3,4-methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)propenyl]benzoyl]benzenesulfonamide
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(3,4-dichlorophenyl)propene-1-one
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(3,4-dimethoxyphenyl)propene-1-one
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(3,4-dihydroxyphenyl)propene-1-one
(E)-N-Methyl-N-[4-(3-oxo-3-(1-(3,4-methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)propenyl]phenyl]acetamide
(E)-2,2-Dimethyl-N-[4-[3-Oxo-3-(1-(3,4-methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)propenyl]phenyl]propionamide
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(3,5-dimethoxyphenyl)propene-1-one
(E)-(N)-{4-[3-[1-(3,4-Methylenedioxyphenyl)-6-fluoro-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-oxopropenyl]phenyl}-acetamide
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(3,4 5-trimethoxyphenyl)propene-1-one
(E)-N-[4-[3-Oxo-3-(1-(3,4-methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)propenyl]phenyl]isobutyramide
(E)-1-[1-(3,4-Methylenedioxyphenyl)-6-fluoro-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-phenylpropene-1-one
(E)-N-(2-Methoxyethyl)-4-[3-oxo-3-(1-(3,4-methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)propenyl]benzamide
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9tetrahydro-β-carbolin-2-yl]-3-(3-hydroxyphenyl)propene-1-one
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(3-methoxyphenyl)propene-1-one
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(3-nitrophenyl)propene-1-one
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-[4-(2-dimethylaminoethoxy)phenyl]propene-1-one
(E)-N-(2-Morpholin-4-ylethyl)-4-[3-oxo-3-(1-(3,4-methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)propenyl]benzamide
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-[4-(1H-tetrazol-5-yl)phenyl]propene-1-one
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(3-aminophenyl)propene-1-one
(E)-N-Cyclohexyl-4-[3-oxo-3-(1-(3,4-methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)propenyl]benzamide
(E)-N-(Tetrahydrofuran-2-ylmethyl)-4-[3-oxo-3-(1-(3,4-methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)propenyl]benzamide
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(3-cyanophenyl)propene-1-one
(E)-N-(4-Piperidine-4-carboxylic acid, ethylester)4-[3-oxo-3-(1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)propenyl]benzamide
(E)-N-(4-Piperidine-4-carboxylic acid)-4-[3-oxo-3-(1-(3,4-methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)propenyl]benzamide
(E)-3-[3-Oxo-3-[1-(3,4-methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-propenyl]benzoic acid
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(3-(4-methylpiperazine-1-carbonyl)phenyl)propene-1-one
(E)-N-(2-Piperazin-1-ylethyl)-3-[3oxo-3-(1-(3,4-methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)propenyl]benzamide
(E)-4-[3-Oxo-3-(1-(3,4-methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)-propenyl]acetic acid ethyl ester
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(3-tetrazolophenyl)propene-1-one
(E)-2-[3-Oxo-3-[1-(3,4-methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-propenyl]benzoicacid, methyl ester
(E)-3-[3-Oxo-3-[1-(3,4-methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-propenyl]benzoic acid, methyl ester
(E)-1-(4-[3-Oxo-3-(1-(3,4-methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)-propenyl]phenyl)piperidine-4-carboxylic acid, ethyl ester
(E)-N-(1-Ethylpyrroidin-2-yl-methyl)-3-[3-oxo-3-(1-(3,4-methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)propenyl]benzamide
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(3-(2-dimethylaminoethoxy)phenyl)propene-1-one
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-y]-3-(3,5-diterbutyl-4-hydroxyphenyl)propene-1-one
(E)-3-[3-Oxo-3-[1-(4-methoxycarbonylphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]propenyl]benzoic acid, methyl ester
(E)-2-[3-Oxo-3-[1-(3,4-methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-propenyl]benzoic acid
(E)-(4-[3-Oxo-3-(1-(3,4-methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)propenyl]phenoxy)acetic acid, ethyl ester
(E)-(4-[3-Oxo-3-(1-(3,4-methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)-propenyl]phenyl)acetic acid
(E)-(4-[3-Oxo-3-(1-(3,4-methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)propenyl]phenoxy)acetic acid
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(3-nitro-4-chlorophenyl)propene-1-one
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(5-nitro-2-chlorophenyl)propene-1-one
(E)-3-Chloro-4-[3-oxo-3-[1-(3,4-methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]propenyl]benzoic acid, methyl ester
(E)-(4-[3-Oxo-3-(1-(3,4-methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)propenyl]benzyloxy)acetic acid
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(5-amino-2-chlorophenyl)propene-1-one
(E)-3-Chloro-4-[3oxo-3-[1-(3,4-methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]propenyl]benzoic acid
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(3,5-dibromo-4-hydroxyphenyl)propene-1-one
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(4-(2-dimethylaminopropoxy)phenyl)propene-1-one
(E)-2-Chloro-5-[3oxo-3-[1-(3,4-methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]propenyl]benzoic acid, methyl ester
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(4-(2-diisopropylaminoethoxy)phenyl)propene-1-one
(E)-2-Chloro-5-[3-oxo-3-[1-(3,4-methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]propenyl]benzoic acid
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(3-hydroxy-4-nitrophenyl)propene-1-one
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(3,5-dimethyl-4-hydroxyphenyl)propene-1-one
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(3-(2-dimethylaminoethoxy)4-nitrophenyl)propene-1-one
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(3-(2-dimethylaminoethoxy)-4-aminophenyl)propene-1-one
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(3-nitro-4-hydroxy-5-methoxyphenyl)propene-1-one
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(3-chlorophenyl)propene-1-one
(E)-1-[1-(4-Methoxy-phenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(2-chloro-5-nitrophenyl)propene-1-one
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(2,6-dichlorophenyl)propene-1-one
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(4-methylaminomethylphenyl)propene-1-one
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(3-methylphenyl)-propene-1-one
(E)-N-Methyl-(4-[3oxo-3-(1-(3,4-methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)propenyl]benzenesulfonamide
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(3-hydroxy-4-acetylphenyl)propene-1-one
(E)-1-[1-(2,3-Dihydrobenzofuran-5-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(2-chloro-5-nitrophenyl)propene-1-one
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(2-hydroxyphenyl)propene-1-one
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(3-nitro-2-piperidin-1-ylphenyl)propene-1-one
(E)-1-[1-(2,3-Dihydrobenzofuran-5-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-phenylpropene-1-one
(E)-1-[1-(4-isopropylphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(3-nitrophenyl)propene-1-one
(E)-1-[1-(2,3-Dihydrobenzofuran-5-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(3-nitrophenyl)propene-1-one
(E)-(R)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-βcarbolin-2yl]-3-phenylpropene-1-one
(E)-(S)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-phenylpropene-1-one
(E)-1-[1-(4-Methoxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3(3-nitrophenyl)propene-1-one
(E)-1-[1-(4-Methylphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(2-chloro-5-nitrophenyl)propene-1-one
(E)-N-(Tetrahydrofuran-2-ylmethyl)-3-[3-oxo-3-(1-(3,4-methylenedioxy)-1,3,4,9-tetrahydro-β-carbolin-2-yl)propenyl]benzamide
(E)-1-[1-(Indan-5-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-phenylpropene-1-one
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(3-acetylphenyl)propene-1-one
(E)-1-[1-(2,3-Dihydrobenzofuran-5-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)]-3-(4-(2-dimethylaminoethoxy)phenyl)propene-1-one
(E)-4-[3-Oxo-3-[1-(4-methoxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]propenyl]-benzoic acid, methyl ester
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(4-methyl-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl)propene-1-one
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(2-hydroxy-5-nitrophenyl)propene-1-one
(E)-4-[3-Oxo-3-[1-(2,3-dihydrobenzofuran-5-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]propenyl]benzoic acid, methyl ester
(E)-4-[3-Oxo-3-[1-(4-methoxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]propenyl]benzoic acid
(E)-4-[3-Oxo-3-[1-(2,3-dihydrobenzofuran-5-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]propenyl]benzoic acid
(E)-1-[1-(Benzofuran-5-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-phenylpropene-1-one
(E)-3-[3-Oxo-3-(1-(3,4-methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)-propenyl]phenyl)trifluoromethanesulfonic acid, phenyl ester
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-[4-(2-hydroxyethoxy)phenyl]propene-1-one
(E)-1-[1-(Benzofuran-5-yl-1,3,4,9-tetrahydro-β-carbolin-2-yl)]-3-(4-(2-dimethylaminoethoxy)phenyl)propene-1-one
(E)-1-[1 (3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(2-dimethylaminophenyl)propene-1-one
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(2-piperidin-1-ylphenyl)propene-1-one
(E)-4-[3-Oxo-3-[1-(benzofuran-5-yl-1,3,4,9-tetrahydro-β-carbolin-2-yl]-propenyl]benzoic acid, methyl ester
(E)-4-[3-(1-Benzofuran-5-yl-1,3,4,9-tetrahydro-β-carbolin-2-yl)-3-oxo-propenyl]benzoic acid
(E)-4-[3-Oxo-3-(1-(3,4-methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)propenyl]phenyl)trifluoromethanesulfonic acid, phenyl ester
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(2-(2-dimethylaminoethoxy)phenyl)propene-1-one
(E)-1-[1-(3-Fluoro-4-methoxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-phenylpropene-1-one
(E)-(R)-1-[1-(2,3-Dihydrobenzofuran-5-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)]-3-(4-(2dimethylaminoethoxy)phenyl)propene-1-one
(E)-1-(2,3-Dihydrobenzo[1,4]dioxin6-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl1-3-phenylpropene-1-one
(E)-1-[1-(2,3-Dihydrobenzofuran-5-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)]-3-(4-(2-pyrrolidin-1-ylethoxy)phenyl)propene-1-one
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-[4-pyrrolidin-1-ylphenyl]propene-1-one
(E)-(R)-1-[1-(2,3-Dihydrobenzofuran-5-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(3-nitrophenyl)propene-1-one
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-[4-imidazol-1-ylphenyl]propene-1-one
(E)-4-[3-[1-(2,3-Dihydrobenzo[1,4]dioxin-6-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-oxopropenyl]benzoic acid, methyl ester
(E)-1-[1-(2,3-Dihydrobenzo[1,4]dioxin-6-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(3-nitrophenyl)propene-1-one
(E)-1-[1-(2,3-Dihydrobenzo[1,4]dioxin-6-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)]-3-(4-(2-dimethylaminoethoxy)phenyl)propene-1-one
(E)-1-[1-(3-Fluoro-4-methoxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)]-3-(4-(2-dimethylaminoethoxy)phenyl)propene-1-one
(E)-4-[3-[1-(2,3-Dihydrobenzo[1,4]dioxin-6-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-oxopropenyl]benzoic acid
(E)-(R)-1-[1-(2,3-Dihydrobenzofuran-5-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-phenylpropene-1-one
(E)-(S)-1-[1-(2,3-Dihydrobenzofuran-5-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)]-3-(4-(2-dimethylaminoethoxy)phenyl)propene-1-one
(E)-1-[1-(2,3-Dihydrobenzofuran-5-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(4-aminophenyl)propene-1-one
(E)-(S)-1-[1-(2,3-Dihydrobenzofuran-5-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-phenylpropene-1-one
(E)-(S)-1-[1-(2,3-Dihydrobenzofuran-5-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(3-nitrophenyl)propene-1-one
(E)-(R)-1-[1-(2,3-Dihydrobenzofuran-5-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)]-3-(4-(1-(S)-methylpyrrolidin-2-yl-methoxy)phenyl)propene-1-one
(E)-(R)-1-[1-(2,3-Dihydrobenzofuran-5-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(3-hydroxyphenyl)propene-1-one
(E)-(R)-1-[1-(2,3-Dihydrobenzofuran-5-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)]-3-(4-(2-dimethylamino-1-methylethoxy)phenyl)propene-1-one
(E)-1-(1-Phenyl-1,3,4,9-tetrahydro-β-carbolin-2-yl)-3-(4-(4-methylpyperazin-1-yl)-phenyl)propene-1-one
(E)-(R)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)]-3-(4-(1-(S)-methylpyrrolidin-2-yl-methoxy)phenyl)propene-1-one
(E)-(R)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)]-3-(4-(2-dimethylamino-1-methylethoxy)phenyl)propene-1-one
(E)-(R)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)]-3-(4-(2-dimethylaminopropoxy)phenyl)propene-1-one
(E)-4-[3-Oxo-3-[1-(3,4-fluorophenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]propenyl]benzoic acid, methyl ester
(E)-(R)-[1-(2,3-Dihydrobenzofuran-5-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)]-3-(4-(2-diethylaminoethoxy)phenyl)propene-1-one
(E)-(R)1-[1-(2,3-Dihydrobenzofuran-5-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)]-3-(4-(2-dimethylaminopropoxy)phenyl)propene-1-one
(E)-4-[3-Oxo-3-[1-(3,4-difluorophenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]propenyl]-benzoic acid
(E)-(R)-1-[1-(2,3-Dihydrobenzofuran-5-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(4-aminophenyl)propene-1-one
(E)-(R)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(4-aminophenyl)propene-1-one
(E)-(R)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)]-3-(4-(2-pyrrolidin-1-ylethoxy)phenyl)propene-1-one
(E)-(R)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)]-3-(4-(2-diethylaminoethoxy)phenylpropene-1-one
(E)-1-[1-(3-Fluoro-4-methoxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)]-3-(3-nitrophenyl)propene-1-one
(E)-(R)-1-[1-(2,3-Dihydrobenzofuran-5-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(4-trifluoromethylphenyl)propene-1-one
(E)-(R)-1-[1-(2,3-Dihydrobenzofuran-5-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(3-trifluoromethylphenyl)propene-1-one
(E)-(R)-1-[1-(2,3-Dihydrobenzofuran-5-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(4-(2-morpholin-4-ylethoxy)phenyl)propene-1-one
(E)-(R)-1-[1-(2,3-Dihydrobenzofuran-5-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(4-(2-(ethylmethylamino)ethoxy)phenyl)propene-1-one
(E)-1-[1-(2,3-Dihydrobenzofuran-5-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(4-(3-(dimethylamino)propenyl)phenyl)propene-1-one
(E)-(R)-1-[1-(2,3-Dihydrobenzofuran-5-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(4-(3-dimethylamino-2-hydroxypropoxy)phenyl)propene-1-one
(E)-(R)-1-(1-(2,3-Dihydrobenzofuran-5-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)-3-(4-formylphenyl)propene-1-one
(E)-(R)-1-[1-(2,3-Dihydrobenzofuran-5-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(4-propylaminomethyl)phenyl)propene-1-one
(E)-(R)-1-[1-(2,3-Dihydrobenzofuran-5-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-[4-(2-dimethylaminoethylamino)phenylpropene-1-one
(E)-(R)-1-[1-(2,3-Dihydrobenzofuran-5-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(4-(2-aminoethoxy)phenyl)propene-1-one
(E)-(R)-1-[1-(2,3-Dihydrobenzofuran-5-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(4-hydroxyphenyl)propene-1-one
(E)-(R)-1-[1-(2,3-Dihydrobenzofuran-5-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(4-(4-methylpiperazin-1-yl)phenylpropene-1-one
(E)-(R)-1-[1-(2,3-Dihydrobenzofuran-5-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(4-methylaminomethyl)phenyl)propene-1-one
(E)-(R)-1-[1-(2,3-Dihydrobenzofuran-5-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(4-isopropylaminomethyl)phenyl)propene-1-one
(E)-(R)-1-[1-(2,3-Dihydrobenzofuran-5-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(4-dimethylaminomethyl)phenyl)propene-1-one
(E)-(R)-1-[1-(2,3-Dihydrobenzofuran-5-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-[4-(3-dimethylaminopropoxy)phenyl]propene-1-one
(E)-(R)-1-[1-(2,3-Dihydrobenzofuran-5-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(4-(2-piperidin-1-ylethoxy)phenyl)propene-1-one
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)-3-(4-(2-piperidin-1-ylethoxy)phenyl]propene-1-one
(E)-(R)-[2-(4-{3-[1-(2,3-Dihydrobenzofuran-5-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-oxopropenyl}phenoxy)ethyl]methylcarbamic acid, tertbutyl ester
(E)-(R)-1-[1-(2,3-Dihydrobenzofuran-5-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-[4-(2-methylaminoethoxy)phenyl]propene-1-one
and pharmaceutically acceptable salts and solvates (e.g. hydrates) thereof. A specific compound of the invention is:
(E)-(R)-1-[1-(2,3-Dihydrobenzofuran-5-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)]-3-(4-(2-dimethylaminoethoxy)phenyl)propene-1-one and pharmaceutically acceptable salts and solvates (e.g. hydrates) thereof.
It has been shown that compounds of the present invention are potent and selective inhibitors of cGMP specific PDE. Thus, compounds of formula (I) are of interest for use in therapy, specifically for the treatment of a variety of conditions where inhibition of cGMP specific PDE is thought to be beneficial.
As a consequence of the selective PDE 5 inhibition exhibited by compounds of the present invention, cGMP levels are elevated, which in turn can give rise to beneficial anti-platelet, anti-neutrophil, anti-vasospastic, vasodilatory, natriuretic and diuretic activities as well as potentiation of the effects of endothelium-derived relaxing factor (EDRF), nitrovasodilators, atrial natriuretic factor (ANF), brain natriuretic peptide (BNP), C-type natriuretic peptide (CNP) and endothelium-dependent relaxing agents such as bradykinin, acetylcholine and 5-HT1. The compounds of formula (I) therefore have utility in the treatment of a number of disorders, including stable, unstable and variant (Prinzmetal) angina, hypertension, pulmonary hypertension, congestive heart failure, renal failure, atherosclerosis, conditions of reduced blood vessel patency (e.g. post-percutaneous transluminal coronary angioplasty), peripheral vascular disease, vascular disorders such as Raynaud's disease, inflammatory diseases, stroke, bronchitis, chronic asthma, allergic asthma, allergic rhinitis, glaucoma, erectile dysfunction and diseases characterised by disorders of gut motility (e.g. irritable bowel syndrome).
It will be appreciated that references herein to treatment extend to prophylaxis as well as treatment of established conditions.
It will also be appreciated that a compound of formula (I), or a physiologically acceptable salt or solvate thereof can be administered as the raw compound, or as a pharmaceutical composition containing either entity.
There is thus provided as a further aspect of the invention a compound of formula (I) for use in the treatment of stable, unstable and variant (Prinzmetal) angina, hypertension, pulmonary hypertension, chronic obstructive pulmonary disease, congestive heart failure, renal failure, atherosclerosis, conditions of reduced blood vessel patency, (e.g. post-PTCA), peripheral vascular disease, vascular disorders such as Raynaud's disease, inflammatory diseases. stroke. bronchitis, chronic asthma, allergic asthma, allergic rhinitis, glaucoma, erectile dysfunction or diseases characterised by disorders of gut motility (e.g. IBS).
According to another aspect of the invention, there is provided the use of a compound of formula (I) for the manufacture of a medicament for the treatment of stable, unstable and variant (Prinzmetal) angina, hypertension, pulmonary hypertension, chronic obstructive pulmonary disease, congestive heart failure, renal failure, atherosclerosis, conditions of reduced blood vessel patency, (e.g. post-PTCA), peripheral vascular disease, vascular disorders such as Raynaud's disease, inflammatory diseases, stroke, bronchitis, chronic asthma, allergic asthma, allergic rhinitis, glaucoma, erectile dysfunction or diseases characterised by disorders of gut motility (e.g. IBS).
In a further aspect, the invention provides a method of treating stable, unstable and variant (Prinzmetal) angina, hypertension, pulmonary hypertension, chronic obstructive pulmonary disease, congestive heart failure, renal failure, atherosclerosis, conditions of reduced blood vessel patency, (e.g. post-PTCA), peripheral vascular disease, vascular disorders such as Raynaud's disease, inflammatory diseases, stroke, bronchitis, chronic asthma, allergic asthma, allergic rhinitis, glaucoma, erectile dysfunction or diseases characterised by disorders of gut motility (e.g. IBS) in a human or non-human animal body which comprises administering to said body a therapeutically effective amount of a compound with formula (I).
Compounds of the invention may be administered by any suitable route, for example by oral, buccal, sub-lingual, rectal, vaginal, nasal, topical or parenteral (including intravenous, intramuscular, subcutaneous and intracoronary) administration. Oral administration is generally preferred.
For administration to man in the curative or prophylactic treatment of the disorders identified above, oral dosages of a compound of formula (I) will generally be in the range of from 0.5-800 mg daily for an average adult patient (70 kg). Thus for a typical adult patient, individual tablets or capsules contain from 0.2-400 mg of active compound, in a suitable pharmaceutically acceptable vehicle or carrier, for administration in single or multiple doses, once or several times per day. Dosages for intravenous, buccal or sublingual administration will typically be within the range of from 0.1-400 mg per single dose as required. In practice the physician will determine the actual dosing regimen which will be most suitable for an individual patient and it will vary with the age, weight and response of the particular patient. The above dosages are exemplary of the average case but there can be individual instances in which higher or lower dosage ranges may be merited, and such are within the scope of this invention.
For human use, a compound of the formula (I) can be administered alone, but will generally be administered in admixture with a pharmaceutical carrier selected with regard to the intended route of administration and standard pharmaceutical practice. For example, the compound may be administered orally, buccally or sublingually, in the form of tablets containing excipients such as starch or lactose, or in capsules or ovules either alone or in admixture with excipients, or in the form of elixirs or suspensions containing flavouring or colouring agents. Such liquid preparations may be prepared with pharmaceutically acceptable additives such as suspending agents (e.g. methylcellulose, a semi-synthetic glyceride such as witepsol or mixtures of glycerides such as a mixture of apricot kernel oil and PEG-6 esters or mixtures of PEG-8 and caprylic/capric glycerides). A compound may also be injected parenterally, for example intravenously, intramuscularly, subcutaneously or intracoronarily. For parenteral administration, the compound is best used in the form of a sterile aqueous solution which may contain other substances, for example salts, or monosaccharides such as mannitol or glucose, to make the solution isotonic with blood.
Thus, the invention provides in a further aspect a pharmaceutical composition comprising a compound of the formula (I) together with a pharmaceutically acceptable diluent or carrier therefor.
There is further provided by the present invention a process of preparing a pharmaceutical composition comprising a compound of formula (I), which process comprises mixing a compound of formula (I) together with a pharmaceutically acceptable diluent or carrier therefor.
A compound of formula (I) may also be used in combination with other therapeutic agents which may be useful in the treatment of the above-mentioned disease states. The invention thus provides, in another aspect, a combination of a compound of formula (I) together with another therapeutically active agent.
The combination referred to above may conveniently be presented for use in the form of a pharmaceutical formulation and thus pharmaceutical compositions comprising a combination as defined above together with a pharmaceutically acceptable diluent or carrier comprise a further aspect of the invention.
The individual components of such a combination may also be administered either sequentially or simultaneously in separate pharmaceutical formulations.
Appropriate doses of known therapeutic agents for use in combination with a compound of formula (I) will be readily appreciated by those skilled in the art.
Compounds of formula (I) may be prepared by any suitable method known in the art or by the following processes which form part of the present invention. In the methods below Ro, R1,R2, R3, and R4 are are as defined in formula (I) above unless otherwise indicated.
There is a further provided by the present invention a process (A) of preparing a compound of formula (I), which process comprises reacting compounds of formula (II) and (III)
Figure US06306870-20011023-C00006
where X represents a hydroxyl or halogen group.
Suitably the reaction is carried out in the presence of 1,3-dicyclohexylcarbodiimide (DCC) or 1-(3-dimethylaminopropyl)-3-ethylcarbodiumide (EDCI) and 1-hydroxybenzotriazole (HOBT) in a suitable organic solvent, such as dimethylformamide (DMF) or dichloromethane (DCM) for several hours, e.g. 8 hours to 2 days.
Compounds of formula (I) may be prepared as individual enantiomers from the appropriate enantiomer of formula (II) or as a racemic mixture from the appropriate racemic compound of formula (II). Individual enantiomers of the compounds of the invention may be prepared from racemates by resolution using methods known in the art for the separation of racemic mixtures into their constituent enantiomers, for example using HPLC on a chiral column such as Hypersil naphtyl urea or using separation of salts of diastereoisomers.
A compound of formula (II) may be prepared by Pictet-Spengler cyclization between a tryptamine derivative of formula (IV) and an aldehyde of formula (V)
Figure US06306870-20011023-C00007
The reaction may conveniently be effected in a suitable solvent such as a halogenated hydrocarbon (e.g. dichloromethane) or an aromatic hydrocarbon (e.g. toluene) in the presence of an acid such as trifluoroacetic acid (TFA). The reaction may conveniently be carried out at a temperature of from 20° C. to reflux to provide a compound of formula (II) in one step. The reaction may also be carried out in a solvent such as an aromatic hydrocarbon (e.g. toluene) under reflux optionally using a Dean-stark apparatus to trap the water produced.
The reaction provides racemic compounds of formula (II). Enantiomers may be obtained from a resolution with N-acetyl leucine using fractional crystallization in EtOAc:MeOH as solvent. (R) and (S) enantiomers may be isolated as salts depending upon whether N-acetyl-(D) and (L)-leucine was used as the starting material.
Compounds of formulae (IV) and (V) are commercially available compounds or prepared by standard synthetic techniques as hereinafter described in the Examples.
A compound of formula (III) can be prepared from a corresponding aldehyde of formula (VI)
Figure US06306870-20011023-C00008
suitably by employing a Wittig reaction followed by basic hydrolysis.
Alternatively a compound of formula (III) may be prepared from a compound of formula (VI) by a Knoevenhagel reaction employing malonic acid.
Compounds of formula (VI) can be prepared from known corresponding alcohol, nitrile, or halide derivatives, using techniques well known in the art of synthetic organic chemistry.
According to a further general process (B) compounds of formula (I) can be converted to alternative compounds of formula (I), employing suitable interconversion techniques such as hereinafter described in the Examples.
Compounds of this invention may be isolated in association with solvent molecules by crystallization from or evaporation of an appropriate solvent.
The pharmaceutically acceptable acid addition salts of the compounds of formula (I) which contain a basic centre may be prepared in a conventional manner. For example, a solution of the free base may be treated with a suitable acid, either neat or in a suitable solution, and the resulting salt isolated either by filtration or by evaporation under vacuum of the reaction solvent. Pharmaceutically acceptable base addition salts may be obtained in an analogous manner by treating a solution of a compound of formula (I) with a suitable base. Both types of salt may be formed or interconverted using ion-exchange resin techniques.
Thus, according to a further aspect of the invention, we provide a process for preparing a compound of formula (I) or a salt or solvate (e.g. hydrate) thereof which comprises process (A) or (B) as hereinbefore described followed by
i) salt formation, or
ii) solvate (e.g. hydrate) formation.
The following additional abbreviations are hereinafter used in the accompanying examples: rt (room temperature), DMSO (dimethylsulphoxide), NBS (N-bromosuccinimide), THF (tetrahydrofuran), TFA (trifluoroacetic acid), PTSA (p-toluene sulphonic acid), AIBN (2,2′-azobis isobutyronitrile), and TBDMSCl (tert-butyldimethylsilyl chloride).
Intermediate 1
1-Phenyl-2,3,4,9-tetrahydro-1H-β-carboline
A solution of tryptamine (15 g, 94.0 mmol) and benzaldehyde (10.9 g, 1.1 equiv.) in DCM (800 mL) was treated with TFA (15 mL, 2 equiv.). The resulting mixture was stirred at rt for one day and then neutralized to pH 7 with a saturated aqueous solution of sodium carbonate. After filtration and concentration to dryness the residue was recrystallized from 2-propanol to give the title compound (11.0 g, 47%) as white crystals.
MP: 175-177° C.
Intermediate 2
1-(4-Methoxyphenyl)-2,3,4,9-tetrahydro-1H-β-carboline
This product was prepared using the same procedure as for Intermediate 1 with tryptamine (15 g, 94.9 mmol), 4-methoxybenzaldehyde (12.9 g, 1.1 equiv.) and TFA (14.6 mL, 2 equiv.) to give the title compound (20.9 g, 80%) as a brownish powder.
MP: 131° C.
Intermediate 3
1-(4-Nitrophenyl)-2,3,4,9-tetrahydro-1H-β-carboline
This product was prepared using the same procedure as for Intermediate 1 with tryptamine (2.0 g, 12.5 mmol), 4-nitrobenzaldehyde (1.88 g, 1 equiv.) and TFA (1.9 mL, 2 equiv.) to give the title compound (3.1 g, 86%) as a yellow powder.
MP: 190° C.
Intermediate 4
1-(4-Trifluoromethoxyphenyl)-2,3,4,9-tetrahydro-1H-β-carboline
This product was prepared using the same procedure as for Intermediate 1 with tryptamine (2.0 g, 12.5 mmol), 4-trifluoromethoxybenzaidehyde (2.4 g, 1 equiv.) and TFA (1.9 mL, 2 equiv.) to give the title compound (1.6 g, 38%) as a white powder.
MP: 68-69° C.
Intermediate 5
1-(4-Chlorophenyl)-2,3,4,9-tetrahydro-1H-β-carboline
This product was prepared using the same procedure as for Intermediate 1 with tryptamine (5.0 g, 30 mmol), 4-chlorobenzaldehyde (4.6 g, 1 equiv.) and TFA (4.6 mL, 2 equiv.) to give the title compound (4.16 g, 49%) as a white powder.
MP: 161° C.
Intermediate 6
1-(4-Methylphenyl)-2,3,4,9-tetrahydro-1H-β-carboline
This product was prepared using the same procedure as for Intermediate 1 with tryptamine (1.0 g, 6.2 mmol), 4-methylbenzaldehyde (0.74 g, 1 equiv.) and TFA (1 mL, 2 equiv.) to give the title compound (1.6 g, 100%) as a white powder.
MP: 207-209° C.
Intermediate 7
1-(3,4-Methylenedioxyphenyl)-2,3,4,9-tetrahydro-1H-β-carboline
This product was prepared using the same procedure as for Intermediate 1 with tryptamine (20.0 g, 120 mmol), 3,4-methylenedioxybenzaldehyde (20.6 g, 1.1 equiv.) and TFA (18 mL, 2 equiv.) to give the title compound (22 g, 60%) as white crystals after recrystallization from ethanol.
MP: 178° C.
Intermediate 8
4-(2,3,4,9-Tetrahydro-1H-β-carbolin-1-yl)benzoic Acid, Methyl Ester
This product was prepared using the same procedure as for Intermediate 1 with tryptamine (2.8 g, 17.4 mmol), 4-formylbenzoic acid, methyl ester (2.87 g, 1.1 equiv.) and TFA (2.7 mL, 2 equiv.) to give the title compound (0.5 g, 9%) as white crystals after recrystallization from isopropanol:H2O.
MP: 179° C.
Intermediate 9
1-Indan-5-yl-2,3,4,9-tetrahydro-1H-β-carboline
This product was prepared using the same procedure as for Intermediate 1 with tryptamine (1.28 g, 8.0 mmol), indan-5-carboxaldehyde (1.3 g, 1.1 equiv.) and TFA (1.2 mL, 2 equiv.) to give the title compound (0.36 g, 14%).
1H NMR (CDCl3) δ7.6 (s, 1H), 7.4 (m, 1H), 6.9-7.2 (m, 6H), 5.1 (s, 1H), 3.3-3.4 (m, 1H), 2.9-3.1 (m, 1H), 2.7-2.9 (m, 6H), 1.9-2.2 (q, 2H).
Intermediate 10
1-(2,3-Dihydrobenzofuran-5-yl)-2,3,4,9-tetrahydro-1H-β-carboline
This product was prepared using a two-step procedure. A solution of tryptamine (32.4 g, 0.2 mol) and 2,3-dihydrobenzofuran-5-carboxaldehyde (30.0 g, 1 equiv.) in toluene (1 L) was heated under reflux for 4 hours. After removal of 4 mL of water and evaporation of toluene the residue was dissolved in DCM (1 L) in the presence of TFA (31 mL, 2 equiv.). The resulting mixture was stirred at rt for 16 hours. Then 1 L of a saturated aqueous solution of NaHCO3 was added. After extraction with DCM and drying over MgSO4, the organic solution was evaporated in vacuo. Recrystallization from DCM:iPr2O (2:30) gave the title compound as white crystals in a 80% yield.
1H NMR (CDCl3) δ7.6 (s, 1H), 7.5-7.6 (m, 1H), 7-7.3 (m, 5H), 6.7-6.75 (d, 1H), 5.1 (s, 1H), 4.5-4.6 (t, 2H), 3.3-3.45 (m, 1H), 3.05-3.2 (t, 3H), 2.7-3 (m, 2H).
Intermediate 11
1-(4-Isopropylphenyl)-2,3,4,9-tetrahydro-1H-β-carboline
This product was prepared using the same procedure as for Intermediate 1 with tryptamine (5.0 g, 31.2 mmol), 4-isopropylbenzaldehyde (5.08 g, 1.1 equiv.) and TFA (4.8 mL, 2 equiv.) to give the title compound (5.9 g, 67%) as white crystals after recrystallization from iPr2O.
MP: 146° C.
Intermediate 12
1-(2,3-Benzofuran-5-yl)-2,3,4,9-tetrahydro-1H-β-carboline
This product was prepared using the same procedure as for Intermediate 1 with tryptamine (2.27 g, 14.1 mmol), 2,3-benzofuran-5-carboxaldehyde (2.1 g, 1 equiv., prepared according to the procedure of Dom, C.P et al EP 481671A1) and TFA (2.2 mL, 2 equiv.) to give the title compound (3.0 g, 74%) as white crystals after recrystallization from cyclohexane.
MP: 134-136° C.
Intermediate 13
1-(2,3-Dihydrobenzo[1.4]dioxin6-yl)-2,3,4,9-tetrahydro-1H-β-carboline
This product was prepared using the same procedure as for Intermediate 1 with tryptamine (4,92 g, 30.7 mmol), 2,3-dihydrobenzo[1,4]dioxin-6-carboxaldehyde (5.05 g, 1.0 equiv.) and TFA (5.0 mL, 2 equiv.) to give the title compound (7.05 g, 75%) as white crystals after recrystallization from iPr2O.
MP: 144° C.
Intermediate 14
1-(3-Fluoro-4-methoxyphenyl)-2,3,4,9-tetrahydro-1H-β-carboline
This product was prepared using the same procedure as for Intermediate 1 with tryptamine (4.80 g, 30.0 mmol), 3-fluoro4-methoxybenzaldehyde (4.86 g, 1.05 equiv.) and TFA (4.6 mL, 2 equiv.) to give the title compound (5.2 g, 59%) as white crystals.
MP: 68° C.
Intermediate 15
1-(3,4-Difluorophenyl)-2,3,4,9-tetrahydro-1H-β-carboline
This product was prepared using the same procedure as for Intermediate 1 with tryptamine (5.4 g, 33.5 mmol), 3,4-difluorobenzaldehyde (5.0 g, 1.05 equiv.) and TFA (5.2 mL, 2 equiv.) to give the title compound (7.8 g, 82%) as white crystals.
MP: 151° C.
Intermediate 16
1-(3,4-Methylenedioxyphenyl)-4-fluoro-2,3,4,9-tetrahydro-1H-β-carboline
This product was prepared using the same procedure as for Intermediate 1 with 5-fluorotryptamine (1.59 g, 8.9 mmol), 3,4-methylenedioxybenzaldehyde (1.47 g, 1.1 equiv.) and TFA (1.4 mL, 2 equiv.) to give the title compound (2,34 g, 85%) as white crystals.
MP: 172° C.
Analysis for C18H15FN2O2:
Calculated: C,69.67; H,4.87; N,6.12.
Found: C,69.47; H,4.85; N,6.23%
Intermediate 17
1-(2-Chlorophenyl)-2,3,4,9-tetrahydro-1H-β-carboline
This product was prepared using the same procedure as for Intermediate 1 with tryptamine (1.0 g, 6.2 mmol), 2-chlorobenzaldehyde (0.7 mL, 1.0 equiv.) and TFA (1.0 mL, 2 equiv.) to give the title compound (1.2 g, 69%).
1H NMR (CDCl3) δ7.6 (s, 1H), 7.45 (d, 1H), 7.40 (d, 1H), 6.9-7.2 (m, 6H), 5.6 (s, 1H), 3.2-3.0 (m, 2H), 2.9-2.7 (m, 2H), 2.4 (s, 1H).
Intermediate 18
(S)-1-(3,4-Methylenedioxyphenyl)-2,3,4,9-tetrahydro-1H-β-carboline
(S)-1-(3,4-Methylenedioxyphenyl)-2,3,4,9-tetrahydro-1H-β-carboline was obtained from the resolution of the corresponding racemic amine with N-acetyl-(L)-Leucine (Sigma) in MeOH followed by a recrystallization from MeOH. Treatment of the suspension of the recrystallized material in DCM with a saturated aqueous solution of NaHCO3 gave the enantiomerically pure (S)-1-(3,4-methylenedioxyphenyl)-2,3,4,9-tetrahydro-1H-β-carboline as beige crystals in a 55% yield.
MP: 173° C.
Analysis for C18H16N2O2. 0.35H2O:
Calculated: C,72.39; H,5.64; N,9.38.
Found: C,72,35; H,5.44; N,9.1%.
[α]D 19.6=−35 (c=0.53, MeOH).
Intermediate 19
(R)-1-(3,4-Methylenedioxyphenyl)-2,3,4,9-tetrahydro-1H-β-carboline
Following the same protocol as for Intermediate 18 (R)-1-(3,4-methylenedioxyphenyl)-2,3,4,9-tetrahydro-1H-β-carboline was obtained from the resolution of the corresponding racemic amine with N-acetyl-(D)-Leucine (Sigma) in MeOH followed by a recrystallization from MeOH. Treatment of the suspension of the recrystallized material in DCM with a saturated aqueous solution of NaHCO3 gave the enantiomerically pure (R)-1-(3,4-methylenedioxyphenyl)-2,3,4,9-tetrahydro-1H-β-carboline as white crystals in a 59% yield.
MP: 92-94° C.
Analalysis for C18H16N2O2:
Calculated: C,73.95; H,5.52; N,9.58.
Found: C,73.72; H,5.52; N,9.52%.
[α]D 21=34(c=0.50, MeOH).
Intermediate 20
(R)-1-(2,3-Dihydrobenzofuran-5-yl)-2,3,4,9-tetrahydro-1H-β-carboline
Following the same protocol as for Intermediate 18 (R)-1-(2,3-dihydrobenzofuran-5-yl)-2,3,4,9-tetrahydro-1H-β-carboline was obtained from the resolution of the corresponding racemic amine with N-acetyl-(D)-Leucine (Sigma) in MeOH:EtOAc followed by a recrystallization from MeOH. Treatment of the suspension of the recrystallized material in DCM with a saturated aqueous solution of NaHCO3 gave the enantiomerically pure (R)-1-(2,3-dihydrobenzofuran-5-yl)-2,3,4,9-tetrahydro-1H-β-carboline as white crystals in a 55% yield.
MP: 98-99° C.
Analysis for C19H18N2O. 0.15H2O:
Calculated: C,77.87; H,6.29; N,9.56.
Found: C,77.83; H,6.33; N,9.44%
[α]D 21=42 (c=0.50, MeOH).
Intermediate 21
(S)-1-(4-(2,3-Dihydrobenzo(b)furan)-2,3,4,9-tetrahydro-1H-β-carboline
Following the same protocol as for Intermediate 18 (S)-1-(2,3-dihydrobenzofuran-5-yl)-2,3,4,9-tetrahydro-1H-β-carboline was obtained from the resolution of the corresponding racemic amine with N-acetyl-(L)-Leucine (Sigma) in MeOH/EtOAc followed by a recrystallization from MeOH. Treatment of the suspension of the recrystallized material in DCM with a saturated aqueous solution of NaHCO3 gave the enantiomerically pure (S)-1-(2,3-dihydrobenzofuran-5-yl)-2,3,4,9-tetrahydro-1H-β-carboline as a pale yellow powder in a 45% yield.
MP: 175° C.
Analalysis for C19H18N2O. 1.0H2O:
Calculated: C,74.0; H,6.54; N,9.08.
Found: C,74.01; H,5.88; N,8.92%.
[α]D 19.7=49 (c=0.50, MeOH).
Intermediate 22
(E)-3-(4-Ureidophenyl)acrylic Acid
A stirred solution of (E)-3-(4-aminophenyl)acrylic acid (1.0 g, 5.0 mmol) and potassium isocyanate (2.0 g, 5 equiv.) in a mixture of water and acetic acid (50 mL) was heated at 100° C. for 12 hours. After cooling, a white solid precipitated out. Filtration, washing of the filter cake with a mixture of water and MeOH, and drying it in vacuo gave the title compound (0.82 g, 80%) as a white solid.
MP>350° C.
Intermediate 23
(E)-3-(4-Acetylmethylaminophenyl)acrylic Acid
A stirred solution of N-(4-formylphenyl)-N-methylacetamide (1.0 g, 5.64 mmol), malonic acid (1.06 g, 1.8 equiv.) and piperidine (0.1 g, catalytic amount) in pyridine (3.5 mL) was heated at 60° C. for 12 hours. Pouring the resulting mixture into HCl (1N) gave a precipitate. Filtration gave the title compound (1.2 g, 98%) as a white solid.
MP: 213-215° C.
Analysis for C12H13NO3. 0.2H2O:
Calculated: C,64.68; H,6.06; N,6.29;
Found: C,64.43; H,6.18; N,6.36%.
N-(4-Formylphenyl)-N-methylacetamide (1.0 g, 46%) was obtained as an oil from N-(4-formylphenyl)acetamide (2.0 g, 12.2 mmol) in THF in the presence of iodomethane (1.2 mL, 1.5 equiv.) and NaH (0.73 g, 1.5 equiv., 60% in mineral oil).
1H NMR (CDCl3, 250 MHz) δ2.0 (s, 3H), 3,4 (s, 3H), 7.4 (d, 2H), 8.0 (d, 2H).
Intermediate 24
(E)-3-[4-(2-Methoxyethylcarbambyl)phenyl]acrylic Acid
The same method was employed as in the preparation of Intermediate 23 but starting from 4-formyl-N-(2-methoxyethyl)benzamide to give the title compound as a white powder in a 57% yield.
MP: 205° C.
4-Formyl-N-(2-methoxyethyl)benzamide (158 mg, 48%) was obtained by oxidation of 4-hydroxymethyl-N-(2-methoxyethyl)benzamide (330 mg, 1.6 mmol) in DCM in the presence of MnO2 (3.0 g, 22 equiv.).
1H NMR (CDCl3, 250 MHz) δ9.9 (s, 1H), 7.8 (s, 4H), 6.8 (s, 1H), 3.4-3.6 (m, 4H), 3.2 (s, 3H).
4-Hydroxymethyl-N-(2-methoxyethyl)benzamide (330 mg, 14%) was obtained as an oil (Rf=0.7, DCM:MeOH (9:1)) by coupling 4-(hydroxymethyl)benzoic acid (1.0 g, 6.5 mmol) with 2-methoxyethylamine (0.6 mL, 6.5 mmol) in the presence of Et3N (0.95 mL, 1.0 equiv.), EDCl (1.2 g, 1.0 equiv.) and HOBT (0.88 g, 1.0 equiv.).
Intermediate 25
(E)-[4-(2-Dimethylaminoethoxy)phenyl]acrylic Acid
The same method was employed as in the preparation of Intermediate 23 but starting from 4-(2-dimethylaminoethoxy)benzaldehyde to give the title compound as a white powder in a 100% yield.
MP: 243° C.
4-(2-Dimethylaminoethoxy)benzaldehyde (20.6 g, 65%) was obtained by alklylation of 4-hydroxybenzaldehyde (20 g, 164 mmol) in DMF with dimethylaminoethyl chloride (144 g, 8 equiv.) and K2CO3 (24,9 g, 1.1 equiv.) for 16 hours at 80° C.
1H NMR (CDCl3, 250 MHz) δ9.85 (s, 1H), 7.9-7.8 (d, 2H), 7-6.9 (d, 2H), 4.2 (t, 2H), 2.7 (t, 2H), 2,3 (s, 6H).
Intermediate 26
(E)-3-[4-(2-Morpholin-4-yl-ethylcarbamoyl)phenyl]acrylic Acid
The same method was employed as in the preparation of Intermediate 23 but starting from 4-formyl-N-(2-morpholin-4-yl-ethyl)benzamide to give the title compound as a gummy solid.
4-Formyl-N-(2-morpholin4-yl-ethyl)benzamide (0.14 g, 55%) was obtained by oxidation of 4-hydroxymethyl-N-(2-morpholin-4-yl-ethyl)benzamide (0.24 g. 0.9 mmol) and MnO2 (1.73 g, 20 mmol).
1H NMR (CDCl3, 250 MHz) δ10 (s, 1H), 7.9 (s, 4H), 6.8 (s, 1H), 3.5 (t, 5H), 2.6 (t, 2H), 2,3 (m, 5H).
4-Hydroxymethyl-N-(2-morpholin4-yl-ethyl)benzamide (240 mg, 14%) was obtained as a colourless oil (Rf=0.6, DCM:MeOH (9:1)) by coupling 4-(hydroxymethyl)benzoic acid (1.0 g, 6.5 mmol) with 2-morpholinethylamine (0.85 g (1.0 equiv.) in the presence of Et3N (0.95 mL, 1.0 equiv.), EDCl (1.2 g, 1.0 equiv.) and HOBT (0.88 g, 1.0 equiv.).
Intermediate 27
(E)-3-(4-Cyclohexylcarbamoylphenyl)acrylic Acid
The same method was employed as in the preparation of Intermediate 23 but starting from N-cyclohexyl-4-formylbenzamide to give the title compound as a white powder in a 54% yield.
MP: 214° C.
N-Cyclohexyl-4-formylbenzamide (0.6 g, 60%) was obtained by oxidation of N-cyclohexyl-4-(hydroxymethyl)benzamide (1.0 g, 4.29 mol) with MnO2 (0.2 g, 22 equiv.), as a white powder.
MP: 163° C.
1H NMR (CDCl3, 250 MHz) δ10 (s, 1H), 7.95 (s, 4H), 6.6 (s, 1H), 4.1 (m, 1H), 3.9-3.7 (m, 3H), 3.4-3.3 (m, 1H), 2.1-1.9 (m, 2H); 1.8-1.7 (m, 2H).
N-Cyclohexyl-4-(hydroxymethyl)benzamide(1.0 g, 66%) was obtained as white crystals by coupling 4-(hydroxymethyl)benzoic acid with cyclohexylamine (0.75 mL, 1 equiv.) in the presence of Et3N (0.95 mL, 1.0 equiv.), EDCl (1.2 g, 1.0 equiv.) and HOBT (0.88 g, 1.0 equiv.).
MP: 185° C.
1H NMR (CDCl3, 250 MHz) δ7.8-7.7 (d, 2H), 7.5-7.4 (d, 2H), 6.8 (s, 1H), 4.8 (s, 2H), 4.2 (m, 1H), 4.0-3.75 (m, 2H), 3.4-3.3 (m, 1H), 2.7 (m, 1H), 2-1.9 (m, 2H), 1.6 (m, 1H), 1.1 (m, 1H).
Intermediate 28
(E)-3-{4-[(Tetrahydrofuran-2-ylmethyl)carbamoyl]phenyl}acrylic Acid
The same method was employed as in the preparation of Intermediate 23 but starting from 4-formyl-N-(tetrahydrofuran-2-ylmethyl)benzamide to give the title compound as a white powder in a 49% yield.
MP: 215° C.
4-Formyl-N-(tetrahydrofuran-2-ylmethyl)benzamide (0.36 g, 50%) (Rf=0.3, DCM:MeOH) was obtained as an oil by oxidation of 4-hydroxymethyl-N-(tetrahydrofuran-2-ylmethyl)benzamide (0.72 g, 3.0 mmol) with MnO2 (0.36 g, 22 equiv.).
4-Hydroxymethyl-N-(tetrahydrofuran-2-ylmethyl)benzamide (0.72 g, 46%) was obtained as a colourless oil (Rf=0.6, DCM:MeOH (9:1)) by coupling 4-(hydroxymethyl)benzoic acid (1.0 g, 6.5 mmol) with tetrahydrofuran-2-yl-methylamine (0.67 mL, 1.0 equiv.) in the presence of Et3N (0.95 mL, 1.0 equiv.), EDCl (1;2 g, 1.0 equiv.) and HOBT (0.88 g, 1.0 equiv.).
Intermediate 29
(E)-1-[4-(2-Carboxyvinyl)benzoyl]piperidine-4carboxylic Acid, Ethyl Ester
The same method was employed as in the preparation of lntermediate 23 but starting from 1-(4-formylbenzoyl)piperidine-4-carboxylic acid, ethyl ester to give the title compound as a white powder in a 46% yield.
MP: 165° C.
1-(4-Formylbenzoyl)piperidine-4-carboxylic acid, ethyl ester (960 mg, 49%) (Rf=0.6, DCM:MeOH(95:5)) was obtained as an oil by oxidation of 1-(4-hydroxymethylbenzoyl)piperidine-4-carboxylic acid, ethyl ester (2.0 g, 6.8 mmol) with MnO2 (13.1 g, 22 equiv.).
1H NMR (CDCl3, 250 MHz) δ10.0 (s, 1H), 7.9 (d, 2H), 7.5 (d, 2H), 4.5 (d, 1H), 4.1 (q, 2H), 3.6 (d, 1H), 3.1 (br s, 2H), 2.5 (m, 1H), 2.1-1.6 (m, 4H), 1.2 (t, 3H).
1-(4-Hydroxymethylbenzoyl)piperidine-4-carboxylic acid, ethyl ester (1.9 g, 100%) was obtained as a colorless oil (Rf=0.1, DCM:MeOH (95:5)) by coupling 4-(hydroxymethyl)benzoic acid (1.0 g, 6.5 mmol) with 4-piperidine-4-carboxylic acid, ethyl ester (1 mL, 6.5 mmol ) in the presence of Et3N (0.95 mL, 1.0 equiv.), EDCl (1.2 g, 1.0 equiv.) and HOBT (0.88 g, 1.0 equiv.).
1H NMR (CDCl3, 250 MHz) δ7.2 (s, 4H), 4.5 (s, 2H), 4.3 (br s, 1H), 4.1 (q, 2H), 3.6 (br s, 1H),3 (t, 2H), 2.5 (m, 1H), 2.1-1.6 (m, 4H), 1.2 (t, 3H).
Intermediate 30
(E)-3-(4-Ethoxycarbonylmethylphenyl)acrylic Acid
The same method was employed as in the preparation of Intermediate 23 but starting from (4-formylphenyl)acetic acid, ethyl ester gave the title compound as a yellow gum in a 52% yield.
1H NMR (CDCl3, 250 MHz) δ7.8-7.6 (m, 3H), 7.4-7.3 (d, 2H), 6.9-6.8 (d, 1H), 4.1-3.9 (q, 2H), 3.55 (s, 2H), 1.2 (t, 3H).
4-(4-Formylphenyl)acetic acid, ethyl ester was prepared according to the procedure of Biagi, G.; Livi, O.; Verugi, E. Farmaco-Ed. Sc. 1988, 43, 597-611.
Intermediate 31
(E)-1-[4-(2-Carboxyvinyl)phenyl]piperidine-4-carboxylic Acid, Ethyl Ester
The same method was employed as in the preparation of Intermediate 23 but starting from 1-(4-formylphenyl)piperidine-4carboxylic acid, ethyl ester to give the title compound as a yellow powder in a 86% yield.
MP: 212° C.
Analysis for C17H21NO4. 0.15H2O:
Calculated: C,66.71; H,7.01; N,4.58;
Found: C,66.77; H,7.01; N,4.79%.
1-(4-Formylphenyl)piperidine-4-carboxylic acid, ethyl ester was prepared according to the procedure of Duckworth, D. M. Hindley, R.; Richard, M. EP 68669A1.
Intermediate 32
(E)-4-(2-Carboxyvinyl)-3-chlorobenzoic Acid, Methyl Ester
The same method was employed as in the preparation of Intermediate 23 but starting from 3-chloro-4-formylbenzoic acid, methyl ester to give the title compound as a white powder in a 58% yield.
MP: 221° C.
3-Chloro4-formylbenzoic acid, methyl ester (4.0 g, 81%) was prepared by reaction of 4-bromomethyl-3-chlorobenzoic acid, methyl ester (6.0 g, 26 mmol) with silver p-toluenesulfonate (15.0 g, 2.0 equiv.) in 100 mL of DMSO in the presence of Et3N (100 mL, 7 equiv.) at rt for 1 hour. Quenching the resulting mixture with 100 mL of water, extraction with 2×100 mL of EtOAc, washing with 50 mL of water, drying over Na2SO4 and flash chromatography with cyclohexane:EtOAc (95:5) as eluting solvent, gave the title compound (2,3 g9 42%) as an oil.
1H NMR (CDCl3, 250 MHz) δ10.5 (s, 1H), 8.1 (s, 1H), 7.8-7.7 (d, 1H), 7.4-7.3 (d, 1H), 3.8 (s, 3H).
4-Bromomethyl-3-chlorobenzoic acid, methyl ester (6.0 g, 87%) was obtained as an orange oil by refluxing for 12 hours 4-methyl-3-chlorobenzoic acid, methyl ester (5.7 g, 31 mmol) with NBS (6.4 g, 1.2 equiv.) in the presence of a catalytic amount of AIBN in CCl4.
1H NMR (CDCl3, 250 MHz) δ8.0 (s, 1H), 7.9-7.8 (d, 1H), 7.45-7.35 (d, 1H), 4.5 (s, 1H), 3.9 (s, 3H).
4-Methyl-3-chlorobenzoic acid, methyl ester (5.7 g, 53%) was obtained as an orange oil by refluxing overnight 4-methyl-3-chlorobenzoic acid (9.9 g, 58 mmol) in MeOH in the presence of PTSA.
1H NMR (CDCl3, 250 MHz) δ8.0 (d, 1H), 7.85 (dd, 1H), 7.3 (d, 1H), 4.0 (s, 3H), 2.5 (s, 3H).
Intermediate 33
(E)-5-(2-Carboxyvinyl)-2-chlorobenzoic Acid, Methyl Ester
The same method was employed as in the preparation of Intermediate 32 but starting from 2-chloro-5-formylbenzoic acid, methyl ester to give the title compound as a yellow powder in a 76% yield.
MP: 194° C.
2-Chloro-5-formylbenzoic acid, methyl ester (0.6 g, 25%) was obtained a gum by reaction of 5-bromomethyl-2-chlorobenzoic acid, methyl ester (3.1 g, 11.7 mmol) with silver p-toluenesulfonate (6.4 g, 1.75 equiv.) in DMSO in the presence of Et3N (1.2 mL, 7 equiv.) at rt for 1 hour.
1H NMR (CDCl3, 250 MHz) δ10 (s, 1H), 8.4 (d, 1H), 7.9 (dd, 1H), 7.7-7.6 (d, 1H), 4.0 (s, 3H).
5-Bromomethyl-2-chlorobenzoic acid, methyl ester (3.1 g, 11.7 mmol) was obtained as a gum in a 45% yield by refluxing for 12 hours 5-methyl-2-chlorobenzoic acid, methyl ester (4.78 g, 25.9 mmol) with NBS (5.56, 1.2 equiv.) in the presence of a catalytic amount of AIBN in CCl4.
1H NMR (CDCl3, 250 MHz) δ7.9 (s, 1H), 7.4 (br s, 2H) 4.5 (s, 2H), 3.9 (s, 3H).
5-Methyl-2-chlorobenzoic acid, methyl ester (4.78 g, 90%) was obtained as a brown oil, by refluxing overnight 3-methyl-4-chlorobenzoic acid (5.0 g, 29 mmol) in MeOH in the presence of a catalytic amount of PTSA.
1H NMR (CDCl3, 250 MHz) δ7.6 (s, 1H), 7.25-7.2 (d, 1H), 7.15-7.1 (d, 1H), 3.8 (s, 3H), 2.2 (s, 3H).
Intermediate 34
(E)-(3-Hydroxy-4-nitrophenyl)acrylic Acid
The same method was employed as in the preparation of Intermediate 23 but starting from 3-hydroxy-4-nitrobenzaldehyde to give the title compound as a white powder in a 88% yield.
MP: 237° C.
Intermediate 35
(E)-(3,5-Dimethyl-4-hydroxyphenyl)acrylic Acid
The same method was employed as in the preparation of Intermediate 23 but starting from 3,5-dimethyl-4-hydroxybenzaldehyde gave the title compound as a white powder in a 94% yield.
MP: 190° C.
Intermediate 36
(E)-(3-Nitro-4-hydroxy-5-methoxphenyl)acrylic Acid
The same method was employed as in the preparation of Intermediate 23 but starting from 3-nitro-4-hydroxy-5-methoxybenzaldehyde to give the title compound as a white powder in a 75% yield.
MP: 248° C.
Intermediate 37
(E)-3-(3-Nitro-2-piperidin-1-yl-phenyl)acrylic Acid
The same method was employed as in the preparation of Intermediate 23 but starting from 2-chloro-3-nitrobenzaldehyde to give the title compound as a yellow powder in a 100% yield.
1H NMR (CDCl3, 250 MHz) δ10.3 (br s, 1H), 8.1 (d,1H), 7.65 (dd, 1H), 7.55 (dd, 1H), 7.05 (t, 41H), 6.3 (d, 1H), 2.9 (m, 2H), 1.6 (m, 6H).
2-Chloro-3-nitrobenzaldehyde (150 mg, 20%) was prepared by reaction of 1-bromomethyl-2-chloro-3-nitrobenzene (1.0 g, 3.9 mmol) with silver p-toluenesulfonate (1.94 g, 1.75 equiv.) in DMSO in the presence of Et3N (4 mL, 7 equiv.) at rt for 1 hour.
1H NMR (CDCl3, 250 MHz) δ10.5 (s, 1H), 8.1 (dd, 1H), 8.0 (dd, 1H), 7.5 (t, 1H). 1-Bromomethyl-2-chloro-3-nitrobenzene (13.3 g, 68%) was obtained as a yellow oil by refluxing for 2 hours a mixture of 2-chloro-3-nitrotoluene (10 g, 58 mmol) with NBS (10.3 g, 1 equiv.) in the presence of a catalytic amount of AIBN in CCl4.
1H NMR (CDCl3, 250 MHz) δ7.75 (dd, 1H), 7.65 (dd, 1H), 7.45 (m, 1H), 4.6 (s, 2H).
Intermediate 38
(E)-3-(4-Methyl-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl)acrylic Acid
The same method was employed as in the preparation of Intermediate 23 but starting from 4-methyl-3,4-dihydro-2H-benzo[1,4]oxazin-6-carboxaldehyde (prepared according to the procedure of Kotha, S.; Bindra, V.; Kuki, A. Heterocyles 1994, 38, 5-8) to give the title compound as a yellow powder in a 61% yield
MP: 190° C.
Analysis for C12H13NO5:
Calculated: C,65.74; H,5.98; N,6.39;
Found: C,65.85; H,6.04; N,6.33%.
Intermediate 39
(E)-3-(2-Hydroxy-5-nitrophenyl)acalic Acid
The same method was employed as in the preparation of Intermediate 23 but starting from 2-hydroxy-5-nitro benzaldehyde to give the title compound as a yellow powder in a 11% yield.
MP: 265-267° C.
Intermediate 40
(E)-3-[3-(Trifluoromethanesulfonyloxy)phenyl]acrylic Acid
The same method was employed as in the preparation of Intermediate 23 but starting from trifluoromethanesulfonic acid, 3-formylphenyl ester (prepared according to the procedure of Kingsbury, W. D.; Pendrak, I.: Leber, J. D.: Boehm, J. C.; Mallet, B.; Sarau, H. M.; Foley, J. J.; Schmidt, D. B.; Daines, R. A. J. Med. Chem. 1993, 36, 3308-3320) to give the title compound as pink crystals in a 36% yield.
MP: 107° C.
Intermediate 41
(E)-3-[4-(Trifluoromethanesulfonyloxy)phenyl]acrylic Acid
The same method was employed as in the preparation of Intermediate 23 but starting from trifluoromethanesulfonic acid, 4-formylphenyl ester (prepared according to the procedure of Creary, X.; Benage, B.; Hilton, K. J. Org. Chem. 1983, 48(17), 2887-2891) to give the title compound as white crystals in a 61% yield.
MP: 194° C.
Intermediate 42
(E)-3-[4-(2-Pyrrolidin-1-ylethoxy)phenyl]acrylic Acid
The same method was employed as in the preparation of Intermediate 23 but starting from 4-(2-pyrrolidin-1-ylethoxy)benzaldehyde (prepared according to the procedure of Sakaguchi, J.; Nishino, H.; Ogawa, N.; Iwanaga, Y.; Yasuda, S.; Kato, H.; Ito, Y. Chem. Pharm. Bull. 1992, 40, 202-211) to give the title compound as a yellow solid in a 60% yield.
MP: 183° C.
Intermediate 43
(E)-3-(4-Pyrrolidin-1-ylphenyl)acrylic Acid
The same method was employed as in the preparation of Intermediate 23 but starting from (4-pyrrolidin-1-ylphenyl)benzaldehyde (prepared according to the procedure of Duckworth, D. M. Hindley, R.; Richard, M. EP 68669A1) to give the title compound as a yellow solid in a 65% yield.
MP: 265° C.
Intermediate 44
(E)-3-(4-Imidazol-1-ylphenyl)acrylic Acid
The same method was employed as in the preparation of Intermediate 23 but starting from 4-imidazol-1-ylbenzaldehyde (prepared according to the procedure of Sircar, I.; Duell, B.; Bristol, J. A.; Weishaar, R. E.; Evans, D. B. J. Med. Chem. 1987, 30, 1023-1029) to give the title compound as pink crystals in a 55% yield.
MP: 326-327° C.
Intermediate 45
(E)-(S)-3-[4-(1-Methylpyrolidin-2-ylmethoxy)phenyl]acrylic Acid
The same method was employed as in the preparation of Intermediate 23 but starting from (S)-4-(1-methylpyrrolidin-2-ylmethoxy)benzaldehyde to give the title compound as a beige powder in a 66% yield.
MP: 251° C.
[α]D 21 =−9(c=0.35, pyridine).
(S)-4-(1-Methylpyrrolidin-2-ylmethoxy)benzaldehyde (0.96 g, 44%) was obtained as an orange oil by refluxing for 12 hours at 80° C., 4-hydroxybenzaldehyde (1.22 g, 10 mmol) with (S)-2-chloromethyl-1-methylpyrrolidine, hydrochloride (2.55 g, 1.5 equiv.) in DMF in the presence of K2CO3 (3.82 g, 2.8 equiv).
1H NMR (CDCl3, 250 MHz) δ9.9 (s, 1H), 7.85 (d, 2H), 7.0 (d, 2H), 4.1 (dd, 1H), 4.0 (dd,1H), 3.1 (d tr, 1H), 2.7 (m, 1H), 2.5 (s, 3H), 2,3 (m, 1H), 2 (m, 1H), 1.8 (m, 3H).
(S)-2-Chloromethyl-1-methylpyrrolidine, hydrochloride was prepared according to the procedure of D'Ambra, T. E.; Bacon, E. R.; Edward, R.; Bell, M. R., Carabateas, P. M.; Eissenstat, M. A.; Kumar, V.; Mallamo, J. P.; Ward, S. J. EP 444451 A2.
Intermediate 46
(E)-3-[4-(2-Dimethylamino-1-methylethoxy)phenyl]acrylic Acid
The same method was employed as in the preparation of Intermediate 23 but starting from 4-(2-dimethylamino-1-methylethoxy)benzaldehyde to give the title compound as a white powder in a 86% yield.
MP: 235° C.
Analysis for C14H19NO3.HCl:
Calculated: C,58.84; H,7.05; N,4,9;
Found C,58.49; H,7.08; N,5.05%.
4-(2-Dimethylamino-1-methylethoxy)benzaldehyde (2.1 g, 18%) was obtained as an orange oil by refluxing for 12 hours, 4-hydroxybenzaldehyde (7 g, 57 mmol), K2CO3 (8.7 g, 1.1 equiv.) and 2-chloropropyldimethylamine, hydrochloride (13.6 g, 1.5 equiv.) in DMF.
1H NMR (CDCl3, 250 MHz) δ9.7 (s, 1H), 7.65 (d, 2H), 6.85 (d, 2H), 4.5 (m, 1H), 2.5 (m, 1H), 2,3 (m, 1H), 2.1 (m, 6H), 1.2 (d, 3H).
Intermediate 47
(E)-3-[4-(4-Methylpiperazin-1-yl)phenyl]acrylic Acid
The same method was employed as in the preparation of Intermediate 23 but starting from 4-(4-methylpiperazin-1-yl)benzaldehyde (prepared according to the procedure of Sakai, K.; Suzuki, M.; Nunami, K.; Yoneda, N.; Onoda, Y. Iwasawa, Y. Chem. Pharm. Bull. 1980, 28, 2384-2393) to give the title compound as a white powder in a 65% yield.
MP: 223-226° C.
Intermediate 48
(E)-3-[4-(2-Dimethylaminopropoxy)phenyl]acrylic Acid
The same method was employed as in the preparation of Intermediate 23 but starting from 4-(2-dimethylaminopropoxy)benzaldehyde (prepared according to the procedure of Mizzoni, R. H. U.S. Pat. No. 3,483,209) to give the title compound as a beige powder in a 100% yield.
MP: 231° C.
Intermediate 49
(E)-3-[4-(2-Morpholin-4-ylethoxy)phenyl]acrylic Acid
The same method was employed as in the preparation of Intermediate 23 but starting from 4-(2-morpholin-4-ylethoxy)benzaldehyde (prepared according to the procedure of Naruto, S.; Mizuta, H.; Sawayama, T.; Yoshida, T.; Uno, H.; Kawashima, K.; Sohji, Y.; Kadokawa,T.; Nishimura, H. J. Med. Chem. 1982, 25, 1240-1245) to give the title compound as a white powder in a 96% yield.
MP: 228° C.
Intermediate 50
(E)-3-{4-[2-(Ethylmethylamino)ethoxy]phenyl}acrylic Acid
The same method was employed as in the preparation of Intermediate 23 but starting from 4-[2-(ethylmethylamino)ethoxy]benzaldehyde to give the title compound as a beige powder in a 73% yield.
MP: 206° C.
Analysis for C14H19NO3.HCl:
Calculated: C,58.84; H,7.05; N,4,9;
Found C,59.08; H,7.07; N,5.02%.
4-[2-(Ethylmethylamino)ethoxy]benzaldehyde(5.0 g, 59%) was obtained as a brown oil by refluxing for 12 hours 4-hydroxybenzaldehyde (5 g, 41 mmol), K2CO3 (6.2 g, 1.1 equiv.) and (2-chloroethyl)ethylmethylamine, hydrochloride (9.7 g, 1.5 equiv.) in DMF.
1H NMR (CDCl3, 250 MHz) δ9.7 (s, 1H), 7.7 (d, 2H), 6.9 (d, 2H), 4.1 (t, 2H), 2.6 (t, 2H), 2. (s, 6H).
Intermediate 51
(E)-3-[4-(3-Dimethylaminopropenyl)phenyl]acrylic Acid
This product was prepared by refluxing for four hours, (E)-3-[4-(3-dimethylaminopropenyl)phenyl]acrylic acid, methyl ester with NaOH (0.16 g, 2 equiv.) in 10 mL of MeOH. After evaporation of the solvent in vacuo, treatment with 5 mL of HCl (1N) gave the title compound (0.4 g, 85%) as a gummy orange solid.
1H NMR (CDCl3, 250 MHz) δ7.6 (d, 2H), 7.4 (d, 1H), 7.2 (d, 2H), 6.6 (d, 1H), 6.4 (d, 1H), 5.8 (m, 1H), 3.7 (d, 2H), 2.6 (s, 6H).
(E)-3-[4-(3-Dimethylaminopropenyl)phenyl]acrylic acid, methyl ester was prepared by the following way: (2-dimethylaminoethyl)triphenylphosphonium bromide (7.2 g, 17.4 mmol) in 30 mL of DMF was treated with KHMDS (27 mL, 1.01 equiv., 0.5 M in toluene) at −78° C. for one hour. At −40° C., 3-(4-formylphenyl)acrylic acid, methyl ester (2.54 g, 13.3 mmol, prepared according to the procedure of Syper, L.; Miochowski, J. Synthesis, 1984, 9, 747-752) was added dropwise. The resulting mixture was stirred for 12 hours at rt and quenched with water. Extraction with EtOAc, drying over MgSO4 and evaporation in vacuo gave a residue that was purified via flash chromatography with DCM:MeOH (90:10) as eluting solvent. The title compound (1.1 g, 34%) was obtained as an orange oil.
1H NMR (CDCl3, 250 MHz) δ7.6 (d, 1H), 7.4 (d, 2H), 7.2 (d, 2H), 6.5 (d, 1H), 6.4 (d, 1H), 5.8 (m, 1H), 3.2 (dd, 2H), 2.1 (s, 6H).
Intermediate 52
(E)-3-[4-(2-(Tertbutyldimethylsilanyloxy)-3-dimethylaminopropenyl)phenyl]acrylic Acid
This product was prepared by refluxing for four hours (E)-3-[4-(2-(tertbutyldimethylsilanyloxy)-3-dimethylaminopropanyl)phenyl]acrylic acid, methyl ester (0.8 g, 2.03 mmol) and NaOH (1N) (4 mL, 2 equiv.) in 10 mL of MeOH. Evaporation of the solvent in vacuo and treatment with 5 mL of HCl (1 N) gave the title compound (0.4 g, 60%) as a beige solid solid.
MP: 207° C.
(E)-3-[4-(2-(Tertbutyldimethylsilanyloxy)-3-dimethylaminopropoxy)phenyl]acrylic acid, methyl ester (0.8 g, 40%) was obtained as a yellow oil by reaction for 4 hours of (E)-3-[4-(3-dimethylamino-2-hydroxypropoxy)phenyl]acrylic acid, methyl ester (1.35 g, 5.13 mmol) with TBDMSCl (0.93 g, 6.2 mmol) in 50 mL of DMF in the presence of imidazole (0.84 g, 2.4 equiv.). After evaporation in vacuo, the residue was taken up in DCM, washed with water, dried over MgSO4, evaporated in vacuo and purified via flash chromatography using DCM:MeOH as eluting solvent.
1H NMR (CDCl3, 250 MHz) δ7.5 (d, 1H), 7.3 (d, 2H), 6.8 (d, 2H), 6.2 (d, 1H), 4.0 (m, 2H), 3.8 (m, 1H), 3.7 (s, 3H), 2.4-2.2 (m, 2H), 2.1 (s, 6H), 0.7 (s, 9 H), 0.0 (d, 6H).
(E)-3-[4-(3-Dimethylamino-2-hydroxypropoxy)phenyl]acrylic acid, methyl ester (1.5 g, 60%) was obtained as an oil by reaction of 4-(3-dimethylamino-2-hydroxypropoxy)benzaldehyde (2.0 g, 8.96 mmol) in 80 mL of toluene with triphenylphosphoranylidene methyl acetate (3.6 g, 1.2 equiv.) at 100° C. for one day. After concentration in vacuo, the residue was taken up in DCM, washed with water, dried over Na2SO4, evaporated in vacuo and purified via flash chromatography using DCM:MeOH (95:5) as eluting solvent.
1H NMR (CDCl3, 250 MHz) δ7.6 (d, 1H), 7.5 (d, 2H), 7.3 (d, 2H), 6.3 (d, 1H), 4.2 (m, 1H), 4.1 (m, 1H), 3.8 (m, 3H), 3.3 (s, 1H), 2.8 (dd, 1H), 2.6 (dd, 1H), 2.4 (s, 6H).
4-(3-Dimethylamino-2-hydroxypropoxy)benzaldehyde (8.2 g, 61%) was obtained as an a yellow oil, by reaction of 4-oxiranylmethoxybenzaldehyde (6 g, 33.6 mmol, prepared according to the procedure of Baldwin, J. J., Hirchmann, R.; Lumma, W. C.; Ponticello, G. S.; Sweet, C. S.; Scriabine, A. J. Med. Chem. 1977, 20, 1024-1029) in 100 mL of MeOH with dimethylamine (34 mL, 2 equiv.). The resulting mixture was stirred at reflux for 2 days. Evaporation in vacuo gave a residue that was taken up in DCM, washed with brine and dried over MgSO4 and evaporated in vacuo.
1H NMR (CDC3, 250 MHz) δ9.7 (s, 1H), 7.6 (d, 2H), 7.0 (d, 2H), 4. (m, 3H), 3.6 (s, 1H), 2.5 (dd, 1H), 2,3 (dd, 1H), 2.25 (s, 6H).
Intermediate 53
(E)-3-[4-(2-(Dimethylaminoethylamino)phenyl]acrylic Acid
The same method was employed as in the preparation of Intermediate 23 but starting from 4-[2-(dimethylaminoethyl)amino]benzaldehyde (prepared according to the procedure of Klaus, M.; Mohr, P.; Weiss, E. EP 331983 A2) to give the title compound as an oil in a 100% yield.
1H NMR (CDCl3, 250 MHz) δ7.5 (d, 1H), 7.2 (d, 2H), 6.5 (d 2H), 6.1 (d, 1H) 4.6 (s, 1H), 3.0 (m, 2H), 2.5 (t, 2H), 2.2 (s, 6H).
Intermediate 54
(E)-3-{4-[2-(1,3-Dioxo-1,3-dihydroisoindol-2-yl)ethoxy]phenyl}acrylic Acid
The same method was employed as in the preparation of Intermediate 23 but starting from 4-[2-(1,3-dioxo-1,3-dihydroisoindol-2-yl)ethoxy]benzaldehyde (prepared from the procedure of Hindley, R. M.; Haigh, D.; Cottam, G. P. WO 9207839 A1) to give the title compound as an oil in a 99% yield.
1H NMR (CDCl3, 250 MHz) δ12.3 (s, 1H), 7.9 (m, 4H), 7.6 (d, 2H), 7.5 (d, 1H), 7.0 (d, 2H), 6.4 (d, 1H), 4.4 (t, 2H), 4.0 (t, 2H).
Intermediate 55
(E)-3-[4-(2-(Piperidin-1-ylethoxy)phenyl]acrylic Acid
The same method was employed as in the preparation of Intermediate 23 but starting from 4-(2-piperidin-1-yl-ethoxy)benzaldehyde (which was prepared according to the procedure of Naruto, S.; Mizuta, H.; Sawayama, T.; Yoshida, T.; Uno, H.; Kawashirna, K.; Sohji, Y.; Kadokawa, T.; Nishimura, H. J. Med. Chem. 1982, 25, 1240-1245), to give the title compound as a white powder in a 60% yield.
MP: 231° C.
Intermediate 56
(E)-3-[4-(2-(Tertbutoxycarbonylmethylamino)ethoxy)phenyl]acrylic Acid
(E)-3-[4-(2-Methylaminoethoxy)phenyl]acrylic acid (0.8 g, 3.6 mmol) in dioxane (100 mL) was treated with NaOH (2N) (22 mL, 12 equiv.). After one hour of stirring at 70° C., ditertbutyldicarbonate (1.6 g, 2 equiv.) was added slowly. The reaction was judged to be complete after 3 hours of stirring at 70° C. After filtration of the white precipitate, the filtrate was acidified to pH=1 with HCl (1 N). A new white solid precipitated out . Filtration and drying in vacuo gave the title compound (0.6 g, 50%) as white crystals.
1NMR (CDCl3, 250 MHz) δ7.8 (d, 1H), 7.65 (d, 2H), 7.0 (d, 2H), 6.4 (d, 1H), 4.25 (t, 2H), 3.7 (t, 2H), 3.1 (s, 3H), 1.5 (s, 9H).
(E)-3-[4-(2-Methylaminoethoxy)phenyl]acrylic acid (1.1 g, 41%) was obtained as a white solid by hydrolysis of (E)-3-[4-(2-methylaminoethoxy)phenyl]acrylic acid, methyl ester (3.0 g, 12.0 mmol) with NaOH (6.0 g, 12 equiv.) in MeOH/THF at 40° C.
MP: 245° C.
(E)-3-[4-(2-Methylaminoethoxy)phenyl]acrylic acid, methyl ester (3.0 g, 70%) was obtained as a yellow oil by reaction of trimethylphosphonoacetate (4.2 g, 23.0 mmol) and n-butyl lithium (9.0 mL, 18.0 mmol, 2.0 M in cyclohexane) at −78° C., followed by the addition of 4-(2-methylaminoethoxy)benzaldehyde (3.2 g, 18.0 mmol) at −40° C. The resulting mixture was stirred at rt for 16 hours, quenched with water, extracted with EtOAc, dried over MgSO4 and concentrated in vacuo.
1H NMR (CDCl3, 250 MHz) δ7.65 (d, 1H), 7.45 (d, 2H), 6.9 (d, 2H), 6.25 (d, 1H), 4.10 (t, 2H), 3.75 (s, 3H), 2.95 (t, 2H), 2.5 (s, 3H).
4-(2-Methylaminoethoxy)benzaldehyde (3.2 g, 51%) was obtained as a yellow oil by reaction of 4-(2-methylaminoethoxy)benzonitrile (7.0 g, 40.0 mmol) with diisobutylaluminum hydride (40 mL, 1.5 equiv., 1.5 M in toluene) in toluene (400 mL) at −78° C. After 4 hours of stirring at −78° C. the resulting mixture was treated with a mixture of water/MeOH (4 mL). At rt an additional 20 mL of water was added. The resulting suspension was filtered on a bed of celite. The celite was washed with Et2O (3×200 mL). The filtrate was concentrated in vacuo and purified via flash chromatography of silica gel using MeOH:DCM (1:9) as eluting solvent.
1H NMR (CDCl3, 250 MHz) δ9.8 (s, 1H), 7.8 (d, 2H), 7.0 (d, 2H), 4.1 (t, 2H), 2.9 (t, 2H), 2.5 (s, 3H).
4-(2-Methylaminoethoxy)benzonitrile (0.6 g, 15%) was obtained as a yellow oil by reaction of 4-(2-chloroethoxy)benzonitrile (2.0 g, 11.0 mmol, prepared according to the procedure of Mizuno, K.; Kimura, Y.; Otsuji, Y. Synthesis, 1979, 9, 688) with methylamine (4.3 mL, 5 equiv., 40% in water) at 70° C. for 16 hours. The resulting mixture was extracted with DCM, dried over MgSO4, concentrated in vacuo and purified via flash chromatography of silica gel using MeOH:DCM (2:8) as eluting solvent, to give the title compound.
1H NMR (CDCl3, 250 MHz) δ7.6 (d, 2H), 7.0 (d, 2H), 4.1 (t, 2H), 3.0 (t, 2H), 2.5 (s, 3H).
EXAMPLE 1
(E)-1-(1-Phenyl-1,3,4,9-tetrahydro-β-carbolin-2-yl)-3-phenylprocene-1-one
To a solution of Intermediate 1 (0.2 g, 0.81 mmol) and NaHCO3 (0.08 g, 1.2 equiv.) in 10 mL of DCM was added (E)-cinnamoyl chloride (0.2 g, 1.5 equiv.). After 4 hours of stirring at rt the reaction was judged to be completed by tlc monitoring (SiO2, DCM:MeOH 98:2) and was quenched with 5 mL of a saturated aqueous solution of NaHCO3. The reaction mixture was extracted with DCM, washed with brine (5 mL), dried over MgSO4 and concentrated in vacuo. Flash chromatography on a 2×20 Cm2 column using DCM:MeOH (98:2) as eluting solvent and removal of the solvent in vacuo gave after recrystallization from 2-propanol, the title compound (0.1 g, 33%) as white crystals.
MP: 130-132° C.
Analysis for C26H22N2O:
Calculated: C,82.51; H,5.86; N,7.40;
Found: C,82.24; H,5.93; N,7.36%.
EXAMPLE 2
(E)-1-(1-Phenyl-1,3,4,9-tetrahydro-β-carbolin-2-yl)-3-(4-nitrophenyl)propene-1-one
The same method as employed as in the preparation of Example 1 but starting from (E)-4-nitrocinnamoyl chloride gave after recrystallization from iPr2O:2-propanol (3:1), the title compound as a yellow powder in a 47% yield.
MP: 230-231° C.
Analysis for C26H21N3O3:
Calculated: C,73.74; H,5.00; N,9.92;
Found: C,73.89; H,5.12; N,9.86%.
EXAMPLE 3
(E)-1-(1-Phenyl-1,3,4,9-tetrahydro-β-carbolin-2-yl)-3-(4-trifluoromethylphenyl)propene-1-one
The same method as employed in the preparation of Example 1 but starting from (E)-4-trifluoromethylcinnamoyl chloride gave after recrystallization from pentane, the title compound as a white powder in a 41% yield.
MP: 211° C.
Analysis for C27H21F3N2O. 0.4H2O:
Calculated: C,71.48; H,4.84; N,6.17;
Found: C,71.84; H,4.81; N,6.19%.
EXAMPLE 4
(E)-1-(1-Phenyl-1,3,4,9-tetrahydro-β-carbolin-2-yl)-3-(4-methoxyphenyl)propene-1-one
The same method as employed in the preparation of Example 1 but starting from (E)-4-methoxycinnamoyl chloride gave after recrystallization from 2-propanol, the title compound as white crystals in a 61% yield.
MP: 160-163° C.
Analysis for C27H24N2O2. 0.5(2-propanol):
Calculated: C,78.06; H,6.44; N,6.39;
Found: C,78.04; H,6.02; N,5.97%.
EXAMPLE 5
(E)-1-[1-(4-Methoxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(4-trifluoromethylphenyl)propene-1-one
The same method as employed in the preparation of Example 1 but starting from Intermediate 2 and (E)-4-trifluoromethylcinnamoyl chloride gave after recrystallization from pentane, the title compound as a white powder in a 61% yield.
MP: 130-135° C.
Analysis for C28H23N2O2F3. 0.3H2O:
Calculated: C,69.79; H,4,94; N,5.81;
Found: C,69.9; H,4.84; N,5.73%.
EXAMPLE 6
(E)-N-[4-[3-Oxo-3-(1-phenyl-1,3,4,9-tetrahydro-β-carbolin-2-yl)propenyl]phenyl]acetamide
To a solution of Intermediate 1 (0.2 g, 0.81 mmol) in 40 mL of DCM were added Et3N (0.13 mL, 1.1 equiv.), DCC (0.18 g, 1.1 equiv.), HOBT (0.12 g , 1.1 equiv.) and (E)-3-(4-acetylaminophenyl)acrylic acid (0.18 g , 1.1 equiv.). After 24 hours of stirring at rt the reaction was judged to be completed by tlc monitoring (SiO2, DCM:MeOH 95:5) and was quenched with 150 mL of water. A white solid precipitated out and was filtered off. The filtrate was extracted with DCM, washed with brine (5 mL), dried over MgSO4 and concentrated in vacuo. Flash chromatography on a 2.5×25 cm2 column of silica gel using DCM:MeOH (98:2) as eluting solvent and removal of the solvent in vacuo gave the title compound (0.18 g, 51%) as yellow crystals after recrystallization from 2-propanol:pentane.
MP: 177-180° C.
Analysis for C28H25N3O2. 0.7H2O:
Calculated: C,75.05; H,5.94; N,9.38;
Found: C,75.01; H,5.81; N,9.22%.
EXAMPLE 7
(E)-1-[1-(4-Method)(phenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-phenylpropene-1-one
The same method as employed in the preparation of Example 1 but starting from Intermediate 2 gave the title compound as white crystals in a 56% yield.
MP: 127° C.
Analysis for C27H24N2O2. 0.5H2O:
Calculated: C,77.67; H,6.04; N,6.71;
Found: C,77.91; H,6.0; N,6.73%.
EXAMPLE 8
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-phenyl-propene-1-one
The same method as employed in the preparation of Example 1 but starting from Intermediate 7 gave after recrystallization from 2-propanol:iPr2O (2:8), the title compound as white crystals in a 38% yield.
MP: 236-238° C.
Analysis for C27H24N2O2. 0.5H2O:
Calculated: C,76.76; H,5.25; N,6.63;
Found: C,76.87; H,5.35; N,6.54%.
EXAMPLE 9
(E)-1-(1-Phenyl-1,3,4,9-tetrahydro-β-carbolin-2-yl)-3-(4-formylphenyl)propene-1-one
The same method as employed in the preparation of Example 6 but starting from (E)-4-formylcinnamic acid gave after recrystallization from acetone:MeOH (10:3), the title compound as yellow crystals in a 60% yield.
MP: 146° C.
Analysis for C27H22N2O2. 0.4H2O:
Calculated: C,78.39; H,5.55; N,6.77;
Found: C,78.33; H,5.54; N,6.67%.
EXAMPLE 10
(E)-N-[4-[3-Oxo-3-(1-(4-nitrophenyl)-1 .3,4,9-tetrahydro-β-carbolin-2-yl)progenyl]phenyl]acetamide
The same method as employed in the preparation of Example 6 but starting from Intermediate 3 gave after recrystallization from 2-propanol, the title compound as white crystals in a 51% yield.
MP: 185° C.
Analysis for C28H24N4O4. 0.6H2O:
Calculated: C,68.45; H,5.17; N,11.4;
Found: C,68.37; H,5.06; N,11.26%.
EXAMPLE 11
(E)-1-[1-(4-Nitrophenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-phenylpropene-1-one
The same method as employed in the preparation of Example 1 but starting from Intermediate 3 gave after recrystallization from 2-propanol, the title compound as a yellow powder in a 15% yield.
MP: 205-206° C.
Analysis for C26H21N3O3. 0.2H2O:
Calculated: C,73.12; H,5.05; N,9.84;
Found: C,72.95; H,5.15; N,9.81%.
EXAMPLE 12
(E)-1-[1-(4-Trifluoromethoxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]3-phenylpropene-1-one
The same method as employed in the preparation of Example 1 but starting from Intermediate 4 gave after recrystallization from pentane, the title compound as white crystals in a 44% yield.
MP: 119° C.
Analysis for C27H21N2O2F3:
Calculated: C,70.12; H,4.58; N,6.06;
Found: C,70.02; H,4.58; N,6.02%.
EXAMPLE 13
(E)-1-[1-(4-Methylphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-phenylpropene-1-one
The same method as employed in the preparation of Example 1 but starting from Intermediate 6 gave after recrystallization from pentane, the title compound as white crystals in a 50% yield.
MP: 125-127° C.
Analysis for C27H24N2O. 0.6H2O:
Calculated: C,80.41; H,6.3; N,6.95;
Found: C,80.49; H,6.2; N,7.25%.
EXAMPLE 14
(E)-N-[4-[3-Oxo-3-(1-(3,4-methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)-propenyl]phenyl]acetamide
The same method as employed in the preparation of Example 6 but starting from Intermediate 7 and (E)-3-(4-acetylaminophenyl)acrylic acid gave after recrystallization from 2-propanol:pentane, the title compound as white crystals in a 85% yield.
MP: 185° C.
Analysis for C29H25N3O4. 0.4H2O:
Calculated: C,71.56; H,5.34; N,8.63;
Found: C,71.59; H,5.32; 8.66%.
EXAMPLE 15
(E)-4-[3-Oxo-3-(1-Phenyl-1,3,4,9-tetrahydro-βcarbolin-2-yl)-Propenyl]benzoic Acid, Methyl Ester
To a solution of Example 9 (0.2 g, 0.49 mmol) in 20 mL of MeOH was added activated MnO2 (0.59 g, 14 equiv.), sodium cyanide (0.05 g, 2 equiv.) and acetic acid (0.05 g, 1.7 equiv.). The resulting mixture was stirred for 5 hours. Tlc monitoring showed a new compound (SiO2,DCM:MeOH (95:5), Rf=0.82). The mixture was filtered through a short column of celite using 150 mL of a mixture of MeOH:EtOAc:CHCl3 (1:25:25). After evaporation in vacuo the residue was purified via flash chromatography on a 2×20 cm2 column using DCM as eluting solvent. Evaporation and recrystallization from EtOH gave the title compound (0.15 g, 70%) as yellow crystals.
MP: 222° C.
Analysis for C28H24N2O3. 0.03H2O:
Calculated: C,76.1; H,5.61; N,6.34;
Found: C,76.05; H,5.68; N,6.15%.
EXAMPLE 16
(E)-1-[1-(2-Chlorophenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-phenylpropene-1-one
The same method as employed in the preparation of Example 1 but starting from Intermediate 17 gave after recrystallization from EtOH, the title compound as white crystals in a 27% yield.
MP: 220-221° C.
Analysis for C26H21N2OCl:
Calculated: C,75.63; H,5.13; N,6.78;
Found: C,75.4; H,5.21; N,6.79%.
EXAMPLE 17
(E)-1-(1-Phenyl-1,3,4,9-tetrahydro-β-carbolin-2-yl)-3-(3,4-methylenedioxyphenyl)-propene-1-one
The same method as employed in the preparation of Example 1 but starting from (E)-(3,4-methylenedioxy)cinnamoyl chloride gave after recrystallization from EtOH, the title compound as a white powder in a 65% yield.
MP: 221° C.
Analysis for C27H22N2O3. 0.3H2O:
Calculated: C,75.79; H,5.32; N,6.55;
Found: C,75.76; H,5.37; N,6.53%.
EXAMPLE 18
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(4-bromophenyl)propene-1-one
The same method as employed in the preparation of Example 1 but starting from Intermediate 7 and (E)-4-bromocinnamoyl chloride gave after recrystallization from EtOH, the title compound as a white powder in a 10% yield.
MP: 188-190° C.
Analysis for C27H21N2O3Br. 0.3H2O:
Calculated: C,63.99; H,4.3; N,5.53;
Found: C,63.53; H,4.23; N,5.38%.
EXAMPLE 19
(E)-1-[1-(4-Chlorophenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-phenylpropene-1-one
The same method as employed in the preparation of Example 1 but starting from Intermediate 5 gave after recrystallization from EtOH, the title compound as white crystals in a 72% yield.
MP: 213-214° C.
Analysis for C26H21N2OCl:
Calculated: C,75.63; H,5.13; N,6.78;
Found: C,75.55; H,5.16; N,6.63%
EXAMPLE 20
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(4-ethoxyphenyl)propene-1-one
To a solution of Intermediate 7 (0.2 g,0.68 mmol) in 40 mL of DCM were added Et3N (0.1 mL, 1.1 equiv.), EDCl (0.14 g, 1.1 equiv.), HOBT (0.12 g, 1.1 equiv.) and (E)-4-ethoxycinnamic acid (0.14 g, 1.1 equiv.). After 48 hours of stirring at rt the reaction was judged to be completed by tlc monitoring (SiO2, DCM:MeOH (95:5)) and was quenched with 50 mL of water. The reaction mixture was extracted with DCM, washed with brine (5 mL), dried over MgSO4 and concentrated in vacuo. Flash chromatography on a 2.5×25 cm2 column of silica gel using DCM:MeOH (98:2) as eluting solvent and removal of the solvent in vacuo gave the title compound (0.21 g, 67%) as white crystals after recrystallization from EtOH.
MP: 199-200° C.
Analysis for C29H26N2O4. 0.3H2O:
Calculated: C,73.8; H,5.68; N,5.94;
Found: C,73.72; H,5.68; N,5.97%.
EXAMPLE 21
(E)-4-[3-Oxo-3-(1-(3,4-methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)propenyl]acetic Acid, Phenyl Ester
The same method as employed in the preparation of Example 20 but starting from (E)-4-acetoxycinnamic acid gave after recrystallization from MeOH, the title compound as white crystals in a 54% yield.
MP: 216° C.
Analysis for C29H24N2O5:
Calculated: C,72.49; H,5.03; N,5.83;
Found: C,72,3; H,5.11; N,5.84%.
EXAMPLE 22
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl-3-(4-hydroxyphenyl)propene-1-one
The same method as employed in the preparation of Example 20 but starting from (E)-4-hydroxycinnamic acid gave after recrystallization from EtOH:pentane the title compound as white crystals in a 57% yield.
MP: 175° C.
Analysis for C27H22N2O4. 0.3H2O:
Calculated: C,73.06; H,5.13; N,6.31;
Found: C,73.14; H,5.36; N,6.44%.
EXAMPLE 23
(E)-1-[1-(3,4-Methylenedioxyyhenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(4-formylphenyl)propene-1-one
The same method as employed in the preparation of Example 20 but starting from (E)-4-formylcinnamic acid gave after recrystallization from MeOH the title compound as white crystals in a 100% yield.
MP: 208° C.
Analysis for C28H22N2O4. 0.3H2O:
Calculated: C,73.77; H,5.00; N,6.15;
Found: C,73.77; H,4,96; N,6.05%.
EXAMPLE 24
(E)-1-[4-[3-Oxo-3-(1-(3,4-methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)-propenyl]phenyl]-3-phenylurea
The same method as employed in the preparation of Example 20 but starting from (E)-3-[4-(3-(phenylureido)phenyl]acrylic acid (which was prepared in situ by reaction of phenylisocyanate (1 equiv.), (E)-4-aminocinnamic acid (1 equiv.) and Et3N (1 equiv.)), gave after recrystallization from EtOH the title compound as white crystals in a 61% yield.
MP: 192° C.
Analysis for C34H28N4O4. 0.22(EtOH:H2O):
Calculated: C,72.48; H,5.26; N,9.82;
Found: C,72.87; H,5.17; N,9.42%.
EXAMPLE 25
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(4-aminophenyl)propene-1-one
The same method as employed in the preparation of Example 20 but starting from (E)-4-aminocinnamic acid gave after recrystallization from EtOH:DCM:2-propanol (10:2:2) the title compound as white crystals in a 63% yield.
MP: 262-265° C.
Analysis for C27H23N3O3. 0.3H2O:
Calculated: C,73.22; H,5.37; N,9.49;
Found: C,72.9; H,5.47; 9.32%.
EXAMPLE 26
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(4-nitrophenyl)-propene-1-one
The same method as employed in the preparation of Example 20 but starting from (E)-4-nitrocinnamic acid gave after recrystallization from EtOH, the title compound as yellow crystals in a 69% yield.
MP: 158° C.
Analysis for C27H21N3O5:
Calculated: C,69.37; H,4.53; N,8.99;
Found: C,69.57; H,4.61; N,8.92%.
EXAMPLE 27
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-1(4-bis(methylsulfonyl)aminophenyl]propene-1-one
This product was prepared by refluxing for two hours a solution of Example 25 (0.2 g, 0.6 mmol), mesyl chloride (0.1 mL, 5 equiv.), Et3N (0.4 mL, 5 equiv.) in 20 mL of THF. The disappearance of the starting material and the formation of a new compound were confirmed by tlc (SiO2, DCM:MeOH (95:5), Rf=0.84). After evaporation of THF the residue was dissolved in DCM (15 mL) and washed with H2O (10 mL). The organic solution was dried over MgSO4 and concentrated in vacuo to give a residue which was purified via flash chromatography on a 2.5×25 cm2 column using DCM:MeOH (98:2) as eluting solvent. Recrystallization from EtOH gave the title compound (0.09 g, 25%) as a white powder.
MP: 276° C.
Analysis for C29H27N3O7S2. 0.3H2O:
Calculated: C,58.14; H,4.64; N,7.01;
Found: C,57.76; H,4.69; N,6.81%.
EXAMPLE 28
(E)-4-(3-Oxo-3-[1-(3,4-methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl1-propenyl]benzoic Acid, Methyl Ester
The same method as employed in the preparation of Example 20 but starting from (E)-4-(2-carboxyvinyl)benzoic acid, methyl ester acid (prepared according to the procedure of Taylor, E. C.; Young, W. B.; Chaudhari, R.; Patel, H. Heterocycles 1993, 36, 1897-1908), gave after recrystallization from MeOH:H2O (99:1), the title compound as yellow crystals in a 84% yield.
MP: 211° C.
Analysis for C29H24N2O5. 0.3H2
O:
Calculated: C,71.68; H,5.1; N,5.76;
Found: C,71.76; H,5.02; N,5.68%.
EXAMPLE 29
(E)-N-[4-[3-Oxo-3-[1-(3,4-methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]propenyl]phenyl]methanesulfonamide
The same method as employed in the preparation of Example 27 but using 1 equiv. of mesyl chloride gave after recrystallization from EtOH the title compound as an off-white powder in a 10% yield.
MP: 203° C.
Analysis for C28H25N3O5S. 0.2H2O:
Calculated: C,64.78; H,4,93N,8.09;
Found: C,64.66; H,5.15; N,7.73%.
EXAMPLE 30
(E)-4-[3-Oxo-3-[1-(3,4-methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]propenyl]benzamide
Into a solution of Example 28 (0.2 g, 0.4 mmol) in 50 mL of MeOH was bubbled ammonia and the resulting mixture was stirred at 35° C. for two days. The mixture was concentrated in vacuo to give a residue which was washed with 2×30 mL of water. Extraction, drying over MgSO4 and concentration in vacuo gave a residue that was purified via radial chromatography using DCM:MeOH (90:10) as eluting solvent and via preparative chromatography (20×20-cm plate, 0.5 mm , SiO2) using the same eluant. The title compound (0.025 g, 13%) was isolated as white crystals after recrystallization from MeOH:H2O.
MP: 183° C.
Analysis for C28H23N3O4:
Calculated: C,70.07; H,5.17; N,8.76;
Found: C,69.97; H,5.16; N,8.84%.
EXAMPLE 31
(E)-4-[3-Oxo-3-[1-(3,4-methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-propenyl]benzoic Acid
This product was prepared by refluxing for four hours a stirred solution of Example 28 (0.5 g, 1.04 mmol) and NaOH (1N) (5.2 mL, 5 equiv.) in 50 mL of MeOH. After evaporation of the solvent in vacuo, the residue was treated with 10 mL of HCl (1N). A solid precipitated out and was filtered off. Recrystallization from MeOH gave the title compound (0.35 g, 72%) as white crystals.
MP: 254-256° C.
Analysis for C28H22N2O5. 0.2H2O:
Calculated: C,72.09; H,4.75; N,6.01;
Found: C,71.60; H,4.84; N,5.88%.
EXAMPLE 32
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(4-cyanophenyl)propene-1-one
The same method as employed in the preparation of Example 20 but starting from (E)-4-cyanocinnamic acid gave after recrystallization from EtOH the title compound as white crystals in a 69% yield.
MP: 167° C.
Analysis for C28H2, N3O3. 0.1H2O:
Calculated: C,74.85; H,4.76; N,9.35;
Found:: C,74.72; H,4.81; N,9.27%.
EXAMPLE 33
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(4-trifluoromethylphenyl)propene-1-one
The same method as employed in the preparation of Example 20 but starting from (E)-4-trifluoromethylcinnamic acid gave after recrystallization from EtOH the title compound as white crystals in a 73% yield.
MP: 233° C.
Analysis for C28H21F3N2O3. 0.2H2O:
Calculated: C,68.07; H,4.37; N,5.67;
Found: C,68.04; H,4.32; N,5.65%.
EXAMPLE 34
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(3,4-methylenedioxyphenyl)propene-1-one
The same method as employed in the preparation of Example 20 but starting from (E)-3,4-methylenedioxycinnamic acid gave after recrystallization from EtOH the title compound as yellow crystals in a 73% yield.
MP: 233° C.
Analysis for C28H22N2O5:
Calculated: C,72.09; H,4.75; N,6.01;
Found: C,71.79; H,4.76; N,5.93%.
EXAMPLE 35
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(4-chlorophenyl)propene-1-one
The same method as employed in the preparation of Example 20 but starting from (E)-4-chlorocinnamic acid gave after recrystallization from EtOH the title compound as white crystals in a 55% yield.
MP: 203° C.
Analysis for C27H21N2O3Cl:
Calculated: C,70.97; H,4.63; N,6.13;
Found: C,71.04; H,4.76; N,6.04%.
EXAMPLE 36
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(4-trifluoromethoxyphenyl)propene-1-one
The same method as employed in the preparation of Example 20 but starting from (E)-4-trifluoromethoxycinnamic acid (prepared according to the procedure of Yagupol'skii, L. M., Troitskaya, V. I. Zhumal Obshchei Khimii 1960, 30, 3102-3104) gave after recrystallization from EtOH the title compound as yellow crystals in a 35% yield.
MP: 203-205° C.
Analysis for C28H21F3N2O4:
Calculated: C,66.4; H,4.18; N,5.53;
Found: C,66.23; H,4.26; N,5.54.
EXAMPLE 37
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(4-methylphenyl)propene-1-one
The same method as employed in the preparation of Example 20 but starting from (E)-4-methylcinnamic acid gave after recrystallization from EtOH:DCM (99:1) the title compound as white crystals in a 67% yield.
MP: 240° C.
Analysis for C28H24N2O3. 0.7H2O:
Calculated: C,74.88; H,5.7; N,6.24;
Found: C,74.83; H,5.45; N,6.35.%.
EXAMPLE 38
(E)-[4-[3-Oxo-3-(1-(3,4-methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)propenyl]phenyl]urea
The same method as employed in the preparation of Example 20 but starting from Intermediate 22 gave after recrystallization from EtOH the title compound as white crystals in a 49% yield.
MP: 208° C.
Analysis for C28H24N4O4. 0.5H2O:
Calculated: C,68.7; H,5.15; N,11.44;
Found: C,68.51; H,5.14; N,11.35%.
EXAMPLE 39
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(4-hydroxymethylphenyl)propene-1-one
This product was prepared by stirring a solution of Example 23 (0.3 g, 0.66 mmol) in 40 mL of MeOH with NaBH4 (0.1 g, 4 equiv.) at rt for two hours. Evaporation of the solvent gave a residue which was dissolved in DCM (100 mL) and washed twice with water (50 mL). Extraction with DCM, drying over MgSO4 and evaporation in vacuo gave the title compound (0.2 g, 67%) as white crystals after recrystallization from EtOH.
MP: 206° C.
Analysis for C28H24N2O4. 0.3EtOH:
Calculated: C,73.66; H,5.58; N,6.01;
Found: C,73.69; H,5.5; N,6.06%.
EXAMPLE 40
(E)-N-Benzyl4-[3-oxo-3-(1-(3,4-methylenedioxyrhenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)propenyl]benzamide
This product was prepared by stirring a solution of Example 31 (0.2 g, 0.43 mmol) in 50 mL of THF with benzylamine (0.5 mL, 9 equiv.), Et3N (1 mL) and diphenylphosphoryl azide (0.5 mL). After two days the reaction mixture was concentrated in vacuo. The residue was taken up in 100 mL of DCM and washed with 3×50 mL of water. Drying over Na2SO4 and evaporation of the solvent gave a residue which was purified via flash chromatography with cyclohexane and Et2O. Evaporation in vacuo and recrystallization from EtOH gave the title compound (0.03 g, 13%) as white crystals.
MP: 203° C.
Analysis for C35H29N3O4:
Calculated: C,75.66; H,5.26; N.7.56;
Found: C,75.5; H,5.22; N,7.55%.
EXAMPLE 41
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(2,4-dichlorophenyl)propene-1-one
The same method as employed in the preparation of Example 20 but starting from (E)-2,4-dichlorocinnamic acid gave after recrystallization from EtOH:H2O the title compound as a white powder in a 66% yield.
MP: 194° C.
Analysis for C27H20N2O3Cl2:
Calculated: C,66.00; H,4.10; N,5.70;
Found: C,65.85; H,4.13; N,5.78%.
EXAMPLE 42
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(3-methoxy-4-hydroxyphenyl)propene-1-one
The same method as employed in the preparation of Example 20 but starting from (E)-3-methoxy4-hydroxycinnamic acid gave after recrystallization from EtOH:H20 (10:1) the title compound as an off-white powder in a 62% yield.
MP: 155° C.
Analysis for C28H24N2O5:
Calculated: C,71.78; H,5.16; N,5.98;
Found: C,71.44; H,5.16; N,5.76%.
EXAMPLE 43
(E)-1-[1-(3,4-Methylenedioxyyhenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(3-hydroxy-4-methoxyphenyl)propene-1-one
The same method as employed in the preparation of Example 20 but starting from (E)-3-hydroxy-4-methoxycinnamic acid gave after recrystallization from EtOH:H2O the title compound as an off-white powder in a 47% yield.
MP: 213° C.
Analysis for C28H24N2O5. 0.3H2O:
Calculated: C,70.96; H,5.23N,5.91;
Found: C,71.09; H,5.60; N,5.66%.
EXAMPLE 44
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(4-fluorophenyl)propene-1-one
The same method as employed in the preparation of Example 20 but starting from (E)-4-fluorocinnamic acid gave after recrystallization from EtOH the title compound as white crystals in a 74% yield.
MP: 138-139° C.
Analysis for C27H21F3N2O3:
Calculated: C,73.62; H,4.81; N,6.36;
Found: C,73.78; H,4.81; N,5.97%.
EXAMPLE 45
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-indan-5-yl-1-propene-1-one
The same method as employed in the preparation of Example 20 but starting from (E)-3-indane-5-ylacrylic acid gave, after precipitation, the title compound as a yellow powder in a 22% yield.
MP: 115° C.
Analysis for C20H26N2O3. 0.6H2O:
Calculated: C,76.12; H,5.79; N,5.92;
Found: C,76.13; H,5.79; N,5.72%.
EXAMPLE 46
(E)-N-[4-[3-Oxo-3-(1-(3,4-methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)propenyl]benzoyl]benzenesulfonamide
The same method as employed in the preparation of Example 20 but starting from Example 31 and benzenesulfonamide gave after recrystallization from EtOH:H2O the title compound as white crytals in a 20% yield.
MP: 134° C.
Analysis for C20H26N2O3. 0.6H2O:
Calculated: C,56.13; H,6.67; N,10.91;
Found: C,55.97; H,6.75; N,10.82%.
EXAMPLE 47
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(3,4-dichlorophenyl)propene-1-one
The same method as employed in the preparation of Example 20 but starting from (E)-3,4-dichlorocinnamic acid gave after recrystallization from EtOH:H2O (99:1) the title compound as a white powder in a 45% yield.
MP: 212° C.
Analysis for C27H20Cl2N2O3:
Calculated: : C,66.00; H,4.10; N,5.70;
Found: C,65.68; H,4.12; N, 5.68%.
EXAMPLE 48
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(3,4-dimethoxyphenyl)propene-1-one
The same method as employed in the preparation of Example 20 but starting from (E)-3,4-dimethoxycinnamic acid gave after recrystallization from EtOH:DCM the title compound as a white powder in a 61% yield.
MP: 233° C.
Analysis for C29H26N2O5. 0.5H2O:
Calculated: C,70.86; H,5.54; N,5.70;
Found: C,70.66; H,5.44; N,5.70%.
EXAMPLE 49
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl-3-(3,4-dihydroxyphenyl)propene-1-one
The same method as employed in the preparation of Example 20 but starting from (E)-3,4-dihydroxycinnamic acid gave after recrystallization from EtOH:DMF the title compound as a white powder in a 41% yield.
MP: 163-165° C.
Analysis for C27H22N2O5. 0.3DMF:
Calculated: C,70.34; H,5.10; N,6.76;
Found: C,70.38; H,5.13; N,6.66%.
EXAMPLE 50
(E)-N-Methyl-N-[4-(3-oxo-3-(1-(3,4-methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)propenyl]phenyl]acetamide
The same method as employed in the preparation of Example 20 but starting from Intermediate 23 gave after recrystallization from EtOH:H2O (10:0.6) the title compound as an off-white powder in a 86% yield EtOH:H2O.
MP: 165° C.
Analysis for C30H27N3O4. 0.4H2O:
Calculated: C,71.96; H,5.6; N,8.39;
Found: C,71.8; H,5.57; N,8.28%.
EXAMPLE 51
(E)-2,2-Dimethyl-N-[4-[3-Oxo-3-(1-(3,4-methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)propenyl]phenyl]propionamide
This product was prepared by condensation of Example 25 (0.2 g, 0.46 mmol) with 2,2-dimethylpropionyl chloride (0.09 mL, 1.5 equiv.) and NaOH (1N) (0.7 mL, 1.5 equiv.) in a mixture of EtOAc:DCM (6:1). When starting material had disappeared, 40 mL of a mixture of DCM:H2O (2:1) was added. Extraction with DCM, washing with a saturated aqueous solution of NH4Cl and brine, drying over MgSO4 and evaporation of the solvent in vacuo gave the title compound (0.2 g, 83%) after recrystallization from EtOH:H2O (1:1).
MP: 172-174° C.
Analysis for C32H31N3O4. 0.1H2O:
Calculated: C,71.23; H,6.16; N,7.79;
Found: C,70.99; H,6.02; N,7.84%.
EXAMPLE 52
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl1]-3-(3,5-dimethoxyphenyl)propene-1-one
The same method as employed in the preparation of Example 20 but starting from (E)-3,5-dimethoxycinnamic acid gave after recrystallization from EtOH the title compound as a white powder in a 61% yield.
MP; 178° C.
Analysis for C29H26N2O5:
Calculated: C,72.19; H,5.43; N,5.81;
Found: C,72.3; H,5.48; N,5.63%.
EXAMPLE 53
(E)-(N)-{4-[3-[1-(3,4-Methylenedioxyphenyl)6-fluoro-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-oxopropenyl]phenyl}-acetamide
The same method as employed in the preparation of Example 20 but starting from Intermediate 16 and and (E)-3-(4-acetylaminophenyl)acrylic acid gave after recrystallization from MeOH the title compound as a white crystals in a 72% yield.
MP:179-181° C.
Analysis for C29H24N3O4F.0.4H2O:
Calculated: C,69.01; H,4,95; N,8.33;
Found: C,68.97; H,4,91; N,8.34%.
EXAMPLE 54
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(3,4,5-trimethoxyphenyl)propene-1-one
The same method as employed in the preparation of Example 20 but starting from (E)-3,4,5-trimethoxycinnamic acid gave after recrystallization from MeOH the title compound as a white powder in a 49% yield.
MP: 211° C.
Analysis for C30H28N2O6:
Calculated: C,70.3; H,5.51; N,5.47;
Found: C,70.49; H,5.59; N,5.34.%.
EXAMPLE 55
(E)-N-[4-[3-Oxo-3-(1-(3,4-methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)propenyl]phenyl]isobutyramide
The same method as employed in the preparation of Example 51 but starting from isobutyryl chloride gave after recrystallization from EtOH the title compound as a white powder in a 85% yield.
MP: 171° C.
Analysis for C31H29N3O4. 0.4(H2O:MeOH):
Calculated: C,72.61; H,6.02; N,7.99;
Found: C,72,33; H,5.77; N,8.33%.
EXAMPLE 56
(E)-1-[1-(3,4-Methylenedioxyphenyl)6-fluoro-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-phenylpropene-1-one
The same method as employed in the preparation of Example 1 but starting from Intermediate 16 gave after recrystallization from EtOH the title compound as white crystals in a 71% yield.
MP: 227-228° C.
Analysis for C27H21N2O3F:
Calculated: C,73.63; H,4.81; N,6.36;
Found: C,73.72; H,4.77; N,6.43%.
EXAMPLE 57
(E)-N-(2-Methoxyethyl)-4-[3-oxo-3-(1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)propenyl]benzamide
The same method as employed in the preparation of Example 20 but starting from Intermediate 24 gave after recrystallization from EtOH the title compound as white crystals in a 43% yield.
MP: 170° C.
Analysis for C27H21N2O3F. 1.3H2O:
Calculated: C,68.07; H,5.82; N.7.68;
Found: C,67.98; H,5.8; N,7.7%.
EXAMPLE 58
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(3-hydroxyphenyl)propene-1-one
The same method as employed in the preparation of Example 20 but starting from (E)-3-hydroxycinnamic acid gave after recrystallization from EtOH:H2O the title compound as white crystals in a 54% yield.
MP: 248° C.
Analysis for C27H22N2O4:
Calculated: C,73.96; H,5.06; N,6.39;
Found: C,74.04; H,5.1; N,6.37%.
EXAMPLE 59
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(3-methoxyphenyl)propene-1-one
The same method as employed in the preparation of Example 20 but starting from (E)-3-methoxycinnamic acid gave after recrystallization from EtOH the title compound as white crystals in a 49% yield.
MP: 218° C.
Analysis for C28H24N2O4:
Calculated: C,74.32; H,5.35; N,6.19;
Found: C,74.37; H,5.61; N,6.32%.
EXAMPLE 60
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(3-nitrophenyl)propene-1-one
The same method as employed in the preparation of Example 20 but starting from (E)-3-nitrocinnamic acid gave after recrystallization from EtOH:H2O (20:1) the title compound as white crystals in a 91% yield.
MP: 156-158° C.
Analysis for C28H24N2O4:
Calculated: C,69.37; H,4.54; N,8.99;
Found: C,69.12; H,4.77; N,8.81%.
EXAMPLE 61
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-[4-(2-dimethylaminoethoxy)phenyl]propene-1-one
The same method as employed in the preparation of Example 20 but starting from Intermediate 25 gave after recrystallization from EtOH:H2O the title compound as white crystals in a 45% yield.
MP: 157° C.
Analysis for C31H31N3O4:
Calculated: C,73.07; H,6.13; N,8.25;
Found: C,72.7; H,6.17; N,8.12%.
EXAMPLE 62
(E)-N-(2-Morpholin-4-ylethyl)-4-[3-oxo-3-(1-(3,4-methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)propenyl]benzamide
The same method as employed in the preparation of Example 20 but starting from Intermediate 26 gave after recrystallization from EtOH:H2O the title compound as white crystals in a 13% yield.
MP: 145° C.
Analysis for C34H34N4O5. 0.7H2O:
Calculated: C,69.07; H,6.03; N9.48;
Found: C,69.08; H, 6.03; N,9.45%.
EXAMPLE 63
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-[4-(1H-tetrazol-5-yl)phenyl]propene-1-one
To a solution of Example 32 (0.25 g, 0.56 mmol) in 10 mL of toluene were added successively trimethylsilylazide (0.30 mL, 4 equiv.) and dibutyltinoxide (0.06 g, 0.4 equiv.). The resulting mixture was stirred at reflux for two days. T/c monitoring showed formation of a new compound (DCM:MeOH (80.20), Rf=0.35). The reaction mixture was concentrated in vacuo. The resulting yellow gum was dissolved in MeOH and concentrated in vacuo. The residue was partitioned between EtOAc (25 mL) and an aqueous saturated solution of NaHCO3 (25 mL). The organic phase was extracted with an additional portion of an aqueous saturated solution of NaHCO3 (25 mL). The combined aqueous extracts were acidified to pH=2 with HCl (1N) and then extracted with EtOAc (2×25 mL). The combined organic extracts were dried over MgSO4, filtered and concentrated to give a yellow powder that was purified via flash chromatography (SiO2, DCM:MeOH (90:10)). Recrystallization from 2-propanol:iPr2O (1:1) gave the title compound (0.19 g, 70%) as white crystals.
MP: 232-233° C.
Analysis for C28H22N6O3. 0.4H2O:
Calculated: C,67.02; H,4.92; N,16.28;
Found: C,66.83; H,4.53; N,15.96%.
EXAMPLE 64
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(3-aminophenyl)propene-1-one
A solution of Example 60 (1.36 g, 2.9 mmol), SnCl2.H2O (2.8 g, 5 equiv.) in EtOH was refluxed overnight. After evaporation of the solvent, the residue was taken up in 50 mL of NaOH (1N). The aqueous phase was extracted with 2×100 mL of DCM and 2×50 mL of EtOAc. The combined organic layers were dried over Na2SO4 and concentrated in vacuo. Flash chromatography (SiO2, DCM:MeOH (95:5) and recrystallization from EtOH:DCM gave the title compound (0.27 g, 21%) as a pale yellow powder.
MP: 139-141° C.
Analysis for C27H23N3O3:
Calculated: C,74.13; H,5.30; N,9.60;
Found: C,73.93; H,5.35; N,9.43%.
EXAMPLE 65
(E)-N-Cyclohexyl-4-[3-oxo-3-(1-(3,4-methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)propenyl]benzamide
The same method as employed in the preparation of Example 20 but starting from Intermediate 27 gave after recrystallization from EtOH:H2O the title compound as white crystals in a 6% yield.
MP: 214° C.
Analysis for C28H21N3O3. 0.1H2O:
Calculated: C,72.19; H,6.24; N,7.43;
Found: C,72.28; H,6.19; N,6.93%.
EXAMPLE 66
(E)-N-(Tetrahydrofuran-2-ylmethyl)-4-[3-oxo-3-(1-(3,4-methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)propenyl]benzamide
The same method as employed in the preparation of Example 20 but starting from Intermediate 28 gave after recrystallization from EtOH:H2O (8:2) the title compound as white crystals in a 61% yield.
MP: 168° C.
Analysis for C32H29N3O5. 0.8H2O:
Calculated: C,69.88; H,5.61; N,7.64;
Found: C,69.74; H,5.78; N,7.22%.
EXAMPLE 67
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(3-cyanophenyl)propene-1-one
The same method as employed in the preparation of Example 20 but starting from (E)-cyanocinnamic acid gave after recrystallization from EtOH:H2O (8:2) the title compound as white crystals in a 46% yield.
MP: 228-230° C.
Analysis for C28H21N3O3. 0.8H2O:
Calculated: C,72.81; H,4.93; N,9.10;
Found: C,72.74; H,4.69; N,8.99%.
EXAMPLE 68
(E)-N-(4-Piperidine-4-carboxylic Acid, Ethyl Ester)-4-[3-oxo-3-(1-(3,4-methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)propenyl]benzamide
The same method as employed in the preparation of Example 20 but starting from Intermediate 29 gave after recrystallization from iPr2O the title compound as white crystals in a 28% yield.
MP: 144-145° C.
Analysis for C36H35N3O6. 0.7H2O:
Calculated: C, 69.93; H,5.93; N,6.8;
Found: C,69.84; H,5.83; N,6.81%.
EXAMPLE 69
(E)-N-(4-Piperidine-4-carboxylic Acid)-4-[3-oxo-3-(1-(3,4-methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)propenyl]benzamide
This product was prepared by refluxing a solution of Example 68 (0.21 g, 0.36 mmol) with NaOH (1 N) (0.72 mL, 2 equiv.) in 20 mL of MeOH for 12 hours. After cooling the mixture was poured into H2O (100 mL) and acidified with HCl (1 N). Extraction with 2×50 mL of DCM, drying over Na2SO4 and concentration in vacuo gave a residue which was recrystallized from MeOH:H2O to give the title compound (0.05 g, 24%) as white crystals.
MP: 204-205° C.
Analysis for C34H31N3O6. 0.4H2O:
Calculated: C,68.56; H,5.58; N,7.05;
Found: C,68.58; H,5.12; N,7.06%.
EXAMPLE 70
(E)-3-[3-Oxo-3-[1-(3,4-methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-propenyl]benzoic Acid
The same method as employed in the preparation of Example 20 but starting from (E)-3-(2-carboxyvinyl)benzoic acid gave after recrystallization from MeOH, the title compound as a white powder in a 21% yield.
MP: 156-158° C.
Analysis for C28H22N2O5. 0.8H2O:
Calculated: C,69.93; H,4.95; N,5.83;
Found: C,69.94; H,4.62; N,5.65%.
EXAMPLE 71
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-3-(3-(4-methylpiperazine-1-carbonyl)phenyl)propene-1-one
The same method as employed in the preparation of Example 20 but starting from Example 70 and 4-methylpiperazine gave after recrystallization from MeOH:H2O, the title compound as a white powder in a 30% yield.
MP: 151° C.
Analysis for C33H32N4O4. H2O:
Calculated: C,69.95; H,6.05; N,9.89;
Found: C,69.63; H,5.93; N,9.99%.
EXAMPLE 72
(E)-N-(2-Piperazin-1-ylethyl)-3-[3-oxo-3-(1-(3,4-methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)propenyl]benzamide
The same method as employed in the preparation of Example 20 but starting from Example 70 and 1-(2-aminoethyl)piperazine gave after recrystallization from iPr2O, the title compound as a white powder in a 23% yield.
MP: 138-140° C.
Analysis for C34H35N5O4. 3.1H2O:
Calculated: C,64.46; H,6.55; N,11.05;
Found: C,64.46; H,6.25; N,11.00%.
EXAMPLE 73
(E)4-[3-Oxo-3-(1-(3,4-methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)-propenyl]acetic Acid Ethyl Ester
The same method as employed in the preparation of Example 20 but starting from Intermediate 30 gave after recrystallization from DCM:pentane, the title compound as a white powder in a 17% yield.
MP: 92-95° C.
Analysis for C31H28N2O5. 0.9H2O:
Calculated: C,70.95; H,5.72; N,5.34;
Found: C,71.32; H,6.0; N,4.93%.
EXAMPLE 74
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(3-tetrazolophenyl)propene-1-one
The same method as employed in the preparation of Example 63 but starting from Example 67 gave after recrystallization from MeOH:H2O, the title compound as a white powder in a 5% yield.
MP: 260-264° C.
Analysis for C28H22N6O3. 2.2H2O:
Calculated: C,63.43; H,5.02; N,15.85;
Found: C,63.31; H,4.37; N,15.47%.
EXAMPLE 75
(E)-2-[3-Oxo-3-[1-(3,4-methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-propenyl]benzoicacid, Methyl Ester
The same method as employed in the preparation of Example 20 but starting from (E)-2-(2-carboxyvinyl)benzoic acid, methyl ester (prepared according to the procedure of Alabaster, R. J.; Cottrell, I. F.; Hands, D.; Humphrey, G. R.; Kennedy, D. J.; Wright, S. H. B. Synthesis 1989, 8, 598-603), gave after recrystallization from MeOH, the title compound as white crystals in a 46% yield.
MP: 203-204° C.
Analysis for C27H21N3O5:
Calculated: C,72.49; H,5.03; N,5.83;
Found: C,72.59; H,5.1; N,5.67%.
EXAMPLE 76
(E)-3-[3-Oxo-3-[1-(3,4-methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-propenyl]benzoic Acid, Methyl Ester
The same method as employed in the preparation of Example 20 but starting from (E)-3-(2-carboxyvinyl)benzoicacid, methyl ester (prepared according to the procedure of Baker, S. R.; Jamieson, W. B.; Todd, A. EP 134111 A1), gave after recrystallization from MeOH, the title compound as yellow crystals in a 61% yield.
MP: 165-167° C.
Analysis for C29H24N2O5:
Calculated: C,72.49; H,5.03; N,5.83;
Found: C,72.53; H,5.02; N,5.93%.
EXAMPLE 77
(E)-1-(4-[3-Oxo-3-(1-(3,4-methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)-propenyl]phenyl)piperidine-4carboxylic Acid, Ethyl Ester
The same method as employed in the preparation of Example 20 but starting from Intermediate 31 gave after recrystallization from MeOH, the title compound as yellow crystals in a 45% yield.
MP: 175° C.
Analysis for C35H35N3O5:
Calculated: C,72.77; H,6.11; N,7.27;
Found: C,72.99; H,6.16; N,7.03%.
EXAMPLE 78
(E)-N-(1-Ethylpyrrolidin-2-yl-methyl)-3-[3-oxo-3-(1-(3,4-methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)propenyl]benzamide
The same method as employed in the preparation of Example 20 but starting from Example 70 and 2-pyrrolidin-1-ylethylamine gave after recrystallization from iPr2O, the title compound as a white powder in a 53% yield.
MP: 128-130° C.
Analysis for C35H36N4O4:
Calculated: C,72.9; H,6.29; N,9.72;
Found: C,72.9; H,6.42; N,10.01%.
EXAMPLE 79
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(3-(2-dimethylaminoethoxy)phenyl)propene-1-one
To a solution of Example 58 (0.25 g, 0.57 mmol) in 50 mL of DMF was added K2CO3 (0.24 g, 3 equiv.) and an excess of dimethylaminodiethyl chloride (about 15 equiv.). The resulting mixture was heated at 60° C. for four hours until disappearance of the Jstarting material (tlc monitoring, DCM:MeOH (90:10). A new compound was formed (Rf=0.20). After evaporation of DMF, the residue was taken up in 150 mL of DCM, washed with 2×50 mL of water, dried over Na2SO4 and recrystallized from EtOH:H2O to give the title compound (0.06 g, 22%) as yellow crystals.
MP: 76-78° C.
Analysis for C31H31N3O4. 0.6H2O:
Calculated: C,71.55; H,6.24; N,8.07;
Found: C,71.34; H,6.45; N,7.8%.
EXAMPLE 80
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(3,5-diterbutyl-4-hydroxyphenyl)propene-1-one
The same method as employed in the preparation of Example 20 but starting from (E)-3,5-ditertbutyl-4-hydroxycinnamic acid gave after recrystallization from cyclohexane, the title compound as yellow crystals in a 45% yield.
MP: 137° C.
EXAMPLE 81
(E)-3-[3-Oxo-3-[1-(4-methoxycarbonylphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]propenyl]benzoic Acid, Methyl Ester
The same method as employed in the preparation of Example 20 but starting from Intermediate 8 and (E)-3-(2-carboxy-vinyl)benzoic acid, methyl ester (prepared according to the procedure of Baker, S. R.; Jamieson, W. B; Todd, A. EP 134111 A1), gave after recrystallization from 2-propanol, the title compound as white crystals in a 70% yield.
MP: 182° C.
Analysis for C30H26N2O5:
Calculated: C,72.86; H,5.3; N,5.66;
Found: C,72.49; H,5.31; N,5.68%.
EXAMPLE 82
(E)-2-[3-Oxo-3-[1-(3,4-methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-propenyl]benzoic Acid
The same method as employed in the preparation of Example 31 but starting from Example 75 gave after recrystallization from MeOH the title compound as off-white crystals in a 78% yield.
MP: 174° C.
Analysis for C28H22N2O5:
Calculated: C,72.09, H,4.75; N,6.01;
Found: C,72.53; H,4.72; N,5.76%.
EXAMPLE 83
(E)-(4-[3-Oxo-3-(1-(3,4-methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)propenyl]phenoxy)acetic Acid, Ethyl Ester
The same method as employed in the preparation of Example 79 but starting from Example 22 and bromoacetic acid, ethyl ester, gave after recrystallization from EtOH:2-propanol the title compound as yellow crystals in a 28% yield.
MP: 99-98° C.
Analysis for C31H28N2O6. 2.4H2O:
Calculated: C,65.57; H,5.82; N,4.93;
Found: C,65.34; H,5.4; N,5.09%.
EXAMPLE 84
(E)-(4-[3-Oxo-3-(1-(3,4-methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)-propenyl]phenyl)acetic Acid
The same method as employed in the preparation of Example 31 but starting from a solution of Example 73 in EtOH gave after recrystallization from iPr2O:2-propanol the title compound as white crystals in a 51% yield.
MP: 231° C.
Analysis for C29H24N2O5. 0.25iPrOH:
Calculated: C, 72.11; H, 5.29; N,5.64;
Found: C, 71.9; H, 5.15; N, 5.74%.
EXAMPLE 85
(E)-(4-[3-Oxo-3-(1-(3,4-methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)propenyl]phenoxy)acetic Acid
The same method as employed in the preparation of Example 31 but starting from Example 83 gave after recrystallization from iPr2O:2-propanol the title compound as yellow crystals in a 45% yield.
MP: 158-160° C.
Analysis for C29H24N2O6. 0.9H2O:
Calculated: C,67.93; H,5.07; N,5.46;
Found: C,68.0; H,4.86; N,5.21%.
EXAMPLE 86
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(3-nitro-4-chlorophenyl)propene-1-one
The same method as employed in the preparation of Example 20 but starting from (E)-3-nitro-4-chlorocinnamic acid gave after recrystallization from EtOH the title compound as yellow crystals in a 56% yield.
MP: 240° C.
Analysis for C27H20N3O5Cl:
Calculated: C,64.61; H,4.02; N,8.37;
Found: C,64.5; H,3.97; N,8.28%.
EXAMPLE 87
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(5-nitro-2-chlorophenyl)propene-1-one
The same method as employed in the preparation of Example 20 but starting from (E)-5-nitro-2-chlorocinnamic acid gave after recrystallization from EtOH:H2O the title compound as yellow crystals in a 44% yield.
MP: 146° C.
Analysis for C27H20N3O5Cl. 0.1H2O:
Calculated: C,64.38; H,4.04; N,8.34;
Found: C,64.12; H,3.81; N,8.35%.
EXAMPLE 88
(E)-3-Chloro-4-[3-oxo-3-[1-(3,4-methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]propenyl]benzoic Acid, Methyl Ester
The same method as employed in the preparation of Example 20 but starting from Intermediate 32 gave after recrystallization from EtOH the title compound as a white powder in a 57% yield.
MP: 166° C.
Analysis for C29H23N2O5Cl. 0.15EtOH:
Calculated: C,67.43; H,4.62; N,5.37;
Found: C,67.09; H,4.56; N,5.51%.
EXAMPLE 89
(E)-(4-[3-Oxo-3-(1-(3,4-methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)propenyl]benzyloxy)acetic Acid
The same method as employed in the preparation of Example 79 but starting from a solution of (E)-(4-[3-oxo-3-(1-(3,4-methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)propenyl]benzyloxy acetic acid, ethyl ester in EtOH gave after recrystallization from MeOH:H2O the title compound as an off-white solid in a 40% yield.
MP: 162-163° C.
Analysis for C30H26N2O6. 0.1H2O:
Calculated: C,68.17; H,5.13; N,5.49;
Found: C,68.16; H,5.46; N,5.51%.
(E)-(4-[3-Oxo-3-(1-(3,4-methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)propenyl]benzyloxy)acetic Acid, Ethyl Ester
To a solution of Example 39 (0.7 g, 1.5 mmol) in 50 mL of DMF was added K2CO3 (0.25 g, 1.2 equiv.) and ethylbromoacetate (0.2 mL, 1.1 equiv.). The resulting mixture was heated at 60° C. for 16 hours until disappearance of the starting material (tic monitoring, DCM:MeOH (95:5)). A new compound was formed (Rf=0.8). After evaporation of DMF, the residue was taken up in 150 mL of DCM, washed with 2×50 mL of water, dried over Na2SO4 and purified via radial chromatography with DCM to give the title compound (0.85 g, 11%) as a white powder.
1H NMR (CDCl3) δ7.8-6.65 (m, 14H), 5.9 (s, 2H), 4.7 (s, 2H), 4.6-4.3 (q, 2H), 4.2-4.0 (m, 4H), 3.6-3.5 (m, 1H), 3.2-2.9 (m, 2H), 1.3-1.2 (t, 3H).
EXAMPLE 90
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(5-amino-2-chlorophenyl)propene-1-one
The same method as employed in the preparation of Example 64 but starting from Example 87 gave after recrystallization from EtOH:DCM, the title compound as a white powder in a 17% yield.
MP: 251-252° C.
Analysis for C27H22ClN3O3. 0.4H2O:
Calculated: C,67.68; H,4.8; N,8.77;
Found: C,67.71; H,4.73; N,8.65%.
EXAMPLE 91
(E)-3-Chloro-4-[3-oxo-3-[1-(3,4-methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]propenyl]benzoic Acid
The same method as employed in the preparation of Example 31 but starting from Example 88 gave after recrystallization from 2-propanol the title compound as a yellow powder in a 40% yield.
MP: 169° C.
Analysis for C28H21N2O5. H2O:
Calculated: C,64.8; H,4.47; N,5.40;
Found: C,64.47; H,4.13; N,5.60%.
EXAMPLE 92
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(3,5-dibromo-4-hydroxyphenyl)propene-1-one
The same method as employed in the preparation of Example 20 but starting from (E)-3,5-dibromo-4-hydroxy cinnamic acid gave after recrystallization from EtOH:H2O the title compound as white crystals in a 13% yield.
MP: 148-150° C.
Analysis for C27H20N2O4Br2. 1.6EtOH:
Calculated: C,54.14; H,4.45; N,4.18;
Found: C,54.1; H,4.15; N,3.77%.
EXAMPLE 93
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(4-(2-dimethylaminopropoxy)phenyl)propene-1-one
The same method as employed in the preparation of Example 79 but starting from Example 22 and dimethylaminopropyl chloride gave after recrystallization from cyclohexane:DCM:pentane the title compound as white crystals in a 16% yield.
MP: 106° C.
Analysis for C32H33N3O4. 0.3H2O:
Calculated: C,72.65; H,6.40; N,7.94;
Found: C,72.74; H,6.56; N,7.63%.
EXAMPLE 94
(E)-2-Chloro-5-[3-oxo-3-[1-(3,4-methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]propenyl]benzoic Acid, Methyl Ester
The same method as employed in the preparation of Example 20 but starting from Intermediate 33 gave after recrystallization from MeOH:DCM the title compound as a white powder in a 59% yield.
MP: 228° C.
Analysis for C29H23ClN2O5. 1.05H2O:
Calculated: C,65.24; H,4.74; N,5.25;
Found: C,64.91; H,4.27; N,5.13%.
EXAMPLE 95
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1 3,4,9-tetrahydro-β-carbolin-2-yl]-3-(4-(2-diisopropylaminoethoxy)phenyl)propene-1-one
The same method as employed in the preparation of Example 79 but starting from Example 22 and diisopropylaminodiethyl chloride gave after recrystallization from MeOH:H2O the title compound as pale yellow crystals in a 12% yield.
MP: 92-93° C.
Analysis for C35H39N3O4:
Calculated: C,74.31; H,6.95; N,7.43;
Found: C,74.34; H,7.16; N,7.10%.
EXAMPLE 96
(E)-2-Chloro-5-[3-oxo-3-[1-(3,4-methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]propenyl]benzoic Acid
The same method as employed in the preparation of Example 31 but starting from Example 94 gave after recrystallization from MeOH the title compound as white crystals in a 78% yield.
MP: 178° C.
Analysis for C28H21N2O5. 0.7MeOH:
Calculated: C,65.86; H,4.58; N,5.35;
Found: C, 65.73; H, 4.44; N, 5.51%.
EXAMPLE 97
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(3-hydroxy-4-nitrophenyl)propene-1-one
The same method as employed in the preparation of Example 20 but starting from Intermediate 34 gave after recrystallization from EtOH the title compound as yellow crystals in a 77% yield.
MP: 172° C.
EXAMPLE 98
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(3,5-dimethyl-4-hydroxyphenyl)propene-1-one
The same method as employed in the preparation of Example 20 but starting from Intermediate 35 gave after recrystallization from MeOH:H2O the title compound as a white powder in a 71% yield.
MP: 151-152° C.
Analysis for C29H26N2O4. 0.4H2O:
Calculated: C,73.52; H,5.7; N,5.91;
Found: C,73.56; H,5.59; N6.29%.
EXAMPLE 99
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(3-(2-dimethylaminoethoxy)-4-nitrophenyl)propene-1-one
The same method as employed in the preparation of Example 79 but starting from Example 97 and dimethylaminodiethyl chloride gave after recrystallization from MeOH the title compound as a pale yellow powder in a 18% yield.
MP: 189° C.
Analysis for C31H30N4O6. 1.5H2O:
Calculated: C,64.02; H,5.72; N,9.63;
Found: C,64.18; H,5.41; N,9.21%.
EXAMPLE 100
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(3-(2-dimethylaminoethoxy)-4-aminophenyl)propene-1-one
The same method as employed in the preparation of Example 64 but starting from Example 99 gave after recrystallization from iPr2O the title compound as a pale yellow powder in a 17% yield.
MP: 143° C.
Analysis for C31H32N4O4. 0.5H2O:
Calculated: C,69.78; H,6.23; N,10.5;
Found: C,69.87; H,5.98; N,10.42%.
EXAMPLE 101
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(3-nitro-4-hydroxy-5-methoxyphenyl)propene-1-one
The same method as employed in the preparation of Example 20 but starting from Intermediate 36 gave after recrystallization from EtOH:DCM the title compound as pale yellow crystals in a 45% yield.
MP: 172° C.
Analysis for C28H23N3O7. 0.8H2O:
Calculated: C,63.7; H,4.7; N,7.96;
Found: C,63.71; H,4.31; N,7.98%.
EXAMPLE 102
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(3-chloro-phenyl)propene-1-one
The same method as employed in the preparation of Example 20 but starting from (E)-3-chlorocinnamic acid, gave after recrystallization from EtOH the title compound as white crystals in a 48% yield.
MP: 212-213° C.
Analysis for C27H21ClN2O:
Calculated: C,70.97; H,4.63; N,6.13
Found: C,70.65; H,4.63; N,6.16%.
EXAMPLE 103
(E)-1-[1-(4-Methoxy-phenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(2-chloro-5-nitrophenyl)propene-1-one
The same method as employed in the preparation of Example 20 but starting from Intermediate 2 and (E)-2-chloro-5-nitrocinnamic acid gave after recrystallization from 2-propanol the title compound as a yellow powder white in a 18% yield.
MP: 136-138° C.
Analysis for C27H22ClN3O4. 0.2H2O:
Calculated: C,65.98; H,4.59; N,8.55;
Found: C,65.91; H,4.4; N,8.42%.
EXAMPLE 104
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(2,6-dichlorophenyl)propene-1-one
The same method as employed in the preparation of Example 20 but starting from (E)-2,6-dichlorocinnamic acid gave after recrystallization from cyclohexane the title compound as a white powder in a 41% yield.
MP: 118-120° C.
Analysis for C27H20Cl2N2O3. 0.2H2O:
Calculated: C,65.52; H,4.15; N,5.66;
Found: C,65.74; H,4.62; N,5.29%.
EXAMPLE 105
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(4-methylaminomethylphenyl)propene-1-one
A solution of (E)-1-[1-(3,4-methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(4-methyliminomethylphenyl)propene-1-one (0.46 g, 1.1 mmol), NaBH3CN (0.14 g, 2.3 mmol) and acetic acid (0.11 mL) in 20 mL of MeOH was stirred at rt for one hour. The reaction mixture was quenched with 50 mL of an aqueous saturated solution of NaHCO3. Extraction with 2×30 mL of DCM, washing with brine, drying over Na2SO4 and concentration in vacuo gave a residue that was purified via flash chromatography of silica gel using DCM:MeOH (97:3) as eluting solvent. Recrystallization from DCM:cyclohexane gave the title compound (0.05 g, 10%) as a white powder.
MP: 201° C.
Analysis for C29H27Cl2N3O3. 0.5H2O:
Calculated: C,73,4; H,5.95; N,8.85;
Found: C,73.66; H,5.82; N,8.57%.
A stirred solution of Example 23 (0.5 g, 1.0 mmol) in MeOH was refluxed with methylamine (1.6 mL, 1.5 equiv., 33% in EtOH) for one hour. Evaporation in vacuo gave (E)-1-[1-(3,4-methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(4-methyliminomethylphenyl)propene-1-one (0.46 g, 90%).
1H NMR (CDCl3, 250 MHz) δ8.2 (d, 1H), 8.1 (s, 1H), 7.8-7.65 (m, 3H), 7.55-7.5 (m, 3H), 7.4-7.1 (m, 3H), 7.0-6.85 (m, 2H), 6.8-6.6 (dd, 2H), 5.9 (s, 2H), 4.2-4.1 (br d, 1H), 3.5 (s+m, 4H), 3.05-2.85 (m, 2H).
EXAMPLE 106
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(3-methylphenyl)-propene-1-one
The same method as employed in the preparation of Example 20 but starting from (E)-3-methylcinnamic acid gave after recrystallization from MeOH the title compound as a white powder in a 67% yield.
MP: 196° C.
Analysis for C28H24N2O3:
Calculated: C,77.04; H,5.54; N,6.62;
Found: C,76.76; H,5.56; N,6.33%.
EXAMPLE 107
(E)-N-Methyl-(4-[3-oxo-3-(1-(3,4-methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)propenyl]benzenesulfonamide
The same method as employed in the preparation of Example 20 but starting from (E)-4-(N-methylsulfonamide)cinnamic acid gave after recrystallization from EtOH:H2O the title compound as white crystals in a 79% yield.
MP: 162° C.
Analysis for C28H25N3O5. 0.4EtOH:
Calculated: C,64.78; H,5.17; N,7.87;
Found: C,64.46; H,4.82; N,7.76%.
EXAMPLE 108
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(3-hydroxy-4-acetylphenyl)propene-1-one
The same method as employed in the preparation of Example 20 but starting from (E)-3-hydroxy-4-acetylcinnamic acid gave after recrystallization from EtOH the title compound as yellow crystals in a 87% yield.
MP: 217-218° C.
Analysis for C29H24N2O5:
Calculated: C,72.49; H,5.03; N,5.83;
Found: C,72.24; H,5.25; N,5.53%.
EXAMPLE 109
(E)-1-[1-(2,3-Dihydrobenzofuran-5-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(2-chloro-5-nitrophenyl)propene-1-one
The same method as employed in the preparation of Example 20 but starting from Intermediate 10 and (E)-2-chloro-5-nitrocinnamic acid gave after recrystallization from EtOH:H2O (95:5) the title compound as yellow crystals in a 62% yield.
MP: 154° C.
Analysis for C27H22ClN3O4. 0.5(H2O:MeOH):
Calculated: C,66.08; H,4.55; N,8.36;
Found: C,66.3; H,4.52; N,7.94%.
EXAMPLE 110
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(2-hydroxyphenyl)propene-1-one
The same method as employed in the preparation of Example 20 but starting from (E)-2-hydroxy cinnamic acid gave after recrystallization from EtOH:H2O, the title compound as white crystals in a 47% yield;
MP: 154° C.
Analysis for C27H22N2O4. 0.6H2O:
Calculated: C,72.18; H,5.2; N,6.24;
Found: C,72.19; H,4.93; N,6.13%.
EXAMPLE 111
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(3-nitro-2-piperidin-1-ylphenyl)propene-1-one
The same method as employed in the preparation of Example 20 but starting from Intermediate 37 gave after recrystallization from MeOH the title compound as yellow crystals in a 31% yield.
MP: 162-163° C.
Analysis for C32H30N4O5. 0.2H2O:
Calculated: C,65.52; H,5.84; N,9.55;
Found: C,65.9; H,5.49; N,9.59%.
EXAMPLE 112
(E)-1-[1-(2,3-Dihydrobenzofuran-5-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-phenylpropene-1-one
The same method as employed in the preparation of Example 1 but starting from Intermediate 10 gave after recrystallization from EtOH the title compound as white crystals in a 52% yield.
MP: 190° C.
Analysis for C28H24N2O2:
Calculated: C,79.98; H,5.75; N,6.66;
Found: C,79.94; H,5.86; N,6.62%.
EXAMPLE 113
(E)-1-[1-(4-Isopropylphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(3-nitrophenyl)propene-1-one
The same method as employed in the preparation of Example 20 but starting from Intermediate 11 and (E)-3-nitrocinnamic acid gave after recrystallization from EtOH the title compound as yellow crystals in a 54% yield.
MP: 195° C.
Analysis for C29H27N3O3:
Calculated: C,74.82; H,5.85; N,9.03;
Found: C,74.43; H,5.84; N,9.17%.
EXAMPLE 114
(E)-1-[1-(2,3-Dihydrobenzofuran-5-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(3-nitrophenyl)propene-1-one
The same method as employed in the preparation of Example 20 but starting from Intermediate 10 and (E)-3-nitrocinnamic acid gave after recrystallization from EtOH the title compound as white crystals in a 35% yield.
MP: 174-176° C.
Analysis for C28H23N3O4. 0.1H2O:
Calculated: C,71.97; H,5.0; N,8.99;
Found: C,71.78; H,4.89; N,8.83%.
EXAMPLE 115
(E)-(R)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-phenylpropene-1-one
The same method as employed in the preparation of Example 1 but starting from Intermediate 19 gave after recrystallization from EtOH the title compound as white crystals in a 60% yield.
MP: 232-233° C.
Analysis for C27H22N2O3. 0.2H2O:
Calculated: C,76.11; H,5.3; N,6.57;
Found: C,76.2; H,5.27; N,6.77%
[α]D 21=−336 (c=0.50, MeOH).
EXAMPLE 116
(E)-(S)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-phenylpropene-1-one
The same method as employed in the preparation of Example 1 but starting from Intermediate 18 gave after recrystallization from iPrOH the title compound as white crystals in a 32% yield.
MP: 235-236° C.
Analysis for C27H22N2O3. 0.1H2O:
Calculated: C,76.43; H,5.27; N,6.6;
Found: C,76.26; H,5.21; N,6.61%.
[α]D 21=378 (c=0.5, MeOH).
EXAMPLE 117
(E)-1-[1-(4-Methoxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3(3-nitrophenyl)propene-1-one
The same method as employed in the preparation of Example 20 but starting from Intermediate 2 and (E)-3-nitrocinnamic acid gave after recrystallization from EtOH the title compound as yellow crystals in a 63% yield.
MP: 227° C.
Analysis for C27H23N3O4. 0.1EtOH:
Calculated: C,71.32; H,5.19; N,9.17;
Found: C,70.96; H,5.14; N,9.23%.
EXAMPLE 118
(E)-1-[1-(4-Methylphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(2-chloro-5-nitrophenyl)propene-1-one
The same method as employed in the preparation of Example 20 but starting from Intermediate 6 and (E)-2-chloro-5-nitrocinnamic acid gave after recrystallization from EtOH the title compound as a yellow powder in a 57% yield.
MP: 211-213° C.
Analysis for C27H23ClN3O3:
Calculated: C,68.72; H,4.7; N,8.9;
Found: C,68.42; H,4.73; N.8.91%.
EXAMPLE 119
(E)-N-(Tetrahydrofuran-2-ylmethyl)-3-[3-oxo-3-(1-(3,4-methylenedioxy)-1,3,4,9-tetrahydro-β-carbolin-2-yl)propenyl]benzamide
The same method as employed in the preparation of Example 20 but starting from Example 70 and tetrahydrofurfurylamine gave after recrystallization from EtOH the title compound as a white powder in a 30% yield.
MP: 172-173° C.
Analysis for C33H31N3O5. 0.4H2O:
Calculated: C,71.18; H,5.76; N,7.55;
Found: C,71.1; H,5.88; N,7.45%.
EXAMPLE 120
(E)-1-[1-(Indan-5-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-phenylpropene-1-one
The same method as employed in the preparation of Example 1 but starting from Intermediate 9 and tetrahydrofurfurylamine gave after recrystallization from EtOH the title compound as white crystals in a 51% yield.
MP: 223° C.
Analysis for C29H26N2O. 0.4H2O:
Calculated: C,81.81; H,5.34; N,6.58;
Found: C,81.87; H,6.34; N,6.5%.
EXAMPLE 121
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(3-acetylphenyl)propene-1-one
The same method as employed in the preparation of Example 20 but starting from 3-acetylcinnamic acid (prepared according to the procedure of Cleland, G. H. J. Org. Chem. 1969, 34, 744-747) gave after recrystallization from EtOH the title compound as a yellow powder in a 42% yield.
MP: 191° C.
Analysis for C29H24ClN2O4:
Calculated: C,74.98; H,5.21; N,6.03;
Found: C,74.85; H,5.28; N,6.1%.
EXAMPLE 122
(E)-1-[1-(2,3-Dihydrobenzofuran-5-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(4-(2-dimethylaminoethoxy)phenyl)propene-1-one
The same method as employed in the preparation of Example 20 but starting from Intermediate 10 and Intermediate 25 gave after recrystallization from CH3CN the title compound as white crystals in a 37% yield.
MP: 146° C.
Analysis for C32H33N3O3. 1.5H2O:
Calculated: C,71.89; H,6.79; N,7.86;
Found; C,72.04; H,7.09; N,7.93%.
EXAMPLE 123
(E)-4-[3-Oxo-3-[1-(4-methoxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]propenyl]benzoic Acid, Methyl Ester
The same method as employed in the preparation of Example 20 but starting from Intermediate 2 and (E)-4-(2-carboxyvinyl)benzoic acid, methyl ester gave after recrystallization from EtOH the title compound as yellow crystals in a 73% yield.
MP: 189° C.
Analysis for C29H26N2O4. 0.1EtOH:
Calculated; C,74.44; H,5.69; N,5.95;
Found: C,74.1; H, 5.65; N,6.01%.
EXAMPLE 124
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(4-methyl-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl)propene-1-one
The same method as employed in the preparation of Example 20 but starting from Intermediate 38 gave after recrystallization from EtOH the title compound as yellow crystals in a 69% yield.
MP: 231-232° C.
Analysis for C29H26N2O4. 0.1EtOH:
Calculated: C,73.01; H,5.51; N, 8.51;
Found: C,72.54; H,5.58; N,8.44%.
EXAMPLE 125
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(2-hydroxy-5-nitrophenyl)propene-1-one
The same method as employed in the preparation of Example 20 but starting from Intermediate 39 gave after recrystallization from EtOH the title compound as yellow crystals in a 30% yield.
MP: 205° C.
Analysis for C27H21N3O6. 0.6EtOH:
Calculated: C,65.78; H,5.14; N,7.94;
Found: C,65.52; H,4.98; N,8.04%.
EXAMPLE 126
(E)-4-[3-Oxo-3-[1-(2,3-dihydrobenzofuran-5-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]propenyl]benzoic Acid, Methyl Ester
The same method as employed in the preparation of Example 20 but starting from Intermediate 10 and (E)-4-(2-carboxyvinyl)benzoic acid, methyl ester gave after recrystallization from EtOH the title compound as white needles in a 88% yield.
MP: 186° C.
Analysis for C30H26N2O4. 0.2H2O:
Calculated: C,74.73; H,5.52; N,5.81;
Found: C,75.45; H, 5.38; N,6.07%.
EXAMPLE 127
(E)-4-[3-Oxo-3-[1-(4-methoxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]propenyl]benzoic Acid
The same method as employed in the preparation of Example 31 but starting from Example 123 gave after recrystallization from MeOH:H2O the title compound as a grey powder in a 43% yield.
MP: 147-149° C.
Analysis for C28H24N2O4:
Calculated: C,74.32; H,5.35; N,6.19;
Found: C,74.3; H,5.37; N,6.07%.
EXAMPLE 128
(E)-4-[3-Oxo-3-[1-(2,3-dihydrobenzofuran-5-yl)-1,3,4,9-TETRAHYDRO-β-carbolin-2-yl]propenyl]benzoic Acid
The same method as employed in the preparation of Example 31 but starting from Example 126 gave after recrystallization from MeOH the title compound as white crystals in a 53% yield.
MP: 222-224° C.
Analysis for C29H24N2O4:
Calculated: C,74.98; H,5.21; N,6.03;
Found: C,75.21; H,5.3; N,6.21%.
EXAMPLE 129
(E)-1-[1-(Benzofuran-5-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-phenylpropene-1-one
The same method as employed in the preparation of Example 1 but starting from Intermediate 12 gave after recrystallization from EtOH the title compound as white crystals in a 35% yield.
MP: 241-242° C.
Analysis for C28H22N2O2:
Calculated: C,80.36; H,5.3; N,6.69;
Found: C,80.44; H,5.3; N,6.89%.
EXAMPLE 130
(E)-3-[3-Oxo-3-(1-(3,4-methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)-propenyl]phenyl)trifluoromethanesulfonic Acid, Phenyl Ester
The same method as employed in the preparation of Example 20 but starting from Intermediate 40 gave after recrystallization from EtOH the title compound as white crystals in a 38% yield.
MP: 169° C.
Analysis for C28H21F3N2O6S. 0.2H2O:
Calculated: C,58.58; H,3.76; N,4.88;
Found: C,58.84; H,3.71; N,4.3%.
EXAMPLE 131
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-[4-(2-hydroxyethoxy)phenyl]propene-1-one
The same method as employed in the preparation of Example 20 but starting from (E)-4-(2-hydroxyethoxy)phenyl (prepared according to the procedure of Oku, T.; Kayakiri, H.; Satoh, S.; Abe, Y.; Sawada, Y.; Inoue, T.; Tanaka, H.; EP 622361) gave after recrystallization from EtOH the title compound as white crystals in a 57% yield.
MP: 136° C.
Analysis for C29H26N2O5. 1.2EtOH:
Calculated: C,58.58; H,3.76; N,4.88;
Found: C,58.84; H,3.71; N,4.3%.
EXAMPLE 132
(E)-1-[1-(Benzofuran-5-yl-1,3,4,9-tetrahydro-β-carbolin-2-yl)]-3-(4-(2-dimethylaminoethoxy)phenyl)propene-1-one
The same method as employed in the preparation of Example 20 but starting from Intermediate 12 and Intermediate 25 gave after recrystallization from CH3CN the title compound as white crystals in a 23% yield.
MP: 159° C.
Analysis for C32H31N3O3. 0.1H2O:
Calculated: C,75.75; H,6.2; N,8.28;
Found: C,75.58; H,5.97; N,8.35%.
EXAMPLE 133
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(2-dimethylaminophenyl)propene-1-one
The same method as employed in the preparation of Example 20 but starting from (E)-2-dimethylaminocinnamic acid (prepared according to the procedure of Suschitzky, H.; Hollywood, F. Synthesis 1982, 662-665) gave after recrystallization from MeOH:H2O the title compound as a yellow powder in a 51% yield.
MP: 172° C.
Analysis for C29H27N3O3:
Calculated: C,74.82; H,9.89; N,9.03
Found: C,74.75; H,5.85; N,8.9%.
EXAMPLE 134
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(2-piperidin-1-ylphenyl)propene-1-one
The same method as employed in the preparation of Example 20 but starting from (E)-2-piperidin-1-ylcinnamic acid (prepared according to the procedure of Suschitzky, H.; Hollywood, F. Synthesis 1982, 662-665) gave after recrystallization from MeOH:H2O the title compound as a yellow powder in a 37% yield.
MP: 129° C.
Analysis for C32H31N3O3:
Calculated: C,76.02; H,6.18; N,8.31;
Found: C,75.66; H,6.18; N,8.29%.
EXAMPLE 135
(E)-4-[3-Oxo-3-[1-(benzofuran-5-yl-1,3,4,9-tetrahydro-β-carbolin-2-yl]-propenyl]benzoic Acid, Methyl Ester
The same method as employed in the preparation of Example 20 but starting from Intermediate 12 and (E)-4-(2-carboxyvinyl)benzoic acid methyl ester gave after recrystallization from EtOH the title compound as yellow crystals in a 76% yield.
MP: 221° C.
Analysis for C30H24N2O4:
Calculated: C,75.62; H,5.08; N,5.88;
Found: C,75.75; H,5.31; N,5.86%.
EXAMPLE 136
(E)-4-[3-(1-Benzofuran-5-yl-1,3,4,9-tetrahydro-β-carbolin-2-yl)-3-oxo-propenyl]Benzoic Acid
The same method as employed in the preparation of Example 31 but starting from Example 135 gave after recrystallization from CH3CN the title compound as yellow crystals in a 66% yield.
MP: 283° C.
Analysis for C29H22N2O4. 0.6H2O:
Calculated: C,73.59; H,4.94; N,5.92;
Found: C,73.48; H,4.78; N,5.93%.
EXAMPLE 137
(E)-4-[3-Oxo-3-(1-(3,4-methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)propenyl]phenyl)trifluoromethanesulfonic Acid, Phenyl Ester
The same method as employed in the preparation of Example 20 but starting from Intermediate 41 gave after recrystallization from EtOH the title compound as white crystals in a 51% yield.
MP: 254° C.
Analysis for C28H21F3N2O6S:
Calculated: C,58.95; H,3.71; N,4.91;
Found: C,58.79; H,3.8; N,4.77%.
EXAMPLE 138
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(2-(2-dimethylaminoethoxy)phenyl)propene-1-one
The same method as employed in the preparation of Example 79 but starting from Example 110 and dimethylaminodiethyl chloride gave after recrystallization from CH3CN:pentane the title compound as yellow crystals in a 70% yield.
MP: 131° C.
Analysis for C31H31N3O4. 1.3H2O:
Calculated: C,68.95; H,6.35; N,7.88;
Found: C,69.77; H,6.28; N,7.84%.
EXAMPLE 139
(E)-1-[1-(3-Fluoro-4-methoxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-phenylpropene-1-one
The same method as employed in the preparation of Example 1 but starting from Intermediate 14 gave after recrystallization from DCM:cyclohemane the title compound as white crystals in a 66% yield.
MP: 122° C.
Analysis for C27H23FN2O2. 0.4CH2Cl2:
Calculated: C,71.47; H,5.21; N,6.08;
Found: C,71.46; H,5.27; N,6.12%.
EXAMPLE 140
(E)-(R)-1-[1-(2,3-Dihydrobenzofuran-5-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)]-3-(4-(2-dimethylaminoethoxy)phenyl)propene-1-one
The same method as employed in the preparation of Example 20 but starting from Intermediate 20 and Intermediate 25 gave after recrystallization from CH3CN the title compound as white crystals in a 85% yield.
MP: 187-189° C.
Analysis for C32H33N3O3:
Calculated: C,75.71; H,6.55; N,8.20;
Found: C,75.60; H,6.76; N,8.10%.
[α]D 21=−310 (c=0.40, CHCl3).
EXAMPLE 141
(E)-1-(2,3-Dihydrobenzo[1,4]dioxin-6-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-phenylpropene-1-one
The same method as employed in the preparation of Example 1 but starting from Intermediate 13 gave after recrystallization from EtOH the title compound as white crystals in a 39% yield.
MP: 216° C.
Analysis for C28H24N2O3. 0.6H2O:
Calculated: C,75.18; H,5.68; N,6.26;
Found: C,75.17; H,5.41; N,6.4%.
EXAMPLE 142
(E)-1-[1-(2,3-Dihydrobenzofuran-5-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)]-3-(4-(2-pyrrolidin-1-ylethoxy)phenyl)propene-1-one
The same method as employed in the preparation of Example 20 but starting from Intermediate 10 and Intermediate 42 gave after recrystallization from 2-propanol:iPr2O the title compound as white crystals in a 26% yield.
MP: 152° C.
Analysis for C34H35N3O3. 0.5H2O:
Calculated: C,75.25; H,6.69; N,7.74;
Found: C,75.31; H,6.6; N,7.69%.
EXAMPLE 143
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-[4-pyrrolidin-1-ylphenyl]propene-1-one
The same method as employed in the preparation of Example 20 but starting from Intermediate 43 gave after recrystallization from EtOH:H2O the title compound as white crystals in a 73% yield.
MP: 154° C.
Analysis for C31H29N3O3. 0.6H2O:
Calculated: C,74.11; H,6.06; N,8.36;
Found: C,74.22; H,5.97; N,7.97%.
EXAMPLE 144
(E)-(R)-1-[1-(2,3-Dihydrobenzofuran-5-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(3-nitrophenyl)propene-1-one
The same method as employed in the preparation of Example 20 but starting from Intermediate 20 and (E)-3-nitrocinnamic acid gave after recrystallization from EtOH the title compound as yellow crystals in a 51% yield.
MP: 155° C.
Analysis for C28H23N3O4:
Calculated: C,72.25; H,4.98; N,9.03;
Found: C,72.2; H,5.0; N,9.01%.
[α]D 19=−347 (c=0.33, MeOH).
EXAMPLE 145
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-[4-imidazol-1-ylphenyl]propene-1-one
The same method as employed in the preparation of Example 20 but starting from Intermediate 44 gave after recrystallization from EtOH the title compound as white crystals in a 69% yield.
MP: 204° C.
Analysis for C30H24N4O3. 0.6H2O:
Calculated: C,72.68; H,5.04; N,11.3;
Found: C,72.67; H,4.85; N,11.34%.
EXAMPLE 146
(E)-4-[3-[1-(2,3-Dihydrobenzo[1,4]dioxin-6-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-oxopropenyl]benzoic Acid, Methyl Ester
The same method as employed in the preparation of Example 20 but starting from Intermediate 13 and (E)-4-(2-carboxyvinyl)benzoic acid, methyl ester gave after recrystallization from MeOH the title compound as a white powder in a 35% yield.
MP: 136° C.
Analysis for C30H26N2O5. 0.1H2O:
Calculated: C,72.6; H,5.32; N, 5.64;
Found: C,72.31; H,5.26; N,5.74%.
EXAMPLE 147
(E)-1-[1-(2,3-Dihydrobenzo[1,4]dioxin-6-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(3-nitrophenyl)propene-1-one
The same method as employed in the preparation of Example 20 but starting from Intermediate 13 and (E)-3-nitrocinnamic acid gave after recrystallization from EtOH the title compound as a pale yellow powder in a 93% yield.
MP: 154° C.
Analysis for C28H23N3O5. 0.6H2O:
Calculated: C,68.31; H,4.95; N,8.54;
Found: C,68.41; H,4.87; N,8.61%.
EXAMPLE 148
(E)-1-[1-(2,3-Dihydrobenzo[1,4]dioxin-6-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)]-3-(4-(2-dimethylaminoethoxy)phenyl)propene-1-one
The same method as employed in the preparation of Example 20 but starting from Intermediate 13 and Intermediate 25 gave after recrystallization from CH3CN the title compound as a white powder in a 65% yield.
MP: 145° C.
EXAMPLE 149
(E)-1-[1-(3-Fluoro-4-methoxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)]-3-(4-(2-dimethylaminoethoxy)phenyl)propene-1-one
The same method as employed in the preparation of Example 20 but starting from Intermediate 14 and Intermediate 25 gave after recrystallization from iPr2O the title compound as a white powder in a 60% yield.
MP: 103° C.
Analysis for C31H32FN3O3. 0.4H2O:
Calculated: C,71.49; H,6.35; N,8.07;
Found: C,71.4; H,6.51; N,8.04%.
EXAMPLE 150
(E)-4-[3-[1-(2,3-Dihydrobenzo[1,4]dioxin-6-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-oxopropenyl]benzoic Acid
The same method as employed in the preparation of Example 31 but starting from Example 146 gave after recrystallization from MeOH the title compound as a white powder in a 93% yield.
MP: 253° C.
Analysis for C29H24N2O5. 0.7H2O:
Calculated: C,70.63; H,5.19; N,5.68;
Found: C,70.78; H,5.09; N,5.72%.
EXAMPLE 151
(E)-(R)-1-[1-(2,3-Dihydrobenzofuran-5-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-phenylpropene-1-one
The same method as employed in the preparation of Example 1 but starting from Intermediate 20 gave after recrystallization from MeOH the title compound as white crystals in a 100% yield.
MP: 267° C.
Analysis for C28H24N2O2:
Calculated: C,79.98; H,5.75; N,6.66;
Found: C,79.86; H,5.89; N,6.72%.
[α]D 22=−362 (c=0.35, CHCl3).
EXAMPLE 152
(E)-(S)-1-[1-(2,3-Dihydrobenzofuran-5-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)]-3-(4-(2-dimethylaminoethoxy)phenyl)propene-1-one
The same method as employed in the preparation of Example 20 but starting from Intermediate 21 and Intermediate 25 gave after recrystallization from CH3CN the title compound as beige crystals in a 79% yield.
MP: 153° C.
Analysis for C32H33N3O3. 0.5H2O:
Calculated: C, 74.39; H,6.63; N,8.13;
Found: C,74.36; H,6.69; N,8.44%.
[α]D 21=314 (c=0.40, CHCl3).
EXAMPLE 153
(E)-1-[1-(2,3-Dihydrobenzofuran-5-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(4-aminophenyl)propene-1-one
The same method as employed in the preparation of Example 20 but starting from Intermediate 10 and (E)-4-aminocinnamic acid gave after recrystallization from iPrOH the title compound as white crystals in a 43% yield.
MP: 183° C.
Analysis for C30H31N3O2. 1.6H2O:
Calculated: C,76.59; H,5.83; 9.57;
Found: C,76.62; H,5.82; N,9.59%.
EXAMPLE 154
(E)-(S)-1-[1-(2,3-Dihydrobenzofuran-5-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-phenylpropene-1-one
The same method as employed in the preparation of Example 1 but starting from Intermediate 21 gave after recrystallization from EtOH the title compound as white crystals in a 98% yield.
MP: 266° C.
Analysis for C28H24N2O2. 0.2H2O:
Calculated: C,79.30; H,5.80; N,6.61;
Found: C,79.24; H,5.92; N,6.48%.
[α]D 20=356 (c=0.35, CHCl3).
EXAMPLE 155
(E)-(S)-1-[1-(2,3-Dihydrobenzofuran-5-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(3-nitrophenyl)propene-1-one
The same method as employed in the preparation of Example 20 but starting from Intermediate 21 and (E)-3-nitrocinnamic acid gave after recrystallization from 2-propanol the title compound as yellow crystals in a 77% yield.
MP: 143° C.
Analysis for C28H23N3O4. 0.3H2O:
Calculated: C,71.42; H,5.05; N,8.92;
Found: C,71.51; H,4.98; N,9.23%.
[α]D 19=294 (c=0.30, CHCl3).
EXAMPLE 156
(E)-(R)-1-[1-(2,3-Dihydrobenzofuran-5-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)]-3-(4-(1-(S)-methylpyrrolidin-2-yl-methoxy)phenyl)propene-1-one
The same method as employed in the preparation of Example 20 but starting from Intermediate 20 and Intermediate 45 gave after recrystallization from 2-propanol the title compound as white crystals in a 73% yield.
MP: 167° C.
Analysis for C34H35N3O3:
Calculated: C,76.52; H,6.61; N,7.87;
Found: C,76.13; H, 6.71; N,7.96%.
[α]D 20=−344 (c=0.30, CHCl3).
EXAMPLE 157
(E)-(R)-1-[1-(2,3-Dihydrobenzofuran-5-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(3-hydroxyphenyl)propene-1-one
The same method as employed in the preparation of Example 20 but starting from Intermediate 20 and (E)-3-hydroxycinnamic acid gave after recrystallization from EtOH the title compound as white crystals in a 93% yield.
MP: 251° C.
Analysis for C28H24N2O3. 0.8H2O:
Calculated: C,74.58; H,5.72; N,6.21;
Found: C,74.58; H,5.65; N,6.17%.
[α]D 21=−342 (c=0.53, CHCl3).
EXAMPLE 158
(E)-(R)-1-[1-(2,3-Dihydrobenzofuran-5-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)]-3-(4-(2-dimethylamino-1-methylethoxy)phenyl)propene-1-one
The same method as employed in the preparation of Example 20 but starting from Intermediate 20 and Intermediate 46 gave after recrystallization from CH3CN the title compound as white crystals in a 100% yield.
MP: 193° C.
Analysis for C33H35N3O3. 0.45H2O:
Calculated: C,74.82; H,6.83; N,7.93;
Found: C,74.85; H, 6.76; N,8.21%.
EXAMPLE 159
(E)-1-(1-Phenyl-1,3,4,9-tetrahydro-β-carbolin-2-yl)-3-(4-(4-methylpyperazin-1-yl)-phenyl)propene-1-one
The same method as employed in the preparation of Example 20 but starting from Intermediate 1 and Intermediate 47 gave after recrystallization from EtOH the title compound as pale yellow crystals in a 26% yield.
MP: 223-226° C.
Analysis for C32H32N4O3. 0.4H2O:
Calculated: C,72.82; H,6.26; N,10.61;
Found C,72.77; H,6.31; N,10.52%.
EXAMPLE 160
(E)-(R)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)]-3-(4-(1-(S)-methylpyrrolidin-2-yl-methoxy)phenyl)propene-1-one
The same method as employed in the preparation of Example 20 but starting from Intermediate 19 and Intermediate 45 gave after recrystallization from iPr2O the title compound as white crystals in a 83% yield.
MP: 164° C.
Analysis for C33H33N3O4. 0.9H2O:
Calculated: C,71.82; H,6.36; N,7.61;
Found C,72.05; H,6.57; N,7.24%.
[α]D 21=−285 (c=0.40, CHCl3).
EXAMPLE 161
(E)-(R)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)]-3-(4-(2-dimethylamino-1-methylethoxy)phenyl)propene-1-one
The same method as employed in the preparation of Example 20 but starting from Intermediate 19 and Intermediate 46 gave after recrystallization from iPr2O the title compound as white crystals in a 56% yield.
MP: 107° C.
Analysis for C32H33N3O4. 0.7H2O:
Calculated: C,71.67; H,6.47; N,7.84;
Found: C,71.6; H, 6.53; N,7.97%.
EXAMPLE 162
(E)-(R)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)]-3-(4-(2-dimethylaminopropoxy)phenyl)propene-1-one
The same method as employed in the preparation of Example 20 but starting from Intermediate 19 and Intermediate 48 gave after recrystallization from iPr2O the title compound as white crystals in a 78% yield.
MP: 193° C.
Analysis for C32H33N3O4. 1.6H2O:
Calculated: C,69.57; H,6.6; N,7.61;
Found: C,69.46; H, 6.59; N,7.33%.
[α]D 21=−266 (c=0.40, CHCl3).
EXAMPLE 163
(E)-4-[3-Oxo-3-[1-(3,4-fluorophenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-propenyl]benzoic Acid, Methyl Ester
The same method as employed in the preparation of Example 20 but starting from Intermediate 15 and (E)-4-(2-carboxyvinyl)benzoic acid, methyl ester gave after recrystallization from EtOH:H2O the title compound as a yellow powder in a 100% yield.
MP: 200° C.
Analysis for C28H22F2N2O3:
Calculated: C,71.18; H,4.69; N,5.93;
Found: C,71.21; H,4.77; N,6.03%.
EXAMPLE 164
(E)-(R)-[1-(2,3-Dihydrobenzofuran-5-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)]-3-(4-(2-diethylaminoethoxy)phenyl)propene-1-one
The same method as employed in the preparation of Example 20 but starting from Intermediate 20 and (E)-3-(4-(2-diethylaminoethoxy)phenyl)acrylic acid (prepared according to the procedure of Sharpe, C. J.; Shabolt, R. S.; Brown, G. R.; Ashford, A.; Ross, J. W. J. Med. Chem. 1971, 14, 836-842), gave after recrystallization from CH3CN the title compound as white crystals in a 80% yield.
MP: 193° C.
Analysis for C34H37N3O3. 0.6H2O:
Calculated: C,74.73; H,7.05; N,7.69;
Found: C,74.53; H, 6.91; N,7.68%.
[α]D 20=−311 (c=0.30, CHCl3).
EXAMPLE 165
(E)-(R)-1-[1-(2,3-Dihydrobenzofuran-5-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)]-3-(4-(2-dimethylaminopropoxy)phenyl)propene-1-one
The same method as employed in the preparation of Example 20 but starting from Intermediate 20 and Intermediate 48 gave after recrystallization from CH3CN the title compound as white crystals in a 79% yield.
MP: 193° C.
Analysis for C33H35N3O3:
Calculated: C,75.98; H,6.76; N,8.06;
Found: C,76.24; H, 6.76; N,8.21%.
[α]D 20=−293 (c=0.40, CHCl3).
EXAMPLE 166
(E)4-[3-Oxo-3-[1-(3,4-difluorophenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]propenyl]benzoic Acid
The same method as employed in the preparation of Example 31 but starting from Example 163 gave after recrystallization from MeOH:H2O the title compound as a white powder in a 100% yield.
MP: 172° C.
Analysis for C27H20F2N2O3:
Calculated: C,68.06; H,4.65; N,5.88;
Found: C,68.15; H,4.55; N,5.99%.
EXAMPLE 167
(E)-(R)-1-[1-(2,3-Dihydrobenzofuran-5-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(4-aminophenyl)propene-1-one
The same method as employed in the preparation of Example 20 but starting from Intermediate 20 and (E)-4-aminocinnamic acid gave after recrystallization from 2-propanol the title compound as white crystals in a 80% yield.
MP: 176° C.
Analysis for C28H25N3O2. 0.23H2O:
Calculated: C,76.49; H,5.84; N,9.56;
Found: C,76.21; H, 5.61; N,9.96%.
[α]D 21=−375.3 (c=0.0.35, CHCl3).
EXAMPLE 168
(E)-(R)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(4-aminophenyl)propene-1-one
The same method as employed in the preparation of Example 20 but starting from Intermediate 19 and (E)-4-aminocinnamic acid gave after recrystallization from 2-propanol:H2O the title compound as white crystals in a 63% yield.
MP: 264° C.
Analysis for C27H23N3O3. 0.6H2O:
Calculated: C,72.34; H,5.44; N,9.37;
Found: C,72.06; H,5.48; 9.55%.
[α]D 21=−266 (c=0.3, MeOH).
EXAMPLE 169
(R)-(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)]-3-(4-(2-pyrrolidin-1-ylethoxy)phenyl)propene-1-one
The same method as employed in the preparation of Example 20 but starting from Intermediate 19 and Intermediate 42 gave after recrystallization from iPr2O the title compound as brown crystals in a 4% yield.
MP: 116° C.
Analysis for C33H33N3O4. 1.7H2O:
Calculated: C,69.99; H,6.48; N,7.42;
Found: C,70.02; H, 6.47; N,7.59%.
EXAMPLE 170
(E)-(R)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)]-3-(4-(2-diethylaminoethoxy)phenylpropene-1-one
The same method as employed in the preparation of Example 20 but starting from 1 Intermediate 19 and (E)-3-(4-(2-diethylaminoethoxy)phenyl)acrylic acid (prepared according to the procedure of Sharpe, C. J.; Shabolt, R. S.; Brown, G. R.; Ashford, A.; Ross, J. W. J. Med. Chem. 1971, 14(9), 836-842) gave after recrystallization from iPr2O the title compound as white crystals in a 67% yield.
MP: 94° C.
Analysis for C33H35N3O4. 0.5H2O:
Calculated: C,72.5; H,6.64; N,7.69;
Found: C,72.48; H,6.64; N,7.58%.
[α]D 21=−287 (c=0.3, CHCl3).
EXAMPLE 171
(E)-1-[1-(3-Fluoro-4-methoxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)]-3-(3-nitrophenyl)propene-1-one
The same method as employed in the preparation of Example 20 but starting from Intermediate 14 and (E)-3-nitrocinnamic acid gave after recrystallization from DCM:2-propanol the title compound as a yellow powder in a 90% yield.
MP: 141° C.
Analysis for C27H22FN3O4. 0.9CH2Cl2:
Calculated: C,61.16; H,4.38; N,7.67;
Found: C,61.1; H,4.39; N,7.56%.
EXAMPLE 172
(E)-(R)-1-[1-(2,3-Dihydrobenzofuran-5-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(4-trifluoromethylphenyl)propene-1-one
The same method as employed in the preparation of Example 20 but starting from Intermediate 20 and (E)-4-trifluoromethylcinnamic acid gave after recrystallization from 2-propanol the title compound as white crystals in a 91% yield.
MP: 141° C.
Analysis for C29H23F3N2O2:
Calculated: C,71.3; H,4.75; N,5.73;
Found: C,71.37; H,4.79; N,5.86%.
[α]D 20=−326 (c=0.3, CHCl3).
EXAMPLE 173
(E)-(R)-1-[1-(2,3-Dihydrobenzofuran-5-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(3-trifluoromethylphenyl)propene-1-one
The same method as employed in the preparation of Example 20 but starting from Intermediate 20 and (E)-3-trifluoromethylcinnamic acid gave after recrystallization from 2-propanol:H2O the title compound as white crystals in a 80% yield.
MP: 223° C.
Analysis for C29H23F3N2O2:
Calculated: C,71.3; H,4.75; N,5.73;
Found: C,71.44, H,4.73; N,5.85%.
[α]D 20=−326 (c=0.3, CHCl3).
EXAMPLE 174
(E)-(R)-1-[1-(2,3-Dihydrobenzofuran-5-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(4-(2-morpholin-4-ylethoxy)phenyl)propene-1-one
The same method as employed in the preparation of Example 20 but starting from Intermediate 20 and Intermediate 49 gave after recrystallization from 2-propanol:H2O the title compound as white crystals in a 66% yield.
MP: 148° C.
Analysis for C34H35N3O4:
Calculated, C,71.3; H,4.75; N,5.73;
Found: C,71.44; H,4.73; N,5.85%.
[α]D 19=−288 (c=0.3, CHCl3).
EXAMPLE 175
(E)-(R)-1-[1-(2,3-Dihydrobenzofuran-5-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(4-(2-(ethylmethylamino)ethoxy)phenyl)propene-1-one
The same method as employed in the preparation of Example 20 but starting from Intermediate 20 and Intermediate 50 gave after recrystallization from iPr2O the title compound as a white powder in a 66% yield.
MP: 107° C.
Analysis for C33H35N3O3. 0.8H2O:
Calculated: C,73.94; H,6.88; N,7.84;
Found: C,74.09; H,7.15; N,7.48%.
[α]D 21=−253 (c=0.3, CHCl3).
EXAMPLE 176
(E)-1-[1-(2,3-Dihydrobenzofuran-5-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(4-(3-(dimethylamino)propenyl)phenyl)propene-1-one
The same method as employed in the preparation of Example 20 but starting from Intermediate 20 and Intermediate 51 gave after recrystallization from EtOH the title compound as a white powder in a 45% yield.
MP: 216° C.
Analysis for C33H33N3O2. 0.2H2O:
Calculated: C,78.14; H,6.88; N,7.84;
Found: C,78.03; H,6.74; N,8.21%.
[α]D 19.8=−312 (c=0.29, CHCl3).
EXAMPLE 177
(E)-(R)-1-[1-(2,3-Dihydrobenzofuran-5-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(4-(3-dimethylamino-2-hydroxypropoxy)phenyl)propene-1-one
At 0° C. to a solution (E)-(R)-1-[1-(2,3-dihydrobenzofuran-5-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(4-(2-(tertbutyldimethylsilanyloxy)-3-dimethylamino-2-hydroxy-propoxy)phenyl)propene-1-one (0.4 g, 0.6 mmol) in 50 mL of anhydrous THF was added tetrabutylammonium fluoride (0.6 mL, 1 equiv., 1 M in THF). The resulting mixture was stirred at rt for one day. Quenching with water, extraction with DCM, washing with brine, drying over MgSO4 and concentration in vacuo gave an oil. Recrystallization from iPrOH:H2O gave the title compound (0.2 g, 62%) as an off-white powder.
MP: 138° C.
Analysis for C33H35N3O4. 0.5H2O:
Calculated: C,72.5; H,6.64; N,7.69;
Found; C,72.21; H,6.75; N,7.48%.
[α]D 20=−283 (c=0.6, CHCl3).
(E)-(R)-1-[1-(2,3-Dihydrobenzofuran-5-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(4-(2-(tertbutyldimethylsilanyloxy)-3-dimethylamino-2-hydroxypropoxy)phenyl)-propene-1-one was obtained in a 89% yield as a yellow oil from the same method as employed in the preparation of Example 20 but starting from Intermediate 20 and Intermediate 52.
1H NMR (CDCl3,250 MHz) δ8.1 (s, 1H), 7.5-7.3 (m, 2H), 6.9-7.2 (m, 7H), 6.8-6.5 (m, 3H), 4.5 (t, 2H), 4.2 (m, 1H), 4.0 (m, 3H), 3.8 (m, 1H) 3.3 (m, 1H), 3.0 (t, 2H), 2.7-2.9 (m, 3H), 2.3-2.15 (m, 2H), 2.1 (s, 6H), 0.8 (s,9H), 0.05 (d, 6H).
EXAMPLE 178
(E)-(R)-1-(1-(2,3-Dihydrobenzofuran-5-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)-3-(4-formylphenyl)propene-1-one
The same method as employed in the preparation of Example 20 but starting from Intermediate 20 and (E)-4-formylcinnamic acid gave after recrystallization from EtOH the title compound as a white powder in a 53% yield.
MP: 175° C.
Analysis for C29H24N2O3. 0.8H2O:
Calculated: C,75.24; H,5.57; N,6.05;
Found: C,75.54; H,5.78; N,6.11%.
[α]D 20=−340 (c=0.33, CHCl3).
EXAMPLE 179
(E)-(R)-1-[1-(2,3-Dihydrobenzofuran-5-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(4-propylaminomethyl)phenyl)propene-1-one
To a solution of a solution of Example 178 (0.5 g, 1.1 mmol) in 50 mL of MeOH was added propylamine (14 mL, 1.5 equiv.). The resulting mixture was stirred at 50° C. for 4 hours. At rt polymer-supported borohydride (1.2 g, 1.2 equiv., 2.5 mmol/g) was added and the resulting mixture was stirred at 50° C. for 6 hours. After evaporation in vacuo, the residue was washed with 2×50 mL of DCM. After filtration, the filtrate was washed with 2×50 mL of water. Drying over Na2SO4, evaporation in vacuo and recrystallization from MeOH gave the title compound (0.4 g, 81%) as a pale yellow powder.
MP: 170° C.
Analysis for C32H33N3O2. 0.4H2O:
Calculated: C,77.05; H,6.83; N,8.42;
Found: C,77.04; H,6.78; N,8.29%.
[α]D 19=−330 (c=0.4, MeOH).
EXAMPLE 180
(E)-(R)-1-[1-(2,3-Dihydrobenzofuran-5-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-[4-(2-dimethylaminoethylamino)phenylpropene-1-one
The same method as employed in the preparation of Example 20 but starting from intermediate 20 and Intermediate 53 gave after recrystallization from EtOH the title compound as yellow crystals in a 12% yield.
MP: 160° C.
Analysis for C32H34N4O2. 0.2H2O:
Calculated: C,75.33; H,6.8; N,10.98;
Found C,75.06; H,6.83; N,10.98%.
[α]D 20=−214 (c=0.1, MeOH).
EXAMPLE 181
(E)-(R)-1-[1-(2,3-Dihydrobenzofuran-5-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(4-(2-aminoethoxy)phenyl)propene-1-one
To a solution of (E)-(R)-2-[2-(4-{3-[1-(2,3-dihydrobenzofuran-5-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-oxo-propenyl}-phenoxy)ethyl]isoindole-1,3-dione (0.85 g, 1.4 mmol) in 50 mL of MeOH:THF was added hydrazine (0.38 mL, 3 equiv., 35% in water). The resulting mixture was stirred at 45° C. for 4 hours. Evaporation in vacuo and flash chromatography with DCM:MeOH (80:20) as eluting solvent gave the title compound (0.17 g, 26%) as yellow powder.
MP: 186° C.
Analysis for C30H29N3O3. 0.3CH2Cl2:
Calculated: C,72.06; H,5.91; N,8.32;
Found C,72.12; H,8.08; N,8.67%.
[α]D 20=−285 (c=0.29, MeOH).
(E)-(R)-2-[2-(4-{3-[1-(2,3-Dihydrobenzofuran-5-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-oxo-propenyl}phenoxy)ethyl]isoindole-1,3-dione was obtained after recrystallization from EtOH, as a gummy solid in a 90% yield using the same method as employed in the preparation of Example 20 but starting from Intermediate 20 and Intermediate 54.
1H NMR (CDCl3 250 MHz) δ8.0-6.7 (m, 19H), 4.5 (t, 2H), 4.2-4.0 (m, 5H), 3.4 (m, 1H), 3.0 (t, 2H), 2.9 (m, 2H).
EXAMPLE 182
(E)-(R)-1-[1-(2,3-Dihydrobenzofuran-5-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(4-hydroxyphenyl)propene-1-one
The same method as employed in the preparation of Example 20 but starting from Intermediate 20 and (E)-4-hydroxycinnamic acid gave after recrystallization from DMF:MeOH the title compound as a white powder in a 90% yield.
MP: 189° C.
Analysis for C28H24N2O3. 0.5DMF:
Calculated: C,75.51; H,5.77; N,7.12;
Found: C,75.31; H,5.84; N,6.81%.
[α]D 20=−310 (c=0.32, MeOH).
EXAMPLE 183
(E)-(R)-1-[1-(2,3-Dihydrobenzofuran-5-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(4-(4-methylpiperazin-1-yl)phenylpropene-1-one
The same method as employed in the preparation of Example 20 but starting from Intermediate 20 and Intermediate 47 gave after recrystallization from DMF:EtOH the title compound as pale yellow crystals in a 48% yield.
MP: 193° C.
Analysis for C33H34N4O2. 1.0DMF:
Calculated: C,73.07; H,6.98; N,11.83;
Found C,72.67; H,7.05; N,11.55%.
[α]D 20=−330 (c=0.3, CHCl3).
EXAMPLE 184
(E)-(R)-1-[1-(2,3-Dihydrobenzofuran-5-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(4-methylaminomethyl)phenyl)propene-1-one
The same method as employed in the preparation of Example 179 but starting from methylamine gave after recrystallization from MeOH.H2O the title compound as a white powder in a 52% yield.
MP: 129° C.
Analysis for C30H29N3O2. 1.1H2O:
Calculated: C,74.54; H,6.51; N,8.69;
Found: C,74.68; H,6.57; N,8.59%.
[α]D 21=−288 (c=0.4, CHCl3).
EXAMPLE 185
(E)-(R)-1-[1-(2,3-Dihydrobenzofuran-5-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(4-isopropylaminomethyl)phenyl)propene-1-one
The same method as employed in the preparation of Example 179 but starting from isopropylamine gave after recrystallization from MeOH:H2O the title compound as a white powder in a 47% yield.
MP: 158° C.
Analysis for C32H33N3O2. 0.3H2O:
Calculated: C,77.33; H,6.81; N,8.45;
Found: C,77.42; H,6.74; N,8.26%.
[α]D 21=−319 (c=0.3, MeOH).
EXAMPLE 186
(E)-(R)-1-[1-(2,3-Dihydrobenzofuran-5-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(4-dimethylaminomethyl)phenyl)propene-1-one
The same method as employed in the preparation of Example 179 but using dimethylamine gave after recrystallization from iPrOH:H2O the title compound as a white powder in a 34% yield.
MP: 153-154° C.
Analysis for C31H31N3O2.0.2H2O:
Calculated: C,77.38; H,6.58; N,8.73;
Found: C,77.4; H,6.49; N,8.61%.
[α]D 21=−336 (c=0.3, MeOH).
EXAMPLE 187
(E)-(R)-1-[1-(2,3-Dihydrobenzofuran-5-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-[4-(3-dimethylaminopropoxy)phenyl]propene-1-one
The same method as employed in the preparation of Example 79 but starting from Example 182 and dimethylaminopropyl chloride gave after recrystallization from CH3CN the title compound as a white powder in a 53% yield.
MP: 186° C.
Analysis for C33H35N3O2. 0.6H2O:
Calculated: C,74.44; H,6.85; N,7.89;
Found: C,74.36; H,6.63; N,7.98%.
[α]D 20=−326 (c=0.3, MeOH).
EXAMPLE 188
(E)-(R)-1-[1-(2,3-Dihydrobenzofuran-5-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(4-(2-piperidin-1-ylethoxy)phenyl)propene-1-one
The same method as employed in the preparation of Example 20 but starting from Intermediate 20 and Intermediate 55 gave after recrystallization from CH3CN the title compound as white crystals in a 50% yield.
MP: 210° C.
Analysis for C35H37N3O3:
Calculated: C,76.75; H,6.81; N,7.67;
Found: C,76.68; H,7.11; N,7.93%.
[α]D 18.9=−290 (c=0.4, CHCl3).
EXAMPLE 189
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)-3-(4-(2-piperidin-1-ylethoxy)phenyl]propene-1-one
The same method as employed in the preparation of Example 20 but starting from Intermediate 55 gave after recrystallization from MeOH:H2O the title compound as a beige solid in a 32% yield.
MP: 102° C.
Analysis for C34H35N3O4. 0.6MeOH:
Calculated: C,73.05; H,6.63; N,7.39;
Found: C,73.24; H,6.87; N,7.02%.
EXAMPLE 190
(E)-(R)-[2-(4-{3-[1-(2,3-Dihydrobenzofuran-5-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-oxopropenyl}phenoxy)ethyl]methylcarbamic Acid, Tertbutyl Ester
The same method as employed in the preparation of Example 20 but starting from Intermediate 20 and Intermediate 56 gave the title compound as a yellow powder in a 95% yield.
MP: 110° C.
Analysis for C36H39N3O5. 0.3H2O:
Calculated: C,72.17; H,6.66; N,7.01;
Found; C,71.9; H,6.86; N,7.17%.
EXAMPLE 191
(E)-(R)-1-[1-(2,3-Dihydrobenzofuran-5-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-[4-(2-methylaminoethoxy)phenyl]propene-1-one
A solution of Example 190 (0.33 g, 0.55 mmol) in DCM (30 mL) was treated with zinc bromide (0.63 g, 5 equiv.) for 16 hours at 30° C. A gummy solid was formed. Extraction with DCM:MeOH, washing with water, drying over Na2SO4 and recrystallization from iPrOH gave the title compound as white crystals in a 98% yield.
MP: 145° C.
Analysis for C31H31N3O3. 0.2H2O:
Calculated: C,74.89; H,6.37; N,8.45;
Found: C,74.90; H,6.70; N,8.49%.
[α]D 20=−337 (c=0.4, MeOH).
EXAMPLE 192
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)-3-(4-(2-piperidin-1-ylethoxy)phenyl]propene-1-one
The same method as employed in the preparation of Example 1 but starting from Intermediate 13 gave after recrystallization from MeOH:H2O the title compound as a beige solid in a 32% yield.
MP: 102° C.
Analysis for C34H35N3O4. 0.6MeOH:
Calculated: C,73.05; H,6.63; N,7.39;
Found: C,73.24; H,6.87; N,7.02%.
Inhibitory Effect on cGMP-PDE
cGMP-PDE activity of compounds of the present invention was measured using a one-step assay adapted from Wells at al. (Wells, J. N., Baird, C. E., Wu, Y. J. and Hardman, J. G., Biochim. Biophys. Acta 384, 430 (1975)). The reaction medium contained 50 mM Tris-HCl,pH 7.5, 5 mM Mg-acetate, 250 μg/ml 5′-Nucleotidase, 1 mM EGTA and 0.15 μM 8-[H3]-cGMP. The enzyme used was a human recombinant PDE 5 (ICOS, Seattle USA).
Compounds of the invention were dissolved in DMSO finally present at 2% in the assay. The incubation time was 30 minutes during which the total substrate conversion did not exceed 30%.
The IC50 values for the compounds examined were determined from concentration-response curves using typically concentrations ranging from 10 nM to 10 μM. Tests against other PDE enzymes using standard methodology also showed that compounds of the invention are highly selective for the cGMP specific PDE enzyme.
cGMP Level Measurements
Rat aortic smooth muscle cells (RSMC) prepared according to Chamley et al. in Cell Tissue Res 177, 503-522 (1977) were used between the 10th and 25th passage at confluence in 24-well culture dishes. Culture media was aspirated and replaced with PBS (0.5 ml) containing the compound tested at the appropriate concentration. After 30 minutes at 37° C., particulates guanylate cyclase was stimulated by addition of ANF (100 nM) for 10 minutes. At the end of incubation, the medium was withdrawn and two extractions were performed by addition of 65% ethanol (0.25 ml). The two ethanolic extracts were pooled and evaporated until dryness, using a Speed-vac system. cGMP was measured after acetylation by scintillation proximity immunoassay (AMERSHAM). The EC50 values are expressed as the dose giving half of the stimulation at saturating concentrations
Biological Data
The compounds according to the present invention were typically found to exhibit an IC50 value of less than 500 nM and an EC50 value of less than 5 μM. In vitro test data for representative compounds of the invention is given in the following table:
TABLE 1
In vitro results
Example No. IC50 nM EC50 μM
14 5 0.45
25 72 0.3
28 55 0.3
31 4 1
55 40 0.4
61 20 1.8
140 2 0.1
142 18 1.5
156 15 <1
164 11 1.5
165 9 <1
177 12 <1
184 44 3
180 25 3.5
181 9 2
183 24 2
182 2 <1
188 24 <1
191 8 <1
The hypotensive effects of compounds according to the invention as identified in Table 2 were studied in conscious spontaneously hypertensive rats (SHR). The compounds were admnistered orally at a dose of 5 mg/kg in a mixture of 5% DMF and 95% olive oil. Blood pressure was measured from a catheter inserted in the carotid artery and recorded for 5 hours after administration. The results are expressed as Area Under the Curve (AUC from 0 to 5 hours, mmHg.hour) of the fall in blood pressure over time.
TABLE 1
In vivo results
Example No. AUC PO (mmHg · h)
14 128
25 72
26 102
28 114
31 86
55 97
61 95
112 71
122 76
140 105
142 74
156 57
175 52
177 100
181 77
188 86
191 84
The application of which this description and claims forms part may be used as a basis for priority in respect of any subsequent application. The claims of such subsequent application may be directed to any novel feature or combination of features described herein. They may take the form of product, composition, process or use claims and may include, by way of example and without limitation, the following claim:

Claims (22)

What is claimed is:
1. A compound of formula (I)
Figure US06306870-20011023-C00009
wherein
R0 represents -hydrogen or -halogen;
R1 is selected from the group consisting of:
-hydrogen,
—NO2,
-trifluoromethyl,
-trifluoromethoxy,
-halogen,
-cyano,
a 5- or 6-membered heterocyclic group selected from the group consisting of pyridyl, pyrrolidinyl, morpholinyl, tetrahydrofuryl, furyl, tetrazolyl, imidazolyl, piperidinyl, and piperizinyl (optionally substituted by —C(═O)ORa or C1-4alkyl),
—C1-6alkyl optionally substituted by ORa,
—C1-3alkoxy,
—C(═O)Ra,
—O—C (═O)Ra,
—C(═O)ORa,
—C1-4alkyleneC(═O)ORa,
—O—C1-4alkylene-C(═O)ORa,
—C1-4alkylene-O—C1-4alkylene-C(═O)ORa,
—C(═O)NRaCO2Rc,
—C(═O)C1-4alkyleneHet, wherein Het represents 5- or 6-membered heterocyclic group as defined above,
—C1-4alkyleneNRaRb,
—C2-6alkenyleneNRaRb,
—C(═O)NRaRb,
—C(═O)NRaRc,
—C(═O)NRaC1-4alkyleneORb,
—C(═O)NRaC1-4alkyleneHet, wherein Het represents a 5- or 6-membered heterocyclic group as defined above,
—ORa,
—OC2-4alkyleneNRaRb,
—OC1-4alkylene-CH(ORa)CH2NRaRb,
—O—C1-4alkyleneHet, wherein Het represents a 5- or 6-membered heterocyclic group as defined above,
—O—C2-4alkylene-ORa,
—O—C2-4alkylene-NRa—C(═O)—ORb,
—NRaRb,
—NRaC1-4alkyleneNRaRb,
—NRaC(═O)Rb,
—NRaC(═O)NRaRb,
—N(SO2C1-4alkyl)2,
—NRa(SO2C1-4alkyl),
—SO2NRaRb, and
—OSO2trifluoromethyl;
R2 is selected from the group consisting of:
-hydrogen,
-halogen,
—ORa,
—C1-6alkyl,
—NO2, and
—NRaRb,
or R1 and R2, together form a 3- or 4-membered alkylene or alkenylene chain, optionally containing at least one heteroatom;
a first R3 is selected from the group consisting of:
-hydrogen,
-halogen,
—NO2,
-trifluoromethoxy,
—C1-6alkyl, and
—C(═O)ORa,
and a second R3 and R4 together, and with the phenyl ring to which they are attached, form a 3- or 4-membered alkylene or alkenylene chain, optionally containing at least one heteroatom,
Ra and Rb, which may be the same or different, are independently selected from hydrogen and C1-6alkyl;
Rc represents phenyl or C4-6cycloalkyl, which phenyl or C4-6cycloalkyl can be optionally substituted by one or more halogen atoms, one or more —C(═O)ORa or one or more —ORa;
n is an integer selected from 1, 2 and 3;
m is an integer selected from 1 and 2;
and pharmaceutically acceptable salts and solvates thereof.
2. A compound represented by formula Ia
Figure US06306870-20011023-C00010
wherein
R5 is selected from the group consisting of —OH, —OC2-4alkyleneNRaRb and —O—C1-4alkyleneHet, wherein Het represents a 5- or 6-membered heterocyclic group selected from the group consisting of pyridyl, pyrrolidinyl, morpholinyl, tetrahydrofuryl, furyl, tetrazolyl, imidazolyl, piperidinyl, and piperizinyl, optionally substituted by C1-4alkyl;
R6 represents
Figure US06306870-20011023-C00011
 wherein C represents a 5- or 6-membered ring which may be saturated or partially or fully unsaturated and comprises carbon atoms and optionally one or two heteroatoms selected from oxygen, sulphur, and nitrogen, optionally substituted by C1-4alkyl;
Ra and Rb, which may be the same or different, are independently selected from hydrogen and C1-6alkyl;
and pharmaceutically acceptable salts and solvates thereof.
3. The compound of claim 1 wherein R0 represents hydrogen.
4. The compound of claim 1 wherein R1 is selected from the group consisting of:
—ORa,
—O—C2-4alkylene NRaRb,
—O—C1-4alkyleneHet, and
—O—C2-4alkylene-ORa.
5. The compound of claim 4 wherein R1 represents —O—C1-4ethyleneNRaRb.
6. The compound of claim 5 wherein at least one of Ra and Rb is methyl.
7. The compound of claim 1 wherein R2 represents hydrogen.
8. The compound of claim 1 wherein R1 and R2 together form a methylenedioxy chain, an ethyleneoxy chain, an ethylenedioxy chain, an ethenyleneoxy chain, a propylene chain, a butylene chain, or —NRaethylene-O—.
9. The compound of claim 1 wherein R1 and R2 together form methylenedioxy, propylene, or —N(CH3)—ethylene-O—.
10. The compound of claim 1 wherein R3 and R4 together form a methylenedioxy chain, an ethylenoxy chain, an ethylenedioxy chain, an ethenyleneoxy chain, a propylene chain, a propylene chain, a butylene chain, or —NRaethylene-O—.
11. The compound of claim 1 wherein R3 and R4 together form a methylenedioxy or ethyleneoxy.
12. The compound of claim 2 wherein R1 represents —OC2-4alkyleneNRaRb, or —O—C1-4alkyleneHet.
13. The compound of claim 2 wherein R2 represents
Figure US06306870-20011023-C00012
14. A compound selected from the group consisting of
(E)-1-(1-Phenyl-1,3,4,9-tetrahydro-β-carbolin-2-yl)-3-phenylpropene-1-one,
(E)-1-(1-Phenyl-1,3,4,9-tetrahydro-β-carbolin-2-yl)-3-(4-nitrophenyl)propene-1-one,
(E)-1-(1-Phenyl-1,3,4,9-tetrahydro-β-carbolin-2-yl)-3-(4-trifluoromethylphenyl)propene-1-one,
(E)-1-(1-Phenyl-1,3,4,9-tetrahydro-β-carbolin-2-yl)-3-(4-methoxyphenyl)propene-1-one,
(E)-1-[1-(4-Methoxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(4-trifluoromethylphenyl)propene-1-one,
(E)-N-[4-[3-Oxo-3-(1-phenyl-1,3,4,9-tetrahydro-β-carbolin-2-yl)propenyl]phenyl]acetamide
(E)-1-[1-(4-Methoxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)-3-phenylpropene-1-one,
(E)-1-(1-Phenyl-1,3,4,9-tetrahydro-β-carbolin-2-yl)-3-(4-formylphenyl)propene-1-one,
(E)-N-[4-[3-Oxo-3-(1-(4-nitrophenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)propenyl]phenyl]acetamide
(E)-1-[1-(4-Nitrophenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-phenylpropene-1-one,
(E)-1-[1-(4-Trifluoromethoxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-phenylpropene-1-one,
(E)-1-[1-(4-Methylphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-phenylpropene-1-one,
(E)-4-[3-Oxo-3-(1-phenyl-1,3,4,9-tetrahydro-β-carbolin-2-yl)-propenyl]benzoic acid, methyl ester,
(E)-1-[1-(2-Chlorophenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-phenylpropene-1-one,
(E)-1-(1-Phenyl-1,3,4,9-tetrahydro-β-carbolin-2-yl)-3-(3,4-methylenedioxyphenyl)-propene-1-one,
(E)-1-[1-(4-Chlorophenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-phenylpropene-1-one,
(E)-N-(2-Morpholin-4-ylethyl)-4-[3-oxo-3-(1-(3,4-methylene-dioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)propenyl]benzamide,
(E)-N-(4-Piperidine-4-carboxylic acid, ethyl ester)-4-[3-oxo-3-(1-(3,4-methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)propenyl]benzamide,
(E)-N-(4-Piperidine-4-carboxylic acid)-4-[3-oxo-3-(1-(3,4-methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)propenyl]benzamide,
(E)-N-(2-Piperazin-1-ylethyl)-3-[3-oxo-3-(1-(3,4-methylene-dioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)propenyl]benzamide,
(E)-N-(1-Ethylpyrrolidin-2-yl-methyl)-3-[3-oxo-3-(1-(3,4-methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)propenyl]benzamide,
(E)-1-[1-(4-Isopropylphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(3-nitrophenyl)propene-1-one,
(E)-1-[1-(4-Methoxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3(3-nitrophenyl)propene-1-one,
(E)-1-[1-(4-Methylphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(2-chloro-5-nitrophenyl)propene-1-one,
(E)-1-[1-(Indan-5-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-phenylpropene-1-one,
(E)-4-[3-Oxo-3-[1-(4-methoxyphenyl)-1,3,4,9-tetra-hydro-β-carbolin-2-yl]propenyl]benzoic acid, methyl ester,
(E)-4-[3-Oxo-3-[1-(4-methoxyphenyl)-1,3,4,9-tetra-hydro-β-carbolin-2-yl]propenyl]benzoic acid,
(E)-1-[1-(3-Fluoro-4-methoxyphenyl)-1,3,4,9-tetra-hydro-β-carbolin-2-yl]-3-phenylpropene-1-one,
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetra-hydro-β-carbolin-2-yl]-3-[4-pyrrolidin-1-ylphenyl]-propene-1-one,
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetra-hydro-β-carbolin-2-yl]-3-[4-imidazol-1-ylphenyl]-propene-1-one,
(E)-1-[1-(3-Fluoro-4-methoxyphenyl)-1,3,4,9-tetra-hydro-β-carbolin-2-yl)]-3-(4-(2-dimethylaminoethoxy)phenyl)propene-1-one,
(E)-(R)-1-[1-(2,3-Dihydrobenzofuran-5-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)]-3-(4-(1-(S)-methylpyrrolidin-2-yl-methoxy)phenyl)propene-1-one,
(E)-1-(1-Phenyl-1,3,4,9-tetrahydro-β-carbolin-2-yl)-3-(4-(4-methylpyperazin-1-yl)-phenyl)propene-1-one,
(E)-(R)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)]-3-(4-(1-(S)-methylpyrrolidin-2-yl-methoxy)-phenyl)propene-1-one,
(E)-4-[3-Oxo-3-[1-(3,4-fluorophenyl)-1,3,4,9-tetra-hydro-β-carbolin-2-yl]propenyl]benzoic acid, methyl ester,
(E)-4-[3-Oxo-3-[1-(3,4-difluorophenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]propenyl]benzoic acid,
(E)-(R)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetrahydro-β-carbolin-2-yl)]-3-(4-(2-pyrrolidin-1-ylethoxy)phenyl)propene-1-one,
(E)-1-[1-(3-Fluoro-4-methoxyphenyl)-1,3,4,9-tetra-hydro-β-carbolin-2-yl)]-3-(3-nitrophenyl)propene-1-one,
(E)-(R)-1-[1-(2,3-Dihydrobenzofuran-5-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(4-(2-morpholin-4-ylethoxy)phenyl)propene-1-one,
(E)-(R)-1-[1-(2,3-Dihydrobenzofuran-5-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(4-(4-methylpiperazin-1-yl)phenylpropene-1-one,
(E)-(R)-1-[1-(2,3-Dihydrobenzofuran-5-yl)-1,3,4,9-tetrahydro-β-carbolin-2-yl]-3-(4-(2-piperidin-1-ylethoxy)phenyl)propene-1-one,
(E)-1-[1-(3,4-Methylenedioxyphenyl)-1,3,4,9-tetra-hydro-β-carbolin-2-yl)-3-(4-(2-piperidin-1-ylethoxy)phenyl]propene-1-one,
and pharmaceutically acceptable salts and solvates thereof.
15. A pharmaceutical composition comprising a compound of claim 1, together with a pharmaceutically acceptable diluent or carrier.
16. A method for the curative or prophylactic treatment of erectile dysfunction in an animal comprising administration of an effective dose of a compound of claim 1, or pharmaceutically acceptable salts and solvates thereof, to the animal.
17. The method of claim 16 wherein the animal is a human.
18. The method of claim 17 wherein the treatment is an oral treatment.
19. A pharmaceutical composition comprising a compound of claim 14, together with a pharmaceutically acceptable diluent or carrier.
20. A method for the curative or prophylactic treatment of erectile dysfunction in an animal comprising administration of an effective dose of a compound of claim 14, or pharmaceutically acceptable salts and solvates thereof, to the animal.
21. The method of claim 20 wherein the animal is a human.
22. The method of claim 21 wherein the treatment is an oral treatment.
US09/592,514 1996-05-10 2000-06-12 N-cinnamoyl derivatives of beta-carboline Expired - Fee Related US6306870B1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9609777.9A GB9609777D0 (en) 1996-05-10 1996-05-10 Chemical compounds
GB9609820 1996-05-10
GBGB9609820.7A GB9609820D0 (en) 1996-05-10 1996-05-10 Chemical compounds
GB9609777 1996-05-10

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
PCT/EP1996/002277 Continuation-In-Part WO1996037757A1 (en) 1995-05-25 1996-05-24 Container
US09/155,811 Continuation-In-Part US6117881A (en) 1996-05-10 1997-05-05 N-cinnamoyl derivatives of (β) carbolines

Publications (1)

Publication Number Publication Date
US6306870B1 true US6306870B1 (en) 2001-10-23

Family

ID=26309303

Family Applications (2)

Application Number Title Priority Date Filing Date
US09/155,811 Expired - Fee Related US6117881A (en) 1996-05-10 1997-05-05 N-cinnamoyl derivatives of (β) carbolines
US09/592,514 Expired - Fee Related US6306870B1 (en) 1996-05-10 2000-06-12 N-cinnamoyl derivatives of beta-carboline

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US09/155,811 Expired - Fee Related US6117881A (en) 1996-05-10 1997-05-05 N-cinnamoyl derivatives of (β) carbolines

Country Status (26)

Country Link
US (2) US6117881A (en)
EP (1) EP0912567B1 (en)
JP (1) JP3418405B2 (en)
KR (1) KR20000010918A (en)
CN (1) CN1067071C (en)
AP (1) AP9801365A0 (en)
AT (1) ATE215950T1 (en)
AU (1) AU711885B2 (en)
BG (1) BG102879A (en)
BR (1) BR9709230A (en)
CA (1) CA2253948C (en)
CZ (1) CZ358598A3 (en)
DE (1) DE69711882T2 (en)
EA (1) EA199800907A1 (en)
EE (1) EE9800390A (en)
ES (1) ES2175404T3 (en)
HU (1) HUP9901478A3 (en)
IL (1) IL126951A0 (en)
IS (1) IS4864A (en)
NO (1) NO985222L (en)
OA (1) OA10920A (en)
PL (1) PL329875A1 (en)
SK (1) SK154498A3 (en)
TR (1) TR199802282T2 (en)
WO (1) WO1997043287A1 (en)
YU (1) YU49898A (en)

Cited By (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040116458A1 (en) * 2001-02-12 2004-06-17 Sawyer Jason S. Chemical compounds
US20040147542A1 (en) * 2001-04-25 2004-07-29 Sawyer Jason S Chemical compounds
US20060004013A1 (en) * 2004-05-26 2006-01-05 Eisai Co., Ltd. Cinnamide compound
US20070010450A1 (en) * 2003-06-13 2007-01-11 Microbia, Inc., A Massachusetts Corporation Methods and compositions for the treatment of gastrointestinal disorders
US20070117798A1 (en) * 2005-11-24 2007-05-24 Eisai R&D Management Co., Ltd. Morpholine type cinnamide compound
US20070117839A1 (en) * 2005-11-24 2007-05-24 Eisai R&D Management Co., Ltd. Two cyclic cinnamide compound
US20070219181A1 (en) * 2006-03-09 2007-09-20 Eisai R&D Management Co., Ltd. Multi-cyclic cinnamide derivatives
US20080207900A1 (en) * 2007-02-28 2008-08-28 Teiji Kimura Two cyclic oxomorphorin derivatives
US20080306272A1 (en) * 2007-05-16 2008-12-11 Eisai R&D Management Co., Ltd. One-pot methods for preparing cinnamide derivatives
US20090048448A1 (en) * 2005-11-18 2009-02-19 Ikuo Kushida Salts of cynnamide compound or solvates thereof
US20090048213A1 (en) * 2006-07-28 2009-02-19 Eisai R&D Management Co., Ltd. Prodrug of cinnamide compound
US20090062529A1 (en) * 2007-08-31 2009-03-05 Teiji Kimura Multi-cyclic compounds
US20090181945A1 (en) * 2005-11-24 2009-07-16 Teiji Kimura Two cyclic cinnamide compound
US7601840B2 (en) 2004-03-15 2009-10-13 Ptc Therapeutics, Inc. Carboline derivatives useful in the inhibition of angiogenesis
US20090270623A1 (en) * 2005-11-18 2009-10-29 Naoyuki Shimomura Process for production of cinnamide derivative
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
US20100179132A1 (en) * 2004-03-15 2010-07-15 Ptc Therapeutics, Inc. Carboline derivatives useful in the inhibition of angiogenesis
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
EP2258357A2 (en) 2005-08-26 2010-12-08 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
US20100317860A1 (en) * 2008-01-28 2010-12-16 Ikuo Kushida Crystalline cinnamide compounds or salts thereof
EP2275095A2 (en) 2005-08-26 2011-01-19 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
US7923563B2 (en) 2004-10-26 2011-04-12 Eisai R&D Management Co., Ltd. Amorphous object of cinnamide compound
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
WO2011063115A1 (en) 2009-11-19 2011-05-26 Braincells Inc. Combination of nootropic agent with one or more neurogenic or neurogenic sensitizing agents for stimulating or increasing neurogenesis
US7985756B2 (en) 2005-10-21 2011-07-26 Braincells Inc. Modulation of neurogenesis by PDE inhibition
WO2011091033A1 (en) 2010-01-20 2011-07-28 Braincells, Inc. Modulation of neurogenesis by ppar agents
US7998971B2 (en) 2006-09-08 2011-08-16 Braincells Inc. Combinations containing a 4-acylaminopyridine derivative
EP2377531A2 (en) 2006-05-09 2011-10-19 Braincells, Inc. Neurogenesis by modulating angiotensin
US8076353B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Inhibition of VEGF translation
US8076352B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
US9453000B2 (en) 2007-08-31 2016-09-27 Eisai R&D Management Co., Ltd. Polycyclic compound

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ358598A3 (en) * 1996-05-10 1999-03-17 Icos Corporation Carboline derivatives
US6331543B1 (en) 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
DE19837069C1 (en) 1998-08-17 2000-01-05 Bayer Ag New cinnamic acid derivatives useful as insecticide intermediates
WO2000015639A1 (en) * 1998-09-16 2000-03-23 Icos Corporation Carboline derivatives as cgmp phosphodiesterase inhibitors
DE19903087A1 (en) * 1999-01-27 2000-08-10 Forssmann Wolf Georg Treatment of erectile dysfunction with C-type natriuretic polypeptide (CNP) as monotherapy or in combination with phosphodiesterase inhibitors
EP1162970B1 (en) 1999-03-24 2003-12-17 Harbor Branch Oceanographic Institution, Inc. Anti-inflammatory uses of manzamines
MXPA00003997A (en) 1999-04-30 2002-03-08 Lilly Icos Llc Articles of manufacture.
US6451807B1 (en) 1999-04-30 2002-09-17 Lilly Icos, Llc. Methods of treating sexual dysfunction in an individual suffering from a retinal disease, class 1 congestive heart failure, or myocardial infarction using a PDE5 inhibitor
WO2001078711A2 (en) 2000-04-19 2001-10-25 Lilly Icos, Llc. Pde-v inhibitors for treatment of parkinson's disease
UA74826C2 (en) * 2000-05-17 2006-02-15 Ortho Mcneil Pharm Inc ?-carboline derivatives as phosphodiesterase inhibitors
US6825197B2 (en) 2000-06-23 2004-11-30 Lilly Icos Llc Cyclic GMP-specific phosphodiesterase inhibitors
US6821978B2 (en) 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
JP4220779B2 (en) * 2001-02-12 2009-02-04 リリー アイコス リミテッド ライアビリティ カンパニー Chemical compound
WO2002098875A1 (en) * 2001-06-05 2002-12-12 Lilly Icos Llc Carboline derivatives as pde-5 inhibitors
WO2003000691A1 (en) * 2001-06-21 2003-01-03 Lilly Icos Llc Carboline derivatives as pdev inhibitors
WO2003042216A1 (en) 2001-11-09 2003-05-22 Schering Corporation Polycyclic guanine derivative phosphodiesterase v inhibitors
WO2003053923A2 (en) 2001-12-20 2003-07-03 Applied Research Systems Ars Holding N.V. Pyrrolidine derivatives as prostaglandin modulators
TWI329111B (en) 2002-05-24 2010-08-21 X Ceptor Therapeutics Inc Azepinoindole and pyridoindole derivatives as pharmaceutical agents
US7595311B2 (en) 2002-05-24 2009-09-29 Exelixis, Inc. Azepinoindole derivatives as pharmaceutical agents
US7872133B2 (en) 2003-06-23 2011-01-18 Ono Pharmaceutical Co., Ltd. Tricyclic heterocycle compound
SA05260149B1 (en) * 2004-05-26 2010-06-16 إيساي آر آند دي منجمنت كو.، ليمتد Cinnamide compound
JP4997976B2 (en) 2004-12-22 2012-08-15 小野薬品工業株式会社 Tricyclic compounds and uses thereof
US8506934B2 (en) 2005-04-29 2013-08-13 Robert I. Henkin Methods for detection of biological substances
TWI435729B (en) 2005-11-09 2014-05-01 Combinatorx Inc Methods, compositions, and kits for the treatment of medical conditions
US8293489B2 (en) 2007-01-31 2012-10-23 Henkin Robert I Methods for detection of biological substances
US8580801B2 (en) 2008-07-23 2013-11-12 Robert I. Henkin Phosphodiesterase inhibitor treatment
US20150297601A1 (en) 2012-10-05 2015-10-22 Robert I. Henkin Phosphodiesterase inhibitor treatment
CN106233141B (en) 2014-02-18 2018-08-21 罗伯特·I·汉金 Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell
CN113527289A (en) 2015-09-23 2021-10-22 米纳瓦生物技术公司 Method for screening agent for differentiating stem cells

Citations (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3644384A (en) 1969-06-09 1972-02-22 Sterling Drug Inc Certain 2-(alpha-haloacetyl) - 1 2 3 4-tetrahydro - 9h - pyrido(3 4-b)indole-3-carboxylates and derivatives
US3717638A (en) 1971-03-11 1973-02-20 Sterling Drug Inc 1,2,3,4,6,7,12,12A-OCTAHYDRO-2-PHENYLPYRAZINO[2',1':6,1]PYRIDO[3,4-b]INDOLES AND INTERMEDIATES THEREFOR
US3917599A (en) 1973-03-30 1975-11-04 Council Scient Ind Res 2-Substituted-1,2,3,4,6,7,12,12A-octahydropyrazino(2{40 ,1{40 :6,1)pyrido(3,4-B)indoles
GB1454171A (en) 1973-10-19 1976-10-27 Council Scient Ind Res Tetracyclic compounds
US4188390A (en) 1977-11-05 1980-02-12 Pfizer Inc. Antihypertensive 4-amino-2-[4-(1,4-benzodioxan-2-carbonyl) piperazin-1-yl or homopiperazin-1-yl]quinazolines
US4686228A (en) 1982-07-24 1987-08-11 Pfizer Inc. Quinoline therapeutic agents
WO1989010123A1 (en) 1988-04-22 1989-11-02 Recordati S.A. Chemical And Pharmaceutical Company Flevoxate and derivatives for erectile dysfunctions
EP0344577A2 (en) 1988-06-01 1989-12-06 Eisai Co., Ltd. Butenoic or propenoic acid derivatives
EP0357122A2 (en) 1988-08-29 1990-03-07 Duphar International Research B.V Use of beta-carbolines, their bio-isosteric benzofuran and benzothiophene analogues for the manufacture of a medicament having cytostatic properties
EP0362555A1 (en) 1988-09-03 1990-04-11 Hoechst Aktiengesellschaft Piperazinediones having psycotropic activity
JPH0344324A (en) 1989-07-13 1991-02-26 Kazuoki Tsuchiya Sexual function invigorator
EP0459666A2 (en) 1990-05-31 1991-12-04 Pfizer Inc. Medicaments against impotence
EP0463756A1 (en) 1990-06-20 1992-01-02 Pfizer Limited Pyrazolopyrimidinone antianginal agents
US5145852A (en) 1989-07-11 1992-09-08 Ronald Virag Vaso-active medicament to treat impotence
EP0526004A1 (en) 1991-07-09 1993-02-03 Pfizer Limited Pyrazolopyrimidinone antianginal agents
US5270323A (en) 1990-05-31 1993-12-14 Pfizer Inc. Method of treating impotence
WO1994005661A1 (en) 1992-08-28 1994-03-17 Pfizer Limited Pyridopyrimidinone antianginal agents
WO1994028902A1 (en) 1993-06-09 1994-12-22 Pfizer Limited Pyrazolopyrimidinones for the treatment of impotence
WO1995019978A1 (en) 1994-01-21 1995-07-27 Laboratoires Glaxo Wellcome S.A. Tetracyclic derivatives, process of preparation and use
US5874437A (en) 1996-11-01 1999-02-23 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
US6043252A (en) * 1997-05-05 2000-03-28 Icos Corporation Carboline derivatives
US6117881A (en) * 1996-05-10 2000-09-12 Icos Corporation N-cinnamoyl derivatives of (β) carbolines

Patent Citations (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3644384A (en) 1969-06-09 1972-02-22 Sterling Drug Inc Certain 2-(alpha-haloacetyl) - 1 2 3 4-tetrahydro - 9h - pyrido(3 4-b)indole-3-carboxylates and derivatives
US3717638A (en) 1971-03-11 1973-02-20 Sterling Drug Inc 1,2,3,4,6,7,12,12A-OCTAHYDRO-2-PHENYLPYRAZINO[2',1':6,1]PYRIDO[3,4-b]INDOLES AND INTERMEDIATES THEREFOR
US3917599A (en) 1973-03-30 1975-11-04 Council Scient Ind Res 2-Substituted-1,2,3,4,6,7,12,12A-octahydropyrazino(2{40 ,1{40 :6,1)pyrido(3,4-B)indoles
GB1454171A (en) 1973-10-19 1976-10-27 Council Scient Ind Res Tetracyclic compounds
US4188390A (en) 1977-11-05 1980-02-12 Pfizer Inc. Antihypertensive 4-amino-2-[4-(1,4-benzodioxan-2-carbonyl) piperazin-1-yl or homopiperazin-1-yl]quinazolines
US4686228A (en) 1982-07-24 1987-08-11 Pfizer Inc. Quinoline therapeutic agents
WO1989010123A1 (en) 1988-04-22 1989-11-02 Recordati S.A. Chemical And Pharmaceutical Company Flevoxate and derivatives for erectile dysfunctions
EP0344577A2 (en) 1988-06-01 1989-12-06 Eisai Co., Ltd. Butenoic or propenoic acid derivatives
EP0357122A2 (en) 1988-08-29 1990-03-07 Duphar International Research B.V Use of beta-carbolines, their bio-isosteric benzofuran and benzothiophene analogues for the manufacture of a medicament having cytostatic properties
EP0362555A1 (en) 1988-09-03 1990-04-11 Hoechst Aktiengesellschaft Piperazinediones having psycotropic activity
US5145852A (en) 1989-07-11 1992-09-08 Ronald Virag Vaso-active medicament to treat impotence
JPH0344324A (en) 1989-07-13 1991-02-26 Kazuoki Tsuchiya Sexual function invigorator
EP0459666A2 (en) 1990-05-31 1991-12-04 Pfizer Inc. Medicaments against impotence
US5270323A (en) 1990-05-31 1993-12-14 Pfizer Inc. Method of treating impotence
EP0463756A1 (en) 1990-06-20 1992-01-02 Pfizer Limited Pyrazolopyrimidinone antianginal agents
EP0526004A1 (en) 1991-07-09 1993-02-03 Pfizer Limited Pyrazolopyrimidinone antianginal agents
WO1994005661A1 (en) 1992-08-28 1994-03-17 Pfizer Limited Pyridopyrimidinone antianginal agents
WO1994028902A1 (en) 1993-06-09 1994-12-22 Pfizer Limited Pyrazolopyrimidinones for the treatment of impotence
WO1995019978A1 (en) 1994-01-21 1995-07-27 Laboratoires Glaxo Wellcome S.A. Tetracyclic derivatives, process of preparation and use
US6117881A (en) * 1996-05-10 2000-09-12 Icos Corporation N-cinnamoyl derivatives of (β) carbolines
US5874437A (en) 1996-11-01 1999-02-23 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
US6043252A (en) * 1997-05-05 2000-03-28 Icos Corporation Carboline derivatives

Non-Patent Citations (98)

* Cited by examiner, † Cited by third party
Title
"Physicians' Desk Reference," (1992) 2207-2208.
"Physicians' Desk Reference," (1992), 1778-1779.
"Physicians' Desk Reference," (1992), 683, 1099-1100, 1344, 1941-1943.
A. Bowman et al., Br. J. Pharmac., (1984), 81, 665-674.
A. Zorgniotti, J. Urol., (Apr. 1992), 147(4), 308A.
Adams et al., J. Urol., (1984), 132, 1208.
Beretta, Acta European Fertilitatis, (1986), 17, 43-45.
Beyer et al., Phys. and Behav., (1981), 27, 731-733.
Bhalla et al., Brit. Med. J., (1972), 2, 1059.
Braña et al., Synthetic Communications, 20(12), 1793-1820 (1990).
Brindley, Brit. J. Phychiat., (1983), 143, 332-337.
Burke et al., Med. J. Aust., (1980), 382-383.
C. Clyne et al., Br. J. Surg., (Apr. 1987), 74, 246-248.
C. Lugnier et al., Biochem. Pharmacol., (1986), 35:10, 1743-1751.
C. Nicholson et al., TIPS, (Jan. 1991), 12, 19-27.
C. Sparwasser et al., J. Urol., (Dec. 1994), 152, 2159-2163.
C. Stief et al., J. Urol., (Nov. 1992), 148, 1437-1440.
C. Stief et al., World J. Urol., (1991), 9, 237-239.
Cimino et al., Biochem. Pharmacology, (1988), 37(14), 2739-2745.
D. Green et al., Geriatrics, (Jan. 1993), 48(1), 46-58.
D. Halsted et al., J. Urol., (Jul. 1986), 136, 109-110.
Dadkar et al., Ind. J. Exp. Biol., (1982), 20, 484-487.
D'Armiento et al., Eur. J. Pharmacol., (1980), 65, 234-247.
Dellouve-Courillon et al., Tetrahedron, 46, No. 9, 3245-3266 (1990).
E. Kim et al., J. Urol., (1995), 153, 361-365.
E. McMahon et al., J. Pharmacol. Exp. Thera., (1989), 251, 1000-1005.
Earl et al., Life Sciences, (1984), 35, 525-534.
F. Holmquist et al., Acta Physiol. Scand., (1991), 143, 299-304.
F. Holmquist et al., Acta. Physiol. Scand., (1991), 141, 441-442.
F. Holmquist et al., J. Urol. (Oct. 1993), 150, 1310-1315.
F. Trigo-Rocha et al., Am. J. Physiol., (Feb. 1993), 264, H419-H422.
F. Trigo-Rocha et al., J. Urol., (Apr. 1993), 149, 872-877.
Funderbunk, New Engl. J. Med., (1974), 290, 630-631.
G. Barbanti, Urol. Res., (1988), 16, 299-302.
G. Gwinup, Annals. of Internal Medicine, (Jul. 1988), 162-163.
Gillespie et al., Molecular Pharmacology, 36:773-781 (1989).
H. Ahn et al., Biochem. Pharmacol., (1989), 39:19, 3331-3339.
H. Hamilton et al., J. Med. Chem., (1987), 30, 91-96.
H. Knispel, Urol. Res., (1992), 20, 253-257.
H. Padma-Nathan et al., Sem. in Urol., (Nov. 1986), vol. IV, No.4, 236-238.
Hess in "Prazosin: Evaluation of a New Antihypertensive Agent," D. Cotton ed., American Elsevier, NY, (1974), 3-15.
Ishida et al., Chem. Pharm. Bull., vol. 33, No. 8, 3237-3249 (1985).
J. Beavo et al., TiPS, (Apr. 1990), 11, 150-155.
J. Cortijo, Br. J. Pharmacol., (Feb. 1993), 108(2), 562-568.
J. Doremieux et al., Ann. Urol. Paris, (1987), 21(6), 429-434.
J. Heaton et al., Urology, (Feb. 1995), 45(2), 200-206.
J. Krall et al., Bio. Reprod., (1988), 39, 913-922.
J. LeBlanc et al., Eur. J. Cardiothorac Surg., (1993), 7, 211-215.
J. Rajfer, N. Eng. J. Med., (Jan. 1992), 326(2), 90-94.
J. Reiser et al., Br. J. Dis. Chest, (1986), 80, 157-163.
J. Taher et al., J. Urol., (Apr. 1993), 149, 285A.
K. Allenby et al., Angiology, (1991), 42, 418-420.
K. Azadzoi et al., J. Urol., (Jan. 1992), 147, 220-225.
K. Azadzoi et al., J. Urol., (Nov. 1992), 148, 1587-1591.
Keogh, Aust. NZ. J. Med., (1989), 19, 108-112.
L. Ignarro et al., Biochem. and Biophys. Res. Comm., (1990), 170(2), 843-850.
M. Giembycz et al., Clin. and Exper. Allergy, (1992), 22, 337-344.
M. Krupp et al., J. Cardiovas. Pharmacol., (1989), 13 (Supp. 2), S11-S19.
M. Webster et al., Hematol. Oncol. Cl. of N. Am., (Feb. 1990), 4(1), 265-289.
M. Wilkins et al., J. Clin. Invest., (Apr. 1990), 85, 1274-1279.
M. Wilkins et al., Proc. Natl. Acad. Sci., USA, (Aug. 1990), 87, 6465-6469.
Martinez-Pineiro et al., Eur. Urol., (1993), 24, 492-499.
Merkel, Cardio. Drug. Rev., (1993), 11(4), 501-515.
Mirone et al., Br. J. Urol., (Mar., 1993), 71(3), 365.
Murray et al., Biochemical Soc. Trans., (1992), 20, 460-464.
Murray, DN&P 6(3), 150-156 (1993).
N. Kim et al., J. Clin. Invest., (1991), 88, 112-118.
P. Bush et al., Circulation, (May 1993), 87 Supp. V, V-30-V-32.
P. Bush et al., Fed. Am. Soc. Exp. Biol., (1991), 5(4), 175.
P. Bush et al., Fed. Am. Soc. Exp. Biol., (1992), 6(4), 2092.
P. Bush et al., J. Urol., (Jun. 1992), 147, 1650-1655.
P. Bush, Ph.D. Thesis (1992), pp. 159-160.
Pickard et al., Br. J. Pharmacol., (1991), 104 755-759.
R. Morales et al., World J. Urol., (1990), 8, 80-83.
R. Pickard et al., Clin. Pharmacol., (Jan. 1993), 35(5), 536P-537P.
R. Pickard et al., J. Urol., (May 1993) 149 (4 Supp.), 245A.
R. Rudd et al., Br. J. Dis. Chest, (1983), 77, 78-86.
R. Weishaar et al., J. Med. Chem., (1985), 28:5, 537-542.
Raeburn et al., Prog. Drug. Res., (1993), 12-32.
Robbins et al., J. Urol., (1983), 130, 975.
Russell et al., Med. J. Aust., (1985), 143, 321.
S. Francis et al., in J. Beavo et al. eds. "Cyclic Nucleotide PDEs," Ch. 5 (1990) 117-140.
S. Korenman et al., Clin. Res., (1988), 36, 123A.
S. Korenman et al., JAGS, (Apr. 1993), 41(4), 363-366.
S. Uckert et al., J. Urol., 151 (5 Supp.), (1994), 495A.
Saxena et al., Journal of Medicinal Chemistry, vol. 16, No. 5, 560-564 (1973).
Segasouthy et al., Med. J. Malaysia, (1982), 37(4), 384.
T. Lincoln, Pharmac. Ther., (1989), 41, 479-502.
T. Lue, "Campbell's Urology," 6th Ed., Chap. 16, P. Walsh et al., Eds., W.B. Saunders Co., 709-728 (1991).
Taher et al., Int. J. Impotence Res., Abstracts, Milan, Italy (Sep. 14-17, 1992).
Trigo-Rocha et al., Neurology and Urodynamics, 13, (1998) 71-80.
V. Mirone et al., Acta. Urol. Ltd., (1992), Suppl. 4, 11-12.
W. Aronson et al., J. Urol., (1991), 145 (4 Supp.), 341A.
W. Aronson et al., J. Urol., (1992), 147 (4 Supp.), 454A.
W. Thompson, Pharmac. Ther., (1991), 51, 13-33.
Watanabe et al., Federation Proceedings, (1982), 41(7), 2292-2399.
Ylitalo et al., Acta Med. Scand., (1983), 213, 319-320.
Zorgniotti et al. Int. J. Impotence Res., 6, 33-36 (1994).

Cited By (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7122554B2 (en) * 2001-02-12 2006-10-17 Lilly Icos Llc. Carboline derivatives
US20040116458A1 (en) * 2001-02-12 2004-06-17 Sawyer Jason S. Chemical compounds
US20040147542A1 (en) * 2001-04-25 2004-07-29 Sawyer Jason S Chemical compounds
US7115621B2 (en) * 2001-04-25 2006-10-03 Lilly Icos Llc Chemical compounds
US8101579B2 (en) 2003-06-13 2012-01-24 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US20100234301A1 (en) * 2003-06-13 2010-09-16 Ironwood Pharmaceuticals, Inc. Methods and Compositions for the Treatment of Gastrointestinal Disorders
US20070010450A1 (en) * 2003-06-13 2007-01-11 Microbia, Inc., A Massachusetts Corporation Methods and compositions for the treatment of gastrointestinal disorders
US9840536B2 (en) 2003-06-13 2017-12-12 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7601840B2 (en) 2004-03-15 2009-10-13 Ptc Therapeutics, Inc. Carboline derivatives useful in the inhibition of angiogenesis
US20110160190A1 (en) * 2004-03-15 2011-06-30 Ptc Therapeutics, Inc. Carboline derivatives useful in the inhibition of angiogenesis
US8367694B2 (en) 2004-03-15 2013-02-05 Ptc Therapeutics, Inc. Carboline derivatives useful in the inhibition of angiogenesis
US8076352B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
US7767689B2 (en) 2004-03-15 2010-08-03 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer
US8076353B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Inhibition of VEGF translation
US20100179132A1 (en) * 2004-03-15 2010-07-15 Ptc Therapeutics, Inc. Carboline derivatives useful in the inhibition of angiogenesis
US8372860B2 (en) 2004-03-15 2013-02-12 Ptc Therapeutics, Inc. Carboline derivatives useful in the inhibition of angiogenesis
US20110086860A1 (en) * 2004-05-26 2011-04-14 Teiji Kimura Compound
US7880009B2 (en) 2004-05-26 2011-02-01 Eisai R&D Management Co., Ltd. Cinnamide compound
US20090281310A1 (en) * 2004-05-26 2009-11-12 Eisai R&D Management Co., Ltd. Cinnamide compound
US20060004013A1 (en) * 2004-05-26 2006-01-05 Eisai Co., Ltd. Cinnamide compound
US7667041B2 (en) 2004-05-26 2010-02-23 Eisai R&D Management Co., Ltd. Cinnamide compound
US20080070902A1 (en) * 2004-05-26 2008-03-20 Teiji Kimura Cinnamide Compound
US7687640B2 (en) 2004-05-26 2010-03-30 Eisai R&D Management Co., Ltd. Cinnamide compound
US7923563B2 (en) 2004-10-26 2011-04-12 Eisai R&D Management Co., Ltd. Amorphous object of cinnamide compound
EP2275095A2 (en) 2005-08-26 2011-01-19 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2275096A2 (en) 2005-08-26 2011-01-19 Braincells, Inc. Neurogenesis via modulation of the muscarinic receptors
EP2258357A2 (en) 2005-08-26 2010-12-08 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP2258359A2 (en) 2005-08-26 2010-12-08 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
EP2258358A2 (en) 2005-08-26 2010-12-08 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP2377530A2 (en) 2005-10-21 2011-10-19 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
US7985756B2 (en) 2005-10-21 2011-07-26 Braincells Inc. Modulation of neurogenesis by PDE inhibition
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20090270623A1 (en) * 2005-11-18 2009-10-29 Naoyuki Shimomura Process for production of cinnamide derivative
US20090048448A1 (en) * 2005-11-18 2009-02-19 Ikuo Kushida Salts of cynnamide compound or solvates thereof
US20090181945A1 (en) * 2005-11-24 2009-07-16 Teiji Kimura Two cyclic cinnamide compound
US20070117839A1 (en) * 2005-11-24 2007-05-24 Eisai R&D Management Co., Ltd. Two cyclic cinnamide compound
US20070117798A1 (en) * 2005-11-24 2007-05-24 Eisai R&D Management Co., Ltd. Morpholine type cinnamide compound
US8048878B2 (en) 2005-11-24 2011-11-01 Eisai R&D Management Co., Ltd. Two cyclic cinnamide compound
US7618960B2 (en) 2005-11-24 2009-11-17 Eisai R&D Management Co., Ltd. Morpholine type cinnamide compound
US7713993B2 (en) 2006-03-09 2010-05-11 Eisai R&D Management Co., Ltd. Multi-cycle cinnamide derivatives
US20070219181A1 (en) * 2006-03-09 2007-09-20 Eisai R&D Management Co., Ltd. Multi-cyclic cinnamide derivatives
US7973033B2 (en) 2006-03-09 2011-07-05 Eisai R&D Management Co., Ltd. Multi-cyclic cinnamide derivatives
US7897632B2 (en) 2006-03-09 2011-03-01 Eisai R&D Management Co., Ltd. Multi-cyclic cinnamide derivatives
US20100168095A1 (en) * 2006-03-09 2010-07-01 Teiji Kimura Multi-cyclic cinnamide derivatives
EP2377531A2 (en) 2006-05-09 2011-10-19 Braincells, Inc. Neurogenesis by modulating angiotensin
EP2382975A2 (en) 2006-05-09 2011-11-02 Braincells, Inc. Neurogenesis by modulating angiotensin
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
US7737141B2 (en) 2006-07-28 2010-06-15 Eisai R&D Management Co., Ltd. Prodrug of cinnamide compound
US20090048213A1 (en) * 2006-07-28 2009-02-19 Eisai R&D Management Co., Ltd. Prodrug of cinnamide compound
US7998971B2 (en) 2006-09-08 2011-08-16 Braincells Inc. Combinations containing a 4-acylaminopyridine derivative
US20100113773A1 (en) * 2007-02-28 2010-05-06 Teiji Kimura Bicyclic oxomorpholine derivative
US8008293B2 (en) 2007-02-28 2011-08-30 Eisai R&D Management Co., Ltd. Bicyclic oxomorpholine derivative
US20080207900A1 (en) * 2007-02-28 2008-08-28 Teiji Kimura Two cyclic oxomorphorin derivatives
US20080306272A1 (en) * 2007-05-16 2008-12-11 Eisai R&D Management Co., Ltd. One-pot methods for preparing cinnamide derivatives
US20090062529A1 (en) * 2007-08-31 2009-03-05 Teiji Kimura Multi-cyclic compounds
US7935815B2 (en) 2007-08-31 2011-05-03 Eisai R&D Management Co., Ltd. Imidazoyl pyridine compounds and salts thereof
US20110065696A1 (en) * 2007-08-31 2011-03-17 Teiji Kimura Imidazoyl pyridine compounds and salts thereof
US9453000B2 (en) 2007-08-31 2016-09-27 Eisai R&D Management Co., Ltd. Polycyclic compound
US20100317860A1 (en) * 2008-01-28 2010-12-16 Ikuo Kushida Crystalline cinnamide compounds or salts thereof
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
WO2011063115A1 (en) 2009-11-19 2011-05-26 Braincells Inc. Combination of nootropic agent with one or more neurogenic or neurogenic sensitizing agents for stimulating or increasing neurogenesis
WO2011091033A1 (en) 2010-01-20 2011-07-28 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use

Also Published As

Publication number Publication date
NO985222D0 (en) 1998-11-09
EA199800907A1 (en) 1999-04-29
ATE215950T1 (en) 2002-04-15
HUP9901478A2 (en) 1999-08-30
ES2175404T3 (en) 2002-11-16
PL329875A1 (en) 1999-04-12
IL126951A0 (en) 1999-09-22
AU711885B2 (en) 1999-10-21
AP9801365A0 (en) 1998-12-31
CA2253948A1 (en) 1997-11-20
JP3418405B2 (en) 2003-06-23
CN1067071C (en) 2001-06-13
DE69711882D1 (en) 2002-05-16
BG102879A (en) 1999-09-30
NO985222L (en) 1999-01-11
OA10920A (en) 2003-02-21
JP2000513717A (en) 2000-10-17
WO1997043287A1 (en) 1997-11-20
CA2253948C (en) 2005-07-26
IS4864A (en) 1998-10-13
CN1218471A (en) 1999-06-02
TR199802282T2 (en) 1999-03-22
AU2891097A (en) 1997-12-05
CZ358598A3 (en) 1999-03-17
SK154498A3 (en) 2000-01-18
EE9800390A (en) 1999-06-15
EP0912567A1 (en) 1999-05-06
BR9709230A (en) 1999-08-10
HUP9901478A3 (en) 1999-11-29
US6117881A (en) 2000-09-12
KR20000010918A (en) 2000-02-25
DE69711882T2 (en) 2002-10-31
EP0912567B1 (en) 2002-04-10
YU49898A (en) 2000-03-21

Similar Documents

Publication Publication Date Title
US6306870B1 (en) N-cinnamoyl derivatives of beta-carboline
US6043252A (en) Carboline derivatives
US8778956B2 (en) Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders
AU702324B2 (en) Cyclic GMP-specific phosphodiesterase inhibitors
US7375226B2 (en) Bi- and tricyclic substituted phenyl methanones
US6001847A (en) Chemical compounds
US6127541A (en) Imidazoquinazoline derivatives
EP1047695B1 (en) Novel bispidine antiarrhythmic compounds
US20070275990A1 (en) Heterocyclic Spiro Compound
SK16972002A3 (en) Beta-carboline derivatives useful as inhibitors of phosphodiesterase
US7034151B2 (en) Process for preparing pyrrolotriazine kinase inhibitors
US5866571A (en) 9-substituted 2-(2-n-alkoxyphenyl)-purin-6-ones
EP0216247A2 (en) Use of alpha 2 adrenergic receptor antagonists for the production of pharmaceutical compositions for treating colonic spasm, irritable bowel syndrome and constipation and process for preparing such pharmaceutical compositions
US4337250A (en) Hexahydro-trans- and tetrahydropyridoindole neuroleptic agents
EP0551527B1 (en) Pyrroloazepine derivative
HU223466B1 (en) Anti-allergy imidazo [1,2a] thieno [2,3-d] azepine derivatives, process for their preparation and pharmaceutical compositions containing them
US4432978A (en) Hexahydro-trans-pyridoindole
EP0252643A1 (en) Pyrido[1,2-a]indole derivatives, process for their preparation and pharmaceutical compounds containing them
US20050282811A1 (en) Diazabicyclic histamine-3 receptor antagonists
US4427679A (en) Hexahydro-trans- and tetrahydropyridoindole neuroleptic agents
US4431649A (en) Hexahydro-trans- and tetrahydropyridoindole neuroleptic agents
HU204054B (en) Process for producing new 1-oxa-2-oxo-8-azaspiro(4,5)decane derivatives and pharmaceutical compositions comprising same
US20040229900A1 (en) Bispidine compounds useful in the treatment of cardiac arrythmias
SK18272001A3 (en) New bispidine compounds useful in the treatment of cardiac arrhythmias
US4431646A (en) Hexahydro-trans- and tetrahydropyridoindole neuroleptic agents

Legal Events

Date Code Title Description
CC Certificate of correction
FPAY Fee payment

Year of fee payment: 4

AS Assignment

Owner name: ICOS CORPORATION, A WASHINGTON CORPORATION, WASHIN

Free format text: MERGER;ASSIGNOR:ICOS CORPORATION, A DELAWARE CORPORATION;REEL/FRAME:017730/0906

Effective date: 20050927

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20091023